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Abstract 
Background: von Willebrand factor (VWF) is a large multimeric plasma 
glycoprotein. It plays an important role in haemostasis by promoting platelet 
adhesion and aggregation at sites of blood vessel damage and by binding to 
and prolonging the half-life of coagulation factor VIII (FVIII). VWF is 
synthesised in endothelial cells where it undergoes post-translational 
modifications including glycosylation and multimerisation. VWF levels vary 
considerably in the normal population and several factors have been 
associated with this variation including ABO blood group and age. However, 
known factors only account for ~65% of variation in level. Previous studies 
suggest that other genetic loci, including VWF, FUT3 and CLEC4M also 
influence VWF level. Aims: To identify genetic factors that influence VWF 
plasma level in the normal population and to investigate the mechanisms by 
which these genetic factors influence VWF level. Methods: DNA samples and 
phenotypic data (including VWF levels, age, gender and ABO blood group) 
were available for ~1100 healthy individuals (HC). Analysis was conducted on 
VWF, FUT3, FUT5, FUT6 and CLEC4M. In silico analysis was used to identify 
variants predicted to affect expression or activity. Variants of interest were then 
genotyped in HC and their association with VWF level was investigated. In 
vitro studies were used to investigate the effect of these variants on VWF 
protein and mRNA expression, exon splice enhancer (ESE) motifs, splicing 
and mRNA half-life. Results: Investigation of 111 single nucleotide variants 
(SNV) in VWF identified 11 with significant association with VWF plasma level, 
of which c.2385T>C and c.2365A>G had been reported in previous studies. In 
vitro analysis showed that both were associated with increased protein, mRNA 
level and mRNA half-life. Investigation of variants in FUT3, FUT5 and FUT6 
showed that only FUT3 c.202T>C was significantly associated with VWF 
plasma level. Investigation of CLEC4M confirmed the association of a 23 
amino acid variable number of tandem repeats (VNTR) with VWF plasma 
level. Conclusion: Variants within and outside VWF are found to be 
significantly associated with VWF plasma level through interfering with protein 
or mRNA levels. These factors were shown to have an additive effect and can 
be considered as risk factors for bleeding or cardiovascular disease.  
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1 Chapter 1: Introduction 
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1.1 Haemostasis 
Haemostasis refers to the process of stopping the bleeding through blood 
clotting (conversion of blood from a liquid to a solid state) in order to repair an 
injured vessel and prevent loss of blood. The process involves several clotting 
factors that are involved in the clotting cascade, for example coagulation factor 
VIII (FVIII). Loss of function or reduction in level of any of these factors 
increases the risk of bleeding disorders such as haemophilia A, while increase 
of level increases the risk of different cardiovascular diseases such as venous 
thrombosis (Jenkins, et al 2012). 
1.2 von Willebrand factor (VWF)  
1.3 VWF and the VWF pseudogene 
The VWF gene (VWF) maps to the short arm of chromosome 12 (12p13.3) 
(Ginsburg, et al 1985, Sadler, et al 1985, Verweij, et al 1985, Mancuso, et al 
1989). It consists of 52 exons (51 coding; 2-17 encoding the pre-pro-peptide, 
18-52 encoding mature VWF, Figure 1-1) (Mercier, et al 1991) transcribed to 
produce an 8.8kb mRNA product which is then translated to form a ~250kDa 
VWF protein (Mancuso, et al 1989, Sadler 1998). The VWF locus is known to 
be highly polymorphic with 8,463 single nucleotide variants (SNV) currently 
known to occur at this genetic locus (which is ~175kb in size) (Eikenboom, et 
al 1994; GeneCards V3, http://www.genecards.org, accessed December 
2015). 
There is also an ~21kb VWF pseudogene (VWFP1) located on chromosome 
22q11.1 which shares ~97% homology with part of VWF (exons 23-34) 
(Mancuso, et al 1991). However, several sequence variants result in 
nonsense, missense, and splice site variation, which can also be used to 
distinguish between the VWF and VWFP1 sequences (Mancuso, et al 1991).  
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Figure 1-1: Location and structure of VWF gene (HapMap). 
 
1.4 VWF protein  
VWF is a large multimeric plasma glycoprotein which plays two central roles 
in the coagulation system (Jaffe, et al 1973, Sporn, et al 1985). First, VWF 
binds to circulating platelets facilitating their adhesion and aggregation to the 
vascular injury site as a result of high shear stress (Section 1.9) (Sadler 1998, 
Mohlke, et al 1999, Ruggeri 2001). Second, VWF binds to FVIII via the D’ and 
D3 domains, protecting FVIII from proteolytic degradation which in turn 
extends the half-life of circulating FVIII (Montgomery, et al 1982, Kroner, et al 
1991, Millar and Brown 2006, McKinnon, et al 2008). In addition, VWF carries 
FVIII, ensuring that FVIII is present at sites of vascular injury. 
Historically, VWF structure consists of four types of conserved domains that 
are repeated throughout the protein (A, B, C and D) and a cysteine knot (CK) 
domain (Shelton-Inloes, et al 1986, Titani, et al 1986). Recent study has 
reviewed and updated the VWF sequence structure (figures 1-2 and 1-3) 
(Zhou, et al 2012). After the translation of the mRNA, it undergoes post-
translational modifications including glycosylation and multimerisation (Titani, 
et al 1986, van Schooten, et al 2008). The final mature multimeric VWF is 
either secreted into the blood constitutively or stored in Weibel-Palade bodies 
in endothelial cells or in platelet α-granules (Wagner 1990). 
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Figure 1-2: The translation product of VWF. Signal peptide highlighted in yellow; propeptide highlighted in light blue; mature peptide 
highlighted in darker blue and showing where different enzymes and compounds attach (Goodeve, et al 2007, Zhou, et al 2012).  
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Figure 1-3: Diagram representing VWF protein structure. The diagram compares the old and new structuring of VWF protein showing each 
domain before and after recent structuring (Zhou, et al 2012). 
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1.5 Synthesis of VWF 
The synthesis of VWF takes place in endothelial cells and megakaryocytes 
(Jaffe, et al 1973, Sporn, et al 1985, Wagner 1990). First, the monomeric VWF 
(pre-pro-VWF) is produced on the ribosome after the translation of VWF 
mRNA. The 2813 amino acid (a.a) pre pro VWF consists of a 22a.a signal 
peptide, a 741a.a propeptide and 2050a.a mature peptide. The pre-pro-VWF 
is translocated to the endoplasmic reticulum via the signal peptide (Sadler 
1998, Sadler 2009).  
In the endoplasmic reticulum (ER), pro-VWF (propeptide and mature peptide) 
is produced via cleavage of the signal peptide from pre-pro-VWF by signal 
peptidase (Figure 1-3). At this stage, the pro-VWF undergoes some post 
translation modifications including N-linked and O-linked glycosylation (for 
more detail, refer to section 1.6).  
The monomeric VWF also undergoes dimerisation by disulphide bonding 
between the CK domains at the carboxyl terminals (between p.Cys2671 and 
p.Cys2813 residues) forming tail to tail binding between two VWF monomers 
(Figure 1-4). The 151a.a following the C6 domain are also reported to be of 
importance in the process of dimerization (Katsumi, et al 2000, Sadler 2009); 
a study expressing recombinant VWF lacking some of the a.a within this region 
showed ER retention of VWF due to its inability to form dimers (Yadegari, et 
al 2013). Following dimerisation, folding of VWF dimers is required before they 
are transferred to the Golgi apparatus for further post-translational 
modification. Incorrect folding could result in intracellular retention and 
proteasomal degradation (Yadegari, et al 2013). This suggests that disruption 
of VWF folding will result in intracellular retention and a reduction in the level 
of secreted VWF. 
Once VWF dimers have been transported to the Golgi apparatus, further 
disulphide bonds bind dimers through the D3 domains to form a pro-VWF 
multimers (Wagner 1990, Sadler 2009, McKinnon, et al 2010). CxxC a.a motif 
sequences in the D1 and D2 domains are sites for protein disulphide 
isomerase activity which catalyses the formation of disulphide bonds between 
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the D3 and D’ domains, which in turn enhances head-to-head multimer 
formation (Denis, et al 2008, McKinnon, et al 2010).  
Finally, the propeptide bond (position p.Arg763-Ser764) is cleaved by Furin to 
produce the mature VWF which ranges in size from 2 to 200 monomers (the 
high molecular weight (HMW) form; Figure1-2) (Denis, et al 2008). The 
cleaved propeptide (VWFpp) remains bound to mature VWF via non-covalent 
bonds that are broken before VWF is secreted (Sadler 2009). VWFpp/VWF:Ag 
ratio can be used to assess the clearance rate of VWF from the circulation as 
an increased ratio suggests increased clearance rate (normal clearance when 
ratio is up to ~2.3 and enhanced clearance when ratio is >3) (Eikenboom, et 
al 2013).  
The molecular weight of circulating VWF is also functionally important. Ultra-
small VWF multimers are less able to recruit platelets to the site of vascular 
injury as they have fewer binding sites for platelets, while ultra large VWF 
multimers increase the risk of micro-vascular thrombosis as they have a very 
large number of binding sites, which might cause them to bind to platelets 
without prior vascular injury (Crawley, et al 2011). A disintegrin and 
metalloproteinase with a thrombospondin type 1 motif member 13 
(ADAMTS13) performs the proteolytic cleavage of the ultra large VWF (Figure 
1-2) (Furlan, et al 1996, Bowen and Collins 2004, Mannucci, et al 2004, 
Crawley, et al 2011). 
Mutations within different VWF domains can in many cases explain the VWD 
phenotype. Mutations that may affect VWF level via a defect of the synthesis 
process are found mainly (but not only) in signalling peptide D or C domains 
(Gadisseur, et al 2009). Mutations in the signalling peptide can in many cases 
lead to intracellular retention as this domain is important in the translocation of 
VWF to the ER (Gadisseur, et al 2009). Mutations in the CK domain are likely 
to affect the dimerization process, thus leading to intracellular retention in the 
ER (Gadisseur, et al 2009). Mutation in D domains can lead to a defect in the 
multimerisation process therefore leading to intracellular retention as 
multimerisation is essential before VWF is secreted (Eikenboom, et al 1996).  
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On the other hand, mutations within these domains might not affect VWF level, 
but instead VWF function. There are many binding positions on VWF for 
different ligands (Figure 1-2), thus mutations affecting the binding may result 
in defects in VWF function instead of level. 
 
 
 
 
 
 
 
Figure 1-4: VWF; dimerization and multimerisation. The figure shows the 
process of VWF multimerisation. A) The translation product of VWF (the 
signal peptide in yellow, propeptide in light blue; mature peptide in blue) 
(Goodeve, et al 2007). B) Dimerization of VWF by disulphide bonding 
between the CK domains (Dong, et al 1994). C) The final multimeric VWF 
product formed by linking of VWF dimers via disulphide bonds between the 
D3 domains (Sadler 2009).  
  
A 
B 
C 
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1.6 VWF glycosylation  
Glycosylation refers to the addition of polysaccharide chains (glycans) to a 
protein. Glycosylation is a post-translational modification that occurs mostly in 
the endoplasmic reticulum and finishes in the Golgi apparatus (Matsui, et al 
1993, Lenting, et al 2010, McKinnon, et al 2010). In total, the glycans added 
to VWF account for ~20% of the VWF molecular weight (McKinnon, et al 
2010). It is reported that there are 10 O-linked glycans and 17 N-linked glycans 
(4 added to the propeptide and 13 to the mature sub-unit) added to each VWF 
monomer (Lynch, et al 1986, Titani, et al 1986, McKinnon, et al 2010).  
Over 300 different structured glycans have been identified to date that can be 
added to VWF (Lenting, et al 2010, Lenting, et al 2015). Due to the small 
number of available glycosylation positions and the large number of available 
glycan structures, this results in large variation between each VWF monomer 
(Lenting, et al 2015). It is worth noting that some of the general features 
observed in these glycans, specifically that: 90% of glycans are sialylated 
including some of the O-linked glycans which have been found to be bi- or tri-
sialylated glycans, five out of the 17 N-linked glycans have been found to be 
sulphated, ABH antigen can be found in ~13% of N-linked glycans and ~1% 
of O-linked glycans (Carew, et al 1990, Canis, et al 2010, Canis, et al 2012).  
VWF glycosylation is found to have both structural and functional importance. 
It is essential for the formation of dimers (Wagner, et al 1986) and is also 
required for correct folding of VWF and promoting its structural stability 
(Lenting, et al 2010). In addition, it protects VWF from proteolytic and 
intracellular degradation, thus prolonging its half-life (Gill, et al 1987, Gallinaro, 
et al 2008). Moreover, glycosylation contributes to the clearance of VWF which 
in turn affects VWF half-life, as exemplified by the effect of the glycosylated 
ABH antigens on the clearance of VWF (section 1.12.1.2) (Millar and Brown 
2006).  
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1.6.1 N-linked glycosylation 
N-linked glycosylation occurs via the addition of glycans to asparagine 
residues in VWF. Of the 17 N-linked positions, 13% correspond to ABH 
glycosylation (Matsui, et al 1992, McKinnon, et al 2008). N-linked glycosylation 
affects the multimerisation of VWF (Wagner, et al 1986). Inhibition of N-linked 
glycosylation prevents VWF from transferring to the Golgi apparatus which in 
turn prevents the multimerisation process (Wagner, et al 1986). 
A recent study investigated the importance of 17 N-linked glycans by mutating 
the Asn, which is required for glycosylation, to Gln at the binding site of each 
of the 17 N-linked glycans, preventing the attachment of one glycan at a time 
and studying the subsequent effect on plasma VWF (McKinnon, et al 2010). 
Mutation of glycosylation sites p.Asn99, p.Asn857 and p.Asn2790 was found 
to influence VWF plasma level. p.Asn99 was found to inhibit the production of 
VWF multimers completely, p.Asn857 was found to cause reduction of 
secreted VWF into the plasma and p.Asn2790 was found to be of importance 
for the dimerization process (McKinnon, et al 2010). Mutating the other N-
linked glycosylation sites had a less significant impact on VWF production and 
secretion, and it was therefore suggested that they have other functional 
importance yet to be known (McKinnon, et al 2010). 
1.6.2 O-linked glycosylation 
Unlike N-linked glycosylation, little is known about O-linked glycosylation. O-
linked glycosylation occurs via the addition of glycans to serine or threonine 
residues in VWF. There are 10 O-linked positions for glycosylation on VWF, 
of which sialyalated T-antigen was found to account for 70-90% while ABH 
antigen was found to account for around 1% (van Schooten, et al 2007, Canis, 
et al 2010, McGrath, et al 2010). It has been reported that O-linked glycans 
influence VWF half-life by an unknown process, although it has been 
suggested that they are associated with ADAMTS13 cleavage susceptibility 
(van Schooten, et al 2007).  
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1.7 VWF storage and secretion 
Synthesised VWF is stored in α-granules in platelets and Weibel-Palade 
bodies (WPB) in endothelial cells (Wagner, et al 1982, Sporn, et al 1985). 
While the formation and packaging of VWF in platelets is still not clear, VWF 
is essential for the formation of WPB (Haberichter, et al 2005). Mutations 
leading to mis-folding of VWF or loss of multimeric VWF would lead to 
alteration in the formation and structure of WPB (Haberichter, et al 2005). WPB 
are suggested to initiate from the trans-Golgi network (Valentijn, et al 2011). 
VWF is compressed 100X in a tubule structure and stored in WPB before 
these structures are detached from the Golgi apparatus (Ferraro, et al 2014). 
This folding of VWF results in cigar-shaped WPB (Valentijn, et al 2008). The 
acidic environment in WPBs supports the self-assembly of VWF between the 
D’-D3 domains (Section 1.12.2.5) (Valentijn, et al 2008).  
After the storage of VWF, platelets are known to release VWF upon activation 
(Nightingale and Cutler 2013). However, the process of release of VWF from 
WPB is not yet clear. Several suggestions have been proposed. The first and 
most widely acceptable is that WPB move randomly inside the cell and when 
they come close to the cell membrane, fusion occurs, resulting in the release 
of VWF into the circulation (Rondaij, et al 2006). However, the release of long 
strings of multimeric VWF was only observed upon stimulation in vitro, 
suggesting that other mechanisms are also involved (Nightingale and Cutler 
2013, Lenting, et al 2015). Fusion of several WPB has also been observed 
resulting in the secretion of larger amounts of VWF after stimulation 
(Nightingale and Cutler 2013). Several proteins have also been associated 
with VWF secretion, including Rab15, Rab37, Ra1A, Munc18c, syntaxin-4, 
and other G proteins (Lenting, et al 2015).  
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1.8 VWF clearance  
The half-life of the final multimeric plasma VWF is 12-20 hours (van Genderen, 
et al 1997). There are several factors influencing the half-life especially the 
size of the plasma VWF i.e. HMW-VWF has longer half-life as it takes longer 
to be cleared from the plasma (Goodeve 2010, Lenting, et al 2015). In addition, 
ABO blood groups was also reported to influence VWF half-life (Gallinaro, et 
al 2008). According to Denis et al. (2008), VWF is cleared by the liver and 
spleen; however, the clearance process is still not fully understood. It is also 
suggested that macrophages contribute to the clearance process (van 
Schooten, et al 2008, Rastegarlari, et al 2012, Lenting, et al 2015). In addition, 
it has been proposed that a glycoprotein receptor found on hepatocytes 
influences the clearance by initiating lysosomal degradation via interaction 
with the oligosaccharides found in VWF (Millar and Brown 2006). 
Several studies have suggested factors that might contribute to VWF 
clearance, such as ABO blood group (section 1.12.1.2) and SNV within VWF 
(section 1.12.1.1). 
Several receptors have been identified to be involved in clearing VWF from 
the circulation. The first identified receptor is called asialoglycoprotein receptor 
(Ashwell receptor) (Grewal, et al 2008). This receptor clears 
asialoglycoproteins from the circulation, but due to the fact that VWF is 
sialylated, this receptor is expected to only clear VWF in the absence/inactivity 
of sialyltransferase enzymes such as ST3Gal-IV (Ellies, et al 2002, Grewal, et 
al 2008). 
Lipoprotein receptor LRP1, which is also expressed in macrophages, has also 
been associated with the clearance of VWF (Rastegarlari, et al 2012), having 
previously been known to be involved in the clearance of FVIII (Morange, et al 
2005). This receptor better recognises unfolded VWF (through the A1 domain), 
therefore, it is of functional importance under shear stress (Wohner, et al 
2015). In addition, a previous study showed that mice deficient in LRP1 had 
an increase in their VWF half-life (Rastegarlari, et al 2012). Furthermore, 
mutations in the LRP1 have been associated with increased VWF plasma 
13 
 
levels in Brazilian normal individuals (Mello, et al 2008). A more recent study 
showed that mutation in LRP1 is associated with reduced VWF clearance and 
thus increased level (Wohner, et al 2015). 
Siglec-5 is another receptor suggested to be involved in VWF clearance 
(Pegon, et al 2012). This receptor is expressed in macrophages supporting 
previous reports that macrophages play an important role in VWF clearance 
(van Schooten, et al 2008). However, the mechanism by which this receptor 
clears VWF is still not clear.  
Recent genome wide association studies showed that CLEC4M is significantly 
associated with VWF plasma level (Smith, et al 2010). Further investigation 
associated L-SIGN, which is the product of CLEC4M, with clearance of VWF 
from the circulation (Rydz, et al 2013). This receptor is reported to be 
expressed in sinusoidal endothelial cells in the liver, which further supports its 
association with VWF clearance.  
1.9 VWF function 
As previously mentioned, VWF has two main functions: 1) binding to 
circulating FVIII and protecting it from proteolytic degradation, therefore 
prolonging its life & delivering to site of vascular injury, and 2) binding and 
recruiting platelets to the site of vascular injury (Baruch, et al 1991, Ruggeri 
2001).  
VWF binds to FVIII via domains D’-D3, therefore mutations within this region 
can result in the inability of VWF to bind to FVIII which in turn results in 
reduction of FVIII level (figure 1-2 and figure 1-5) (Nishino, et al 1989, Sadler, 
et al 2006). This leads to type 2N VWD (section 1.11.1) which exhibits a mild 
haemophilia A-like phenotype. 
VWF recruits platelets to the site of injury, helping to form a blood clot which 
prevents further bleeding. In a normal scenario, VWF multimers circulate in a 
folded state, reducing the number of binding sites for platelets in order to 
prevent spontaneous binding of platelets to VWF which might cause a blood 
clot within the small arteries (arterioles) or veins (venules) (Sadler 1998, 
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Ruggeri 2001). However, after vascular injury, VWF binds to collagen 
(normally present in the sub-endothelial matrix) through the A3 and A1 
domains, which causes VWF to linearize with the help of shear stress from the 
flow of blood (Reininger 2008). This in turn exposes more platelet binding sites 
in the VWF multimers which allows more platelets to bind to VWF through the 
platelet receptor glycoprotein Ibα (GpIbα) receptor (Savage, et al 1996, 
Reininger 2008). Bound platelets become activated, change in shape and 
begin to express the glycoprotein IIb-IIIa (GPIIb-IIIa) receptor which rapidly 
binds to VWF through domain C4 (Keeney and Cumming 2001). Further 
circulating VWF binds to activated platelets, becomes linearized by shear 
stress leading to recruitment of further platelets and eventually to formation of 
a thrombus (figure 1-5) (Kenny, et al 2002).  
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Figure 1-5: VWF interaction with platelets and FVIII at the site of 
vascular injury. Following vascular injury, VWF binds to collagen (via the A1 
and A3 domains) and undergoes conformational changes due to high shear 
stress which changes its form from folded to linear and leads to the binding 
of platelet receptor GpIbα via the A1 domain (Fujimura, et al 1986, Hoylaerts, 
et al 1997, Mazzucato, et al 1999).  
  
Shear stress 
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1.10 Types of VWF  
There are two forms of VWF, plasma VWF and platelet VWF. Both plasma 
and platelet VWF are encoded by VWF, however, plasma VWF is produced in 
endothelial cells while platelet VWF is produced by megakaryocytes. Both 
types of VWF are found to have significant differences in their structure and 
glycosylation pattern (Denis, et al 2008, McGrath, et al 2010). Plasma VWF is 
found to go through more extensive proteolysis compared to platelet VWF 
(McGrath, et al 2010). Storage is also different, with plasma VWF stored in 
Weibel-Palade bodies and platelet VWF stored in α-granules (Ruggeri and 
Zimmerman 1980, Wagner 1990). Platelet VWF is also found not to bind and 
carry FVIII in the circulation as it is suggested to be permanently stored and 
not released from the platelets in mice (Yarovoi, et al 2003). The majority of 
investigations, including this study focus on plasma VWF. 
1.11 VWF level 
Normal plasma levels of VWF range between 50-200 IU/dL in 95% of the 
general population and therefore shows a wide range compared to most other 
coagulation factors such as FII, FV, FIX, FX, FXI and FXII where the normal 
level ranges between 70-130 IU/dL (Gill, et al 1987, Mannucci, et al 1989, 
Iverson, et al 2007). High VWF levels (>200 IU/dL) are associated with 
increased thrombotic risk, myocardial infarction and stroke (Galbusera, et al 
1997, Lemmerhirt, et al 2006, Morga-Ramirez, et al 2010, van Schie, et al 
2011a, van Schie, et al 2011d) and low VWF levels (<50 IU/dL) are associated 
with the bleeding disorder von Willebrand disease (VWD) (Lemmerhirt, et al 
2006, Mazzeffi and Stone 2011).  
1.11.1 von Willebrand disease (VWD)  
VWD was first reported in 1926 by Finnish physician Dr Erik von Willebrand. 
VWD is the most common inherited bleeding disorder and is caused by either 
a quantitative or qualitative deficiency in VWF mainly as a result of VWF 
mutation (Sadler 2004, Sadler, et al 2006, Nichols, et al 2008, Lenting, et al 
2012). It results in various symptoms including bleeding after surgery or tooth 
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extraction, subcutaneous bleeding and increased risk of epistaxis 
(Rodeghiero, et al 1987, Sadler, et al 2006, Tosetto, et al 2006).  
There are three main types of VWD; type 1, type 2 and type 3. Type 1 (VWD1) 
is the most common and accounts for around 70% of all VWD cases. It is 
caused by a reduction in plasma VWF level and is characterised by a 
mild/moderate bleeding phenotype (Eikenboom, et al 2006). VWD1 is 
generally inherited in an autosomal dominant manner. VWD1 patients with the 
same mutations have been shown to have variable VWF plasma levels and 
VWD1 can also demonstrate incomplete penetrance, i.e. an individual with a 
known VWD1 mutation might not exhibit symptoms (Cumming, et al 2006). 
Different types of mutations have been reported to result in VWD1 including 
missense, nonsense and splice site mutations. 
Type 3 is the rarest and most severe type of VWD, occurring in 5% of all VWD 
patients, and is characterised by almost a complete lack of plasma VWF 
(Sadler, et al 2006). It has autosomal recessive inheritance. The most common 
causative mutations for this type are nonsense mutations which account for 
~30%, although other mutations including deletions, insertions and splice site 
mutations can also be causative.  
Type 2 VWD is caused by defects of VWF function and is divided into four 
subtypes; 2A, 2B, 2M and 2N. Type 2A occurs in a reduction in the HMW VWF 
(Enayat, et al 2001). It is mostly inherited in an autosomal dominant manner 
with mutations resulting in loss of HMW VWF either due to enhanced 
ADAMTS13 cleavage or a defect in the dimerization or multimerisation 
processes (Goodeve 2010). Type 2B is inherited in an autosomal dominant 
manner and occurs in an increased VWF binding affinity to platelet GpIbα 
which is due to missense mutations in the A1 domain (Sadler, et al 2006, 
Lenting, et al 2012). Type 2M is also inherited in an autosomal dominant 
manner and occurs from reduced binding of VWF to platelets (Lenting, et al 
2012). Type 2N is inherited in an autosomal recessive manner and occurs in 
a decreased binding affinity of VWF toward FVIII (Sadler 1998, Sadler, et al 
2006).  
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Given that mild bleeding symptoms are common even in the normal 
population, it is hard to distinguish between patients with mild VWD1 and 
normal healthy individuals. Due to these factors, the prevalence of VWD1 
patients diagnosed with VWD is approximately 1/10,000, while the actual 
prevalence could be much higher (Lillicrap 2007). In addition, several VWD1 
studies failed to identify mutations in a subset of their patients (Goodeve, et al 
2007, James, et al 2007), suggesting that other genetic factors are expected 
to contribute to a VWD-like phenotype. 
 
1.12 Factors influencing VWF plasma level  
Due to the fact that several genetic and environmental factors are reported to 
have an effect on VWF level, there is no accurate distribution of these factors 
with VWF level (Figure 1-6). 
 
Figure 1-6: Pie chart showing factors influencing VWF plasma level 
with their extent of contribution in the general population (Desch 2012).  
  
Environmental 
factors 35%
ABO blood group 
21%
VWF Locus 5%
Other genetic 
factors 39%
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1.12.1 Genetic factors 
1.12.1.1 VWF   
Polymorphic variation within and adjacent to VWF has been shown to 
influence VWF level. VWF is a quantitative trait locus (QTL) for VWF levels 
and is responsible for ~20% variation in VWF plasma level after accounting for 
ABO blood group (De Visser, et al 2003). This includes the (GT)n repeat in the 
promoter region and the SNV c.2771G>A (p.Arg924Gln) (Hough, et al 2008, 
Hickson, et al 2010, Hickson, et al 2011). The (GT)n repeat has been shown 
to affect VWF promoter activity and contributes to variation in VWF levels by 
around 10%, with longer repeats found to have higher VWF promoter activity 
(Hough, et al 2008, Hickson, et al 2011), which contradicts the results of 
another smaller study (Daidone, et al 2009).  
Studies have also identified four SNVs located in the promoter region of VWF 
associated with plasma VWF level; c.-3268G>C, c.-2709C>T, c.-2661A>G 
and c.-2527G>A (Zhang, et al 1994, Keightley, et al 1999, Harvey, et al 2000). 
The association of these SNV was more significant in individuals over 40 years 
old. Using some in silico analysis, these SNV were predicted to potentially 
interact with several transcription factors such as GATA-2, c-Ets and Sp1, 
which may play a role in regulating VWF expression (Keightley, et al 1999, 
Harvey, et al 2000). However, a more recent study which investigated a larger 
number of individuals showed no significant association between c.-2527G>A 
and VWF plasma level, which can also be applied to the other three SNVs 
because all four SNVs are in complete linkage disequilibrium (LD) (Hickson, 
et al 2011) suggesting that these variants might be in partially strong LD with 
another variant that is responsible for the observed association. 
1.12.1.2 ABO blood group 
Gill et al. (1987) was the first to report an association between ABO blood 
group and VWF plasma level. There are three main antigens in the ABO 
system; A, B and H. A antigen is found in people with blood group A, B antigen 
is found in people with blood group B, both A and B antigens are found in 
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people with blood group AB, whereas H antigen is found in people with blood 
group O. 
The synthesis of different ABH antigens starts with a basic precursor (glycan 
chain) (Figure 1-7). First, the precursor is converted to H antigen by α-2-
fucosyltransferase  which is encoded by fucosyltrasferase 1 (FUT1) 
(O'Donnell, et al 2005). H antigen is then converted to A or B antigens via a 
glycosyltransferase which is encoded by the ABO gene. ABO encoded N-
acetyl-D-galactosamine transferase adds N-acetyl-D-galactosamine to H 
antigen converting it to A antigen, while ABO encoded D-galactose transferase 
adds galactose to H antigen converting it to B antigen (Klarmann, et al 2010). 
ABO encodes three main allelic forms of which A and B encode different forms 
of glycosyltransferase while O encodes an inactive form of glycosyltransferase 
resulting from a single nucleotide deletion (Figure 1-7) (Dean 2005). 
Individuals with different ABO blood groups are found to have different VWF 
levels (Gill, et al 1987, O'Donnell, et al 2005). Individuals with more complex 
ABH antigens (i.e. AB blood group individuals) have a longer VWF half-life 
compared to individuals with less complex ABH antigens (i.e. O blood group 
individuals) who have on average ~25% lower VWF level compared to non O 
blood group individuals (Figure 1-8) (Gill, et al 1987, Gallinaro, et al 2008, 
Castaman, et al 2010, McGrath, et al 2010). More complex antigens cause 
VWF to be less susceptible to clearance from the circulation (Gallinaro, et al 
2008, Castaman, et al 2010).  
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Figure 1-7: Synthesis of ABH antigens. The figure shows the synthesis of 
different ABH antigens (starting with the basic precursor glycan) by the 
required enzymes. It shows the precursor glycan (A), H antigen (B), A 
antigen (C) and B antigen (D) (Klarmann, et al 2010). (Glc, glucose; Gal, 
galactose; Nac, N-acetyl; Fuc, Fucose; R, the rest of the glycan chain). 
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Figure 1-8: The effect of different ABH antigens on VWF plasma level. 
Individuals with AB blood group are found to have highest VWF plasma 
levels (average 123.3 IU/dL), followed by individuals with A blood group 
(116.9 IU/dL), then B blood group (105.9 IU/dL) and O blood group (74.8IU 
/dL). Individuals with Bombay blood group are found to have the lowest VWF 
plasma levels (~10% lower than O-blood group individuals) (Gill, et al 1987, 
O'Donnell, et al 2005).  
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1.12.1.3 Bombay and para-Bombay blood groups 
Individuals with a Bombay blood group lack all ABH antigens in their plasma 
and exocrine secretions due to their inability to express FUT1 and FUT2 as a 
result of null mutations in both encoding genes (O'Donnell, et al 2005). On the 
other hand, Individuals with a para-Bombay blood group have H antigen in 
their exocrine secretion due to their ability to express FUT2, while they lack 
the H antigen in their plasma due to their inability to express FUT1 (O'Donnell, 
et al 2005). Recent studies reported that individuals with Bombay or para-
Bombay blood groups have 10-15% lower VWF plasma levels compared to 
individuals with O blood group as a result of increased proteolysis 
susceptibility by ADAMTS13 (O'Donnell, et al 2005, Klarmann, et al 2010). 
1.12.1.4 Arginine vasopressin 2 receptor (V2R)  
Recent research was conducted on normal individuals to study the association 
between V2R and VWF plasma level because V2R is responsible for 
maintaining blood pressure and volume, and is expressed by endothelial cells. 
The study found that V2R is associated with ~10% VWF level (Nossent, et al 
2010). V2R regulates the secretion of VWF into plasma by Weibel-Palade 
bodies. Mutations (i.e. p.Gly12Glu, p.Ala245Cys and p.Ser331Ser) in AVPR2, 
the gene encoding V2R mapped to the X chromosome, leads to a high binding 
affinity between V2R and arginine vasopressin (AVP), which increases signals 
transduction, resulting in increased excretion of VWF from Weibel-Palade 
bodies (Kaufmann, et al 2000, Nossent, et al 2010). However, the association 
of V2R was not observed in association studies such as the CHARGE and 
GAIT studies (Souto, et al 2003, Smith, et al 2010), which may be due to V2R 
having a weak association with VWF level. 
1.12.1.5 Genome-wide association studies  
Several genome-wide association studies (GWAS) have been conducted in 
order to find novel genetic loci associated with VWF plasma levels. 
The Cohort for Heart and Aging Research in Genome Epidemiology 
(CHARGE) study, examined 23,608 Caucasian individuals from 5 centres 
(Smith, et al 2010). The study scanned the participants for SNVs associated 
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with VWF level, FVIII and FVII activity. Eight different genetic loci were 
associated with VWF levels, including VWF and ABO (Smith, et al 2010). The 
other genetic loci were STXBP5, SCARA5, STAB2, STX2, TC2N and 
CLEC4M, none of which was previously reported to be associated with VWF 
level (Smith, et al 2010). These genes are suggested to be of functional 
importance toward VWF level as they were suggested to be associated with 
transport and cell membrane receptors, which may influence VWF synthesis, 
storage or clearance (Smith, et al 2010).  
The Genetic Analysis of Idiopathic Thrombophilia (GAIT) study identified 
several genetic loci associated with VWF plasma level in 21 Spanish families: 
1p36.13, 2q23.2, 5q31.1, 6p22.3, 9q34.2 and 22q11.1 (Souto, et al 2003). 
None of the identified genetic loci were reported by the CHARGE study except 
for ABO (9q34.2). However, this study failed to identify specific genes that 
might be responsible for this association due to the small sample number used 
(n= 398) and the lack of extended family pedigrees.  
Recent association studies further confirmed the association of ABO and VWF 
with VWF plasma level (Campos, et al 2011, Zabaneh, et al 2011). Campos 
and colleagues (2011) studied the association of different SNV and haplotypes 
within VWF with VWF plasma level and identified 18 SNV with significant 
association, all of which are present within a 50kb region covering exons 13-
24 which encodes the D2, D’ and D3 domains. One of these SNVs (rs1063857 
in exon 18) was identified previously by the CHARGE study (Smith, et al 2010). 
In addition, they identified 9 different haplotypes from the previous SNVs with 
significant association with VWF plasma level. On the other hand, Zabaneh 
and colleagues (2011) studied the association of different genetic loci with 
VWF plasma level. This study identified 2 new genetic loci with a weak 
association to VWF plasma level; estrogen receptor 1 (ESR1) and neuregulin 
1 (NRG1). Not much is known about ESR1 in relation to VWF level, however, 
NRG1 is reported to be expressed in plasma by endothelial cells and has been 
associated with chronic heart failure (Ky, et al 2011).    
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1.12.1.6 Animal studies 
Several studies have been conducted on inbred mice of two different strains, 
RIIIS/J, which is a strain that exhibits a VWD1 phenotype with prolonged 
bleeding and low VWF and FVIII level, and PWK/Ph, which is a strain with a 
normal VWF level (Nichols, et al 1994). These studies have found seven 
genetic loci associated with VWF plasma level, Mvwf1-7 (Mohlke, et al 1996, 
Lemmerhirt, et al 2006, Lemmerhirt, et al 2007, Shavit, et al 2009), all of which 
occur in locations distinct from Vwf except for Mvwf2 and Mvwf5 (Shavit, et al 
2009). Mohlke and colleagues (1996) identified a locus that is associated with 
a 20-fold decrease in plasma VWF level, which occurs on chromosome 11, 
and named it Mvwf1 (Mohlke, et al 1996). It is believed that a gain of function 
mutation at this locus is responsible for this effect on VWF plasma level 
(Mohlke, et al 1999). Further study on this locus led to the identification of the 
gene Galgt2 (Mohlke, et al 1999). It is suggested that the Mvwf1 human 
Ortholog (B4GALNT2) may have similar associations with VWF plasma level 
(Mohlke, et al 1996, Mohlke, et al 1999, Dall'Olio, et al 2014).  
Mvwf2 mapped to mouse Vwf and a p.Arg2657Gln (c.7970G>A) mutation at 
this locus was found to affect the secretory pathway of VWF by influencing the 
synthesis and secretion of VWF (Lemmerhirt, et al 2006). Mvwf2 was found to 
be responsible for around 29% of the variation in mouse VWF level 
(Lemmerhirt, et al 2007). 
A variant in Mvwf5 was found to affect the binding of regulatory components 
in Vwf itself such as transcription regulation or RNA stability, which in turn 
affects the expression of Vwf (Shavit, et al 2009). Although the mechanisms 
associated with Mvwf3, Mvwf4, Mvwf6 and Mvwf7 are yet to be known, a 
potential human orthologue for Mvwf6 was reported in the GAIT study to be 
present within 12q12 and 21q22.3, which might suggest that these loci are 
also important in influencing VWF plasma level (Souto, et al 2003, Shavit, et 
al 2009).  
26 
 
1.12.2 Environmental factors 
1.12.2.1 Ethnic background 
Research conducted by Kadir and colleagues (1999) found that black women 
tend to have significantly higher VWF levels in comparison to other ethnic 
groups. This result confirmed several previous studies which found that black 
individuals had higher VWF levels than white individuals (Meade, et al 1977, 
Meade, et al 1978, Conlan, et al 1993). This difference in VWF level was 
thought to be due to differences in living habits such as smoking habits, and 
genetic background (i.e. genomic variation) in individuals from different ethnic 
backgrounds (Meade, et al 1978). 
1.12.2.2 Gender 
The effect of gender on VWF plasma level has been a controversial topic. 
Some studies suggest that males and females do not differ in VWF plasma 
level, while other studies found that males have higher VWF levels than 
females, and others believe that females have higher VWF plasma levels 
compared to males (Conlan, et al 1993). However, another study aimed to 
reassess the effect of gender on VWF plasma level and suggested that there 
are no significant differences in levels between males and females (Favaloro, 
et al 2005) which was supported by a recent study (Zhou, et al 2014). 
1.12.2.3 Age 
Several studies have shown an association of age with plasma VWF level. 
Individuals exceeding 40 years old are found to have increased VWF plasma 
levels (Chakrabarti, et al 1975, Conlan, et al 1993, Kadir, et al 1999, Konkle 
2014) and 4.8% of variation in VWF plasma level is reported to be due to the 
effect of age (Campos, et al 2011). It has also been reported that adults have 
an average 10 IU/dL VWF level increase per decade (Laffan, et al 2004). 
Another study conducted on young children found that after 1-3 months, VWF 
plasma level decreased until the age of 13 months to 4 years, when the VWF 
plasma level then starts to increase again (Klarmann, et al 2010).  
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1.12.2.4 Estrogen level 
In vitro, estrogen is found to increase secretion of VWF by endothelial cells. 
(Harrison and McKee 1984). However, this observation has not been tested in 
vivo, which might make these findings questionable.  
1.12.2.5 Golgi apparatus pH level 
Wagner and colleagues (1986) suggested that an acidic environment is 
essential for the formation of multimeric VWF inside the Golgi apparatus. A 
recent review by Sadler (2009) reported that a basic environment inside the 
Golgi apparatus inhibits the formation of the disulphide bonds required for 
VWF multimerisation, thereby lowering the production of HMW-VWF, which is 
in line with previous findings (Wagner, et al 1986). 
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1.13 Aims and hypothesis 
The main goal of this project is to identify novel genetic factors that may 
contribute to the wide variation in VWF plasma levels (50-200 IU/dL) reported 
in the general population; these factors may also explain the difference in 
VWD/thrombosis severity in patients with the same causative mutations. 
Therefore, the aims of this project are: 
1. To identify novel genetic loci associated with VWF plasma level 
2. To investigate the mechanism(s) by which these genetic loci influence 
VWF plasma level 
Given that a large number of genes have been suggested to be associated 
with VWF plasma level, this study initially focused on those genes strongly 
associated with VWF levels for further laboratory investigation: VWF, FUT3 
and CLEC4M. It is hypothesised that variants within and outside VWF are 
associated with VWF plasma level in the normal population. 
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2 Chapter 2: Materials and Methods 
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2.1 Materials 
2.1.1 Study population 
The study population consisted of 1166 healthy control individuals (HC) who 
were recruited to the European Union study, Molecular and Clinical Markers 
for the Diagnosis and Management of Type 1 von Willebrand Disease 
(MCMDM-1VWD), by 12 European partners (P): P1) Sheffield, UK; P2) 
Vicenza, Italy; P3) Milan, Italy; P4) La Coruña, Spain; P5) Paris and Lille, 
France; P6) Leiden, the Netherlands; P7) Hamburg, Germany; P8) Aarhus, 
Denmark; P9) Prague, Czech Republic; P10) Malmo and Lund, Sweden; P11) 
Leicester, UK and P12) Birmingham, UK. Ethical review and informed consent 
were obtained prior to study participation.  
Phenotypic data including age, gender, ABO blood group, von Willebrand 
factor (VWF) plasma antigen levels (VWF:Ag), ristocetin cofactor activity 
(VWF:RCo), VWF propeptide (VWFpp) plasma level and factor VIII activity 
(FVIII:C), were available for the majority of HC (Goodeve, et al 2007, 
Eikenboom, et al 2013). Caucasian was the ethnicity of the majority of the 
recruited individuals. Genomic DNA from HC was previously extracted from 
citrated whole blood using standard procedures and stored at -20°C. 
2.1.2 Chemicals, reagents and commercial kits 
Chemicals and reagents used in this project were obtained from various 
sources. OneTaq DNA polymerase and Q5 high fidelity DNA polymerase were 
obtained from New England Biolabs Ltd. (Hitchin, UK). KAPA HiFi polymerase 
was obtained from KAPA Biosystems Ltd. (London, UK). Lipofectamine LTX 
(transfection reagent) was obtained from Invitrogen by Life Technologies (Ltd. 
Paisley, UK). 5× passive lysis buffer (5× PLB) and Renilla Luciferase Assay 
System were obtained from Promega Ltd. (Southampton, UK). All restriction 
enzymes and related buffers were obtained from New England Biolabs Ltd. 
Antibodies used for ELISA were obtained from Enzyme Research 
(Laboratories Ltd. Swansea, UK). ELISA standard VWF:Ag calibrator was 
obtained from Quadratech (Diagnostics Ltd. Epsom, UK). Hyperladder 
molecular weight markers and agarose powder, which were used for 
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performing gel electrophoresis were obtained from Bioline Limited (London, 
UK). 
QIAquick Gel Extraction Kit, which was used to extract DNA from agarose gel, 
EndoFree plasmid maxi and QIAprep Spin Miniprep kits (which were used to 
extract DNA from competent cells) were all obtained from QIAGEN Ltd. 
(Crawley, UK). Quikchange Lightning Site Directed Mutagenesis kit and XL10-
gold E-coli were obtained from Agilent Technologies Ltd. (UK, Stockport). 
Luria Bertoni (LB) and NZY broth and agar were obtained from Merck 
(Darmstadt, Germany). 
Dulbecco’s Modified Eagles cell culture Media (DMEM), foetal bovine serum 
(FBS) and 10x phosphate buffered saline (PBS) were obtained from Life 
Technologies.  
2.1.3 Primers 
The oligonucleotide primers used in this study (Tables 2-1, 2-2, 2-3 and 2-4) 
were ordered lyophilised from Eurofins MWG Operon (Ebersburg, Germany) 
and on arrival were diluted to 100pmol/μl according to the manufacturer’s 
guidelines. Refer to section 2.2.1.5 for primer design and validation. 
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Table 2-1: PCR primers used for amplification and sequencing in this 
study.  
Primer  Sequence (5' to 3') 
FUT3F M13-TTACCTGCAAAACCCAGTCC1 
FUT3R M13-TCAGTGTGGCAAGGTCTCTG1  
FUT5F M13-GCACTGGCTCTTTCCTCATC1  
FUT5R M13-AGTAGGTGCAGCCTCCAGAA1  
FUT6F M13-GACCCTTGCCCATGTAGAAA1  
FUT6R M13-TCAGCCAGAACCATCACTCA1  
FUTseqF1 AATCTCACCATGTCCTACCG  
FUTseqR1 CGTACACGTCCACCTTGAGA  
FUTseqF2 TGGCTGTGTGTTTCTTCTCC  
FUTseqR2 TTGTCCAGCTCCTGCAGGTA  
CLEC4MrepF FAM-GAGACCTTGGCTCTCACAAA2 
CLEC4MrepR GTGTTCTCATTTCACAGGGG 
CLEC4M_SNV_F M13-GGTGAGTTGCCAGACCAGTC1 
CLEC4M_SNV_R M13-GTGTACCTGCTCCTCAGCAG1 
CLEC4M_7_F M13-GCAGGAACTGAAGGCAACAT 
CLEC4M_7_R M13-GGAAACTTGGAGGCATCAGA 
FUT3_expression_F ACATGGCCTTTCCACATCC 
FUT3_expression_R AGGCGTGACTTAGGGTTGG 
CLEC_4M_expression_F AAGTCAGGAACAATCCG 
CLEC_4M_expression_R1 ACTGGTCTGGCAACTCA 
CLEC_4M_expression_R2 TTGGAAGAATGTCCAGTC 
pcDNA-Dupseq CACTCAACCCTATCTCGGTCTA 
FUT3_qPCR_F AGCCAAGCCACAATGGCCAT 
FUT3_qPCR_R GGGTTGGACATGATATCCCAG 
1M13F (5’-TGTAAAACGACGGCCAGT-3’) or M13R (5’-
CAGGAAACAGCTATGACC-3’) were attached in order to facilitate 
sequencing; 2a 6-carboxyfluorescein (6-FAM) fluorescent tag was attached to 
facilitate accurate sizing of amplified products.  
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Table 2-2: Mutagenic primers.  
Variant  Sequence (5' to 3') 
a2365g ctgaagggctcgagtgtgccaaaacgtgcc 
a2365g_antisense ggcacgttttggcacactcgagcccttcag 
t2385c ccaaaacgtgccagaactacgacctggagtgcat 
t2385c_antisense atgcactccaggtcgtagttctggcacgttttgg 
 
Table 2-3: Primers used for pET01 plasmid preparation. 
Variant Sequence (5' to 3') 
p.Arg924Gln_F TTTCCCAGTCACGACGTTGGGATCCcagtggga 
ctctaatgggct 
p.Arg924Gln_R CAACGTCGTGACTGGGAAACGCCGGCGacac 
acacaaagaaacccgg 
p.Leu1382=_F TTTCCCAGTCACGACGTTGGGATCCtgtggatgg 
cctagaacaacgagt 
p.Leu1382=_R CAACGTCGTGACTGGGAAACGCCGGCGgggga 
agaggctgtgtgataaagt 
VWF_exon_18_F TTTCCCAGTCACGACGTTGGGATCCtcttttcaagcc 
tgggtctg 
VWF_exon_18_R CAACGTCGTGACTGGGAAACGCCGGCGgcccctg 
ggaaaattctagt 
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Table 2-4: Oligos used to prepare pcDNA-Dup (SF2-ASF3x) plasmid for 
ESE assay. 
Variant Sequence (5' to 3') 
pcDupBR2int11F 
(-ve) 
AATTCTGTTGTCCAGGTCACATTCAATTATAGGG 
pcDupBR2int11R 
(-ve) 
GATCCCTATAATTGAATGTGACCTGGACAACAG 
2385T_F AATTCAACGTGCCAGAACTATGACCTGGAGTGCATGG 
2385T_R GATCCCATGCACTCCAGGTCATAGTTCTGGCACGTTG 
2385C_F AATTCAACGTGCCAGAACTACGACCTGGAGTGCATGG 
2385C_R GATCCCATGCACTCCAGGTCGTAGTTCTGGCACGTTG 
2365A_F AATTCGAAGGGCTCGAGTGTACCAAAACGTGCCAGAG 
2365A_R GATCCTCTGGCACGTTTTGGTACACTCGAGCCCTTCG 
2365G_F AATTCGAAGGGCTCGAGTGTGCCAAAACGTGCCAGAG 
2365G_R GATCCTCTGGCACGTTTTGGCACACTCGAGCCCTTCG 
2385T/2365A_F AATTCAGTGTACCAAAACGTGCCAGAACTATGACCTG 
2385T/2365A_R GATCCAGGTCATAGTTCTGGCACGTTTTGGTACACTG 
2385C/2365G_F AATTCAGTGTGCCAAAACGTGCCAGAACTACGACCTG 
2385C/2365G_R GATCCAGGTCGTAGTTCTGGCACGTTTTGGCACACTG 
5844C_F  AATTCGCGTGTGCACAGGCAGCTCCACTCGGCACAG 
5844C_R  GATCCTGTGCCGAGTGGAGCTGCCTGTGCACACGCG 
5844T_F  AATTCGTGTGTGCACAGGCAGCTCCACTCGGCACAG 
5844T_R  GATCCTGTGCCGAGTGGAGCTGCCTGTGCACACACG 
3789G_F  AATTCTGTGGAGGACATCTCGGAACCGCCGTTGCACG 
3789G_R  GATCCGTGCAACGGCGGTTCCGAGATGTCCTCCACAG 
3789A_F  AATTCTGTGGAGGACATCTCAGAACCGCCGTTGCACG 
3789A_R  GATCCGTGCAACGGCGGTTCTGAGATGTCCTCCACAG 
1451A_F  AATTCACCTCCGCATCCAGCATACAGTGACGGCCTCG 
1451A_R  GATCCGAGGCCGTCACTGTATGCTGGATGCGGAGGTG 
1451G_F  AATTCACCTCCGCATCCAGCGTACAGTGACGGCCTCG 
1451G_R  GATCCGAGGCCGTCACTGTACGCTGGATGCGGAGGTG 
2771G_F  AATTCTGAAATGCAAGAAACGGGTCACCATCCTGGTG 
2771G_R  GATCCACCAGGATGGTGACCCGTTTCTTGCATTTCAG 
2771A_F  AATTCTGAAATGCAAGAAACAGGTCACCATCCTGGTG 
2771A_R  GATCCACCAGGATGGTGACCTGTTTCTTGCATTTCAG 
2880G_F AATTCAATTCGTGGAGTCTGGCCGGTACATCATTCTG 
CTGG 
2880G_R GATCCCAGCAGAATGATGTACCGGCCAGACTCCACG 
2880A_F AATTCGTGGAGTCTGGCCGATACATCATTCTGCTGG 
2880A_R R:GATCCCAGCAGAATGATGTATCGGCCAGACTCCACG 
1548T_F AATTCCTGTCCCCCGTCTATGCCGGGAAGACCTGCG 
1548T_R GATCCGCAGGTCTTCCCGGCATAGACGGGGGACAGG 
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1548C_F AATTCCTGTCCCCCGTCTACGCCGGGAAGACCTGCG 
1548C_R GATCCGCAGGTCTTCCCGGCGTAGACGGGGGACAGG 
4146G_F AATTCCTCCCGCATCACCCTGCTCCTGATGGCCAGG 
4146G_R GATCCCTGGCCATCAGGAGCAGGGTCATGCGGGAGG 
4146T_F AATTCCTCCCGCATCACCCTTCTCCTGATGGCCAGG 
4146T_R GATCCCTGGCCATCAGGAGAAGGGTGATGCGGGAGG 
4146A_F AATTCCTCCCGCATCACCCTACTCCTGATGGCCAGG 
4146A_R GATCCCTGGCCATCAGGAGTAGGGTGATGCGGGAGG 
4146C_F AATTCCTCCCGCATCACCCTCCTCCTGATGGCCAGG 
4146C_R GATCCCTGGCCATCAGGAGGAGGGTGATGCGGGAGG 
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2.1.4 TaqMan® probes 
TaqMan® probes (obtained from Life Technologies) were used for two 
different purposes in this project, which were, first, to study two SNV in FUT6 
(Table 2-5), and second, for quantification of mRNA for VWF, B2M, and 
CLEC4M (Table 2-6). 
 
Table 2-5: TaqMan® probes used for genotyping FUT6 variants. 
Targeted SNV Sequence (5’ to 3’) 
c.370C>T 
rs778805 
CCTCG[A3/G4]GGAGCGT1 
c.977G>A 
rs61739552 
ACGCTGC[G3/A4]GCCTC2  
1TaqMan® assay probes previously designed and available (assay ID 
C_801652_20); 2TaqMan® assay custom designed for the current study; 
3fluorescently tagged with VIC; 4fluorescently tagged with 6-fluorescein 
amidite (6-FAM). 
 
Table 2-6: TaqMan® probes used for mRNA quantification. 
Target gene Assay ID 
VWF Hs01109446_m1 
B2M Hs00984230_m1 
CLEC4M Hs03805885_g1 
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2.1.5 Plasmids 
1.1.1.1 Splice analysis 
The pcDNA-Dup (SF2-ASF3x) plasmid used for exon splice enhancer assays 
was generously donated by Dr. Pascaline Gaildrat (Inserm UMR 1079, Faculté 
de Médecine et de Pharmacie, Rouen, France) (Tournier, et al 2008, Gaildrat, 
et al 2012). The pET01 plasmid used for the acceptor / donor motif splicing 
assay was obtained from MoBiTec (GmbH, Germany) (Appendix 2). 
1.1.1.2 VWF expression analysis  
A bacterial plasmid expressing wild-type VWF was kindly provided by Prof. 
Reinhard Schneppenheim (Hamburg, Germany) (Schneppenheim, et al 
2001). The plasmid was composed of full length VWF cDNA (8.6kb) inserted 
in a pcDNA3.1/Hygro (-) plasmid (Life Technologies) (5.6 kb); the total size of 
the plasmid was ~14.2kb (Appendix 3). This plasmid was used subsequently 
to investigate the effect of genetic changes on VWF expression in addition to 
the possible mechanism of any effect on expression level (for example RNA 
half-life). 
1.1.1.3 Preparation of Renilla plasmid 
A plasmid containing the Renilla gene (phRL-null) (Promega) was used in this 
study to normalise for transfection efficiency variation. This is a humanised 
version of the pRL-null plasmid, i.e. the codons have been replaced with more 
efficient human codons resulting in better expression in human cell lines 
(Promega.co.uk). The plasmid expresses renilla protein that emits florescence 
(from enzyme-independent oxidation) which is measured using luminometry. 
It was co-transfected along with VWF expression plasmid and measured 
independently to take into account variations that might occur during the 
transfection process such as variation in transfection efficiency or cell number. 
It was prepared using the maxiprep technique (section 2.2.2.1.11) from a 
previously prepared -80°C glycerol stock. 
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2.1.6 Cell line 
The adherent Human Embryonic Kidney (HEK) 293T cell line, which was used 
for various experiments including RNA and protein quantification as well as 
splicing analysis, was obtained from LGC Standards (Middlesex, UK). 
HEK293T is an adherent cell line that mimics, to an extent, endothelial cells 
(by naturally producing pseudo Weibel-Palade bodies) but does not express 
endogenous VWF. In addition, these cells express SV40 large T antigen which 
binds to SV40 to enhance plasmid expression. Therefore, it was an excellent 
model to study VWF expression.    
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2.2 Methods 
2.2.1 In silico analysis 
In silico analysis was performed using several web-based tools. All tools were 
accessed March 2012 unless otherwise stated. 
2.2.1.1 General in silico tools 
Some web tools were used for general in silico purposes such as checking for 
the reference sequence of DNA using the University of California Santa Cruz 
(UCSC) Human Genome Browser (GRCh37/hq19) (http://genome.ucsc.edu/) 
and National Centre for Biotechnology Information (NCBI) (build number 37.2) 
(http://www.ncbi.nlm.nih.gov/) or for cDNA using the Ensembl Genome 
Browser (build 62) (http://www.ensembl.org/index.html). UCSC (PCR tool) 
was also used to give the expected product from a given primer pair. All three 
tools were also used to check for the position of any SNV, splice variants, 
exon/intron starting points, and surrounding genes. Finally, NCBI Basic local 
alignment search tool (BLAST) was further used to either align two given 
sequences or one given sequence with the human genome to identify similar 
sequences. 
2.2.1.2 Protein prediction tools 
Several web tools were used to predict the effect of a given variant on its 
protein function. The result from one web tool is not sufficient because each 
tool uses a different algorithm which investigates SNV from a different aspect 
(i.e. some SNV that have an effect might not be detected, or SNV that do not 
have an effect might be detected). Therefore several web tools were used in 
order to maximise the accuracy of the obtained results. 
These tools include Sorting Intolerant from Tolerant (SIFT) http://sift.jcvi.org/, 
accessed April 2012, Align GVGD (Grantham Variation and Grantham 
Deviation) http://agvgd.iarc.fr/agvgd_input.php, accessed April 2012 (Mathe, 
et al 2006), polymorphism phenotyping V2 (PolyPhen-2) 
http://genetics.bwh.harvard.edu/pph2/, accessed April 2012 (Adzhubei, et al 
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2010) and mutation tasting http://www.mutationtaster.org/, accessed August 
2015 (Schwarz, et al 2010). 
2.2.1.3 mRNA prediction tools 
Several web tools were used to predict the effect of given SNV on mRNA 
splicing for the same reason as using several protein prediction tools. mRNA 
prediction tools investigated two aspects of splicing. First, tools that investigate 
the effect of SNV on exon splice enhancers included ESEfinder2.0 
http://rulai.cshl.edu/tools/ESE2/ (Cartegni, et al 2003) and Human Splicing 
Finder - Version 2.4.1 http://www.umd.be/HSF/ (Desmet, et al 2009). 
Second, tools that investigated the effect of SNV on acceptor / donor splicing 
motifs. These tools include NetGene2 
http://www.cbs.dtu.dk/services/NetGene2/ (Brunak, et al 1991), Splice Site 
Prediction by Neural networks http://www.fruitfly.org/seq_tools/splice.html 
(Reese, et al 1997), Automated Splice Site And Exon Definition Analyses 
(ASSEDA) http://splice.uwo.ca/ (accessed May 2014), Alternative Splice Site 
Predictor (ASSP) http://wangcomputing.com/assp/ (accessed May 2014) 
(Wang and Marin 2006) and Human Splicing Finder - Version 2.4.1 
http://www.umd.be/HSF/ (Accessed May 2014). 
In addition, RNAsnp web server http://rth.dk/resources/rnasnp was used to 
investigate the effect of a given SNV on mRNA secondary structure by 
comparing it to WT sequence (accessed May 2015) (Sabarinathan, et al 
2013). miRNA was also investigated using miRBASE web tool 
http://www.mirbase.org/ (Accessed May 2015) (Griffiths-Jones, et al 2008, 
Kozomara and Griffiths-Jones 2011). 
2.2.1.4 Other in silico tools 
Other web tools includes Sequence Manipulation Suite (v2) 
http://www.bioinformatics.org/sms2/dna_stats.html which was used to 
calculate the GC percentage of a given sequence, ClustalW2 
http://www.ebi.ac.uk/Tools/msa/clustalw2/ which was used to align given 
sequences (Larkin, et al 2007), dbSNP (build 132) 
http://www.ncbi.nlm.nih.gov/projects/SNP/ which was used to obtain 
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information on a given SNV such as rs number, a.a change and number, and 
nucleotide position and change as well as minor allele frequency in different 
populations, HapMap haploview (V4.2) http://hapmap.ncbi.nlm.nih.gov/ to 
investigate the linkage disequilibrium (LD) between different SNV (Barrett, et 
al 2005) and SNPStats (v0.95) 
http://bioinfo.iconcologia.net/SNVstats/start.htm, accessed July 2012, to 
calculate the LD between different SNVs from a given dataset and their 
association with a given response in addition to testing the Hardy Weinberg 
equilibrium (Sole, et al 2006). SnapGene viewer v.2.1 was used to view and 
manipulate plasmids (http://www.snapgene.com/, Accessed April 2014). 
2.2.1.5 Oligo design and validation 
2.2.1.5.1 Primers for PCR amplification 
Primers were designed using two different methods. The Primer3 v0.4.0 web-
tool (http://frodo.wi.mit.edu/primer3/, accessed March 2012) (Rozen and 
Skaletsky 2000) was used to design the majority of primers. Each primer was 
designed to meet several parameters to achieve the best results including 
primer length between 20-25 nucleotides, GC content between 45-55% and 
no single nucleotide to exceed four repeats.  
Designed primers were validated using the UCSC genome browser PCR tool 
and NCBI BLAST in order to avoid non-specific binding of primers. The UCSC 
PCR tool indicated the expected product(s) of each primer pair, thus defining 
any possible nonspecific binding of the primers, while BLAST indicated 
whether similar nucleotide sequences to the designed primers occurred 
elsewhere in the human genome. Primer annealing sites were then checked 
for the presence of any SNV, which might completely prevent the primers from 
binding to DNA samples carrying the SNV (if homozygous for the SNV) or 
cause individuals heterozygous for the SNV to appear homozygous (due to 
the primer binding to one allele but not the other).  
Primers were designed manually (following the same criteria) if Primer3 failed 
to design appropriate primers, if primers designed using Primer3 failed the 
validation process, or if primers needed designing in a specific location (for 
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example, internal sequencing primers for FUT3, FUT5 and FUT6 were 
designed at positions where all three genes were homologous).  
2.2.1.5.2 Primers for site directed mutagenesis 
Primers were designed for each specific mutagenic reaction using the 
provided tool at www.aglient.com/genomics/qcpd (accessed March 2013) 
according to the manufacturer’s specifications: the desired change in the 
middle of the primer, primer size between 25-45 bp, melting temperature ≥ 
78°C, GC content between 40-60% and the primers ending with C or G 
nucleotide.  
For each mutagenesis reaction, primers were diluted to the appropriate 
concentration, equating to 125ng/µ calculated using the following equation 
Required concentration (pmols/µl) = (desired ng X 1000) / (330 X length of 
primers). 
2.2.1.6 Polymerase chain reaction (PCR) 
PCR is a procedure that is used to produce identical and sufficient copies of a 
target DNA sequence to be used for subsequent investigation such as 
sequencing (Mullis 1990). PCR amplification goes through three main steps. 
The first step is denaturation, in which double stranded DNA is denatured 
(always at high temperature, separating double stranded DNA to allow the 
primers to bind). The second step is annealing, where primers attach to 
complementary target DNA. The last step is extension, where nucleotides bind 
next to the annealed primers, forming a complementary DNA strand. 
The annealing temperatures (AT) were originally based on the primer melting 
temperature (TM), calculated using the following formula: 
TM = 69.3 + (GC% X 0.41) – (650 / primer length) 
2.2.1.6.1 Standard PCR 
The standard protocol was used to amplify small sized products (≤800bp). 
PCR amplification was performed using ReddyMix™ (Fisher Scientific UK 
Ltd., Loughborough) following the manufacturer’s guidelines for the 
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preparation: 22.5 μl ReddyMix™ (containing 75mM Tris-HCl (pH 8.8), 20 mM 
(NH4)2SO4, 0.01% Tween® 20, 1.5mM MgCl2 and 0.2mM dNTPs), 1.0 μl 
dH2O, 0.5 μl forward and reverse primers (at 10 pmol/μl) and 0.5 μl DNA (or 
dH2O for a negative control) per 25μl reaction.  
PCR amplifications were electrophoresed on a 96-Well GeneAmp® PCR 
System 9700 (Life Technologies, Warrington, UK), the conditions varying 
depending on the primer, the expected PCR product size and the protocol 
used. Standard PCRs were amplified using the following conditions: 94.0°C 
for 5 min, [94.0°C for 30 sec, X °C (annealing temperature which is primer 
specific) for 30 sec, 72.0°C for 30 sec] for 35 cycles, 72.0°C for 10 min, then 
cooling to 4°C until being removed from the thermocycler. 
2.2.1.6.2 Long-range PCR 
A long range PCR protocol was used to amplify products of larger sizes 
(>800bp) and was performed using OneTaq® Hot Start DNA polymerase (New 
England Biolabs). The manufacturer’s guidelines were followed for the 
preparation: 12.5μl OneTaq® Hot Start Master Mix (containing 20 mM Tris-
HCl (pH8.8), 22 mM KCl, 0.2 mM dNTPs, 1.8 mM MgCl2, 5% glycerol, 0.05% 
Tween®-20, 25 units/ml OneTaq DNA Polymerase, 22 mM NH4Cl, and 0.06% 
IGEPAL® CA-630), 10.5μl dH2O, 0.5μl forward and reverse primers (at 
10pmol/μl), and 1.0μl DNA (or dH2O for a negative control) per 25μl reaction. 
Long range PCRs were amplified using the following conditions: 94.0°C for 30 
sec, [94.0°C for 30 sec, 57.0°C for 45 sec, 68.0°C for 70 sec] for 30 cycles, 
68.0°C for 5 min. 
2.2.1.6.3 High Fidelity PCR 
High Fidelity polymerases were used to amplify products with much more 
amplification (copying) accuracy, specifically when amplified products were to 
be used for cloning purposes. Two high-fidelity polymerases were used during 
this project, KAPA HiFi and Q5 high-fidelity. For both polymerases, the 
manufacturer’s guidelines were used. For KAPPA HiFi, 10µl 5X KAPA HiFi 
Fidelity Buffer, 1.5 µl 10mM KAPA dNTPs Mix, 1.5 µl 10 µM forward primer, 
1.5 µl 10 µM reverse primer, 1.0 µl 100ng DNA in 50 µl reaction made up with 
44 
 
dH2O. For Q5 high-fidelity, 5µl 5X Q5 reaction buffer, 0.5 µl 10mM dNTPs, 
1.25 µl 10mM forward primer, 1.25 µl 10mM reverse primer, 1.0 µl 100ng DNA, 
0.25 µl Q5 high-fidelity DNA polymerase made up to 25 µl with dH2O. PCR 
was performed using the following conditions: KAPA HiFi, 95.0 °C for 3 min, 
[98.0 °C for 20 sec, X°C for 15 sec, 72.0 °C for 40 sec] for 35 cycles, 72.0 °C 
for 1 min; Q5 high-fidelity, 98.0 °C for 30 sec, [98.0 °C for 10 sec, X°C for 30 
sec, 72.0 °C for 30 sec] for 30 cycles, 72.0 °C for 2 min.  
2.2.1.6.4 PCR troubleshooting 
If the initial PCR failed to work, the temperature was adjusted either by 
increasing (to increase specificity) or decreasing (if no products were obtained) 
it slightly. On the other hand, the magnesium concentration in each kit already 
provides the reaction with the required amount of magnesium. However, the 
magnesium concentration can be increased, which in turn increases the 
activity of the polymerase and reduces the specificity for greater chance of 
primer annealing.  
2.2.1.7 Agarose gel electrophoresis 
In order to check whether the PCR amplification had succeeded and that 
products of the expected size had been obtained, agarose gel electrophoresis 
was performed. The idea behind gel electrophoresis is that an electrical charge 
is run through the gel migrating the loaded DNA (which is positively charged) 
from the top (positive charge) to the bottom (negative charge) of the gel. DNA 
with different sizes move at different speeds through the gel pores (i.e. larger 
DNA fragments move more slowly than smaller fragments), resulting in the 
separation of the loaded DNA according to size. 
Different agarose gel concentrations were used depending on the size of the 
PCR product; products ≤700bp were run in 2% w/v agarose gels and products 
>700bp were run in 1% agarose gels. Decreasing the concentration of the 
agarose increased the pore size within the agarose gel allowing larger 
products to migrate faster through the gel. 
Gels were made using 1 or 2g agarose (Bioline) dissolved in 100ml 0.5x Tris-
borate ethylenediaminetetraacetic acid (EDTA) buffer (1X TBE containing: 
45 
 
0.89M Tris, 0.89M Boric Acid and 0.02M EDTA) with a final concentration of 
1mM ethidium bromide (3,8-diamino-5ethyl-6 phenylphennanthridinium 
bromide). Ethidium bromide interacts with DNA and emits orange fluorescence 
that becomes stronger after binding to DNA and makes it visible under UV 
lighting. For each gel, 5μl of sample DNA was loaded in each lane and run 
against a HyperLadderTM size standard (Bioline) added to another lane. Gels 
were run in 0.5x TBE at 80-130V (voltage reduced for smaller sized products 
to allow better separation) for 50 min and visualised using a UV 
transilluminator (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). 
2.2.1.8 Polyacrylamide gel electrophoresis  
Polyacrylamide gel electrophoresis was used to check for small size oligos 
(less than 100bp). 4% Polyacrylamide gel was prepared as follows: 1.88ml 
40% acrylamide/Bis (w/v), 1.50ml 5x TBE and 11.63ml dH2O were mixed. 
Then 150µl 10% ammonium persulfate (APS) and 15µl 
Tetramethylethylenediamine (TEMED) were added to begin polymerisation. 
The gel was immediately poured into a prepared cassette and was left to 
completely solidify for 1h. 5µl sample or DNA ladder was added to each well. 
The gel was run in 0.5x TBE at 200V, 150mA for ~30mins. The gel was gently 
removed and incubated in 100ml 0.5x TBE with 10µl ethidium bromide for 
15min on an orbital shaker at 20rpm before being visualised using a UV 
transilluminator (Bio-Rad). 
2.2.1.9 PCR purification 
PCR purification was performed to remove any unwanted components within 
amplified products which might disrupt downstream applications, for example 
DNA sequencing. The ExoSAP-IT® reagent (GE Healthcare, Little Chalfont, 
UK) was primarily used in this study. ExoSAP-IT® reagent is based on Shrimp 
Alkaline Phosphatase and Endonuclease I; it degrades unused primers 
following PCR and dephosphorylates dNTPs for better and cleaner reading. 
The ExoSAP-IT® purification method was performed using 6μl reagent added 
to 6μl PCR product and incubated at 37.0 °C for 30 min (to activate the 
enzymes), 80.0 °C for 10 min (to degrade the enzymes), and 14.0 °C for 7 
min. 
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Some products were not adequately purified using ExoSAP-IT®, so the 
AMPure XP purification system (Beckman Coulter (UK) Ltd., High Wycombe) 
was used instead (performed by the Core Genetics Facility, Medical School, 
University of Sheffield). This method uses magnetic beads to bind to the DNA 
products, washes are subsequently applied to eliminate any contaminants 
unbound to the magnetic beads resulting in clean DNA products. 
Gel extractions were also used for DNA purification. If there were non-specific 
products and a band(s) of the expected size that needed to be selectively 
extracted or after performing restriction enzyme digestion and unwanted 
digested products needed eliminating, then gel extractions were performed 
using a QIAquick Gel Extraction Kit (QIAGEN Ltd.) following the 
manufacturer’s guidelines. The gel was cut (around the product of interest) 
using a sterile scalpel. It was then weighed and QG buffer was added (to 
dissolve the gel) at a volume equal to 3X the gel weight (in g). The gel was 
then incubated at 50°C until completely dissolved. Isopropanol was added at 
a volume equal to 1X the gel weight and the mixture was transferred to the 
provided QIAquick column. The column was centrifuged at 13000 x g for 1 
min, 500µl QG buffer was added and the column centrifuged again at 13000 x 
g for 1 min. Next, 750µl PE buffer (wash buffer) was added, the column 
centrifuged at 13000 x g for 1 min, the flow through was discarded and another 
minute of centrifugation at the same speed was performed. Finally, the column 
was transferred to a 1.5mL micro-centrifuge tube, 20µl elution buffer (EB) 
buffer was added to the column and incubated at room temperature for 1 min. 
Following incubation, the column was centrifuged at 13000 x g for 1 min to 
elute the sample. 
2.2.1.10 DNA sequencing and analysis 
DNA sequencing was performed by the Core Genetics Facility using the Big 
Dye® Terminator v3.1 cycle sequencing kit (Applied Biosystems). Sequenced 
products were cleaned (i.e. had impurities which could reduce the sequencing 
quality removed) using the Agencourt® CleanSEQ kit (Beckman Coulter) and 
run on an ABI 3730 DNA analyzer (Life Technologies). The principle of 
sequencing is that DNA denaturation occurs at high temperature where the 
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double-stranded DNA is separated. Following that, annealing of a primer takes 
place and nucleotides (labelled with different fluorescent dyes) bind according 
to the sequence; when a nucleotide is attached it releases a signal (pre-
attached dye) that is then detected and the assigned nucleotide is reported. 
Generated sequence data was analysed using the Staden package v4.8b1 
(Bonfield, et al 1998), which allows generated sequences to be compared 
directly against a known reference sequence allowing identification of variants 
(Section 2.2.1.1). 
Following mutagenesis, the sequence data provided in FASTA format was 
compared to the reference sequence (VWF Gene ID: ENSG00000110799) 
using the NCBI BLAST tool to check for the presence of the desired change. 
In addition, the rest of the VWF cDNA was also checked for the presence of 
any additional changes that might have accidently been created during the 
mutagenesis process. 
2.2.1.11 Genotyping 
2.2.1.11.1 TaqMan genotyping 
TaqMan® analysis uses quantitative real-time PCR (qRT-PCR) to investigate 
the presence of a specific nucleotide allele using a pair of fluorescently tagged 
probes each specific for a different allele. When either probe attaches to the 
target DNA, amplification releases a specific fluorescent dye (for that specific 
allele) which is then detected (Figure 2-1). In this study, TaqMan® was used 
to analyse two SNVs in FUT6 (c.370C>T and c.977G>A) and was performed 
by the Core Genetics Facility using an Applied Biosystems® 7900HT Fast 
Real-Time PCR System (Life Technologies).  
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Figure 2-1: Principle of the TaqMan® genotyping method.  Primers and 
specific probes first attach to the target DNA (A). When amplification takes 
place, allele identification occurs after the dye is released (B). Each dye is 
specific for one allele, thus, depending on the released dye(s), the related 
allele is called. F= FAM dye while V=VIC dye. 
 
  
A 
 
 
 
B 
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2.2.1.11.2 VNTR genotyping  
VNTR genotyping was performed to accurately measure the size of amplified 
PCR products. Fluorescently labelled primers were used to amplify the region 
of interest (and 15bp of flanking DNA sequence) and PCR products were run 
on an ABI 3730 DNA Analyzer (Life Technologies; performed by the Core 
Genetics Facility). PCR products were run against a GeneScan™ 1200 LIZ® 
size standard (Life Technologies) and size analysis was performed using Peak 
Scanner™ software v1.0 (Life Technologies) (Figure 2-2). 
 
 
Figure 2-2: Principle of the VNTR Genotyping method.  Amplification of the 
target DNA is performed using a fluorescently (6-JOE, SE (6-Carboxy-4',5'-
Dichloro-2',7'-Dimethoxyfluorescein, Succinimidyl Ester) tagged forward 
primer (A). This generates a fluorescently tagged PCR product (B). The size 
of the PCR product(s) indicates the genotype, for example an individual 
homozygous for 6 repeats, (C) or an individual heterozygous for 6 and 7 
repeats (D).  
  
A                                                          B 
C                                                                  D 
50 
 
2.2.2 In vitro analysis 
In order to validate the findings obtained using in silico analysis and 
genotyping, further experiments were performed in vitro using HEK293T cells. 
2.2.2.1 Tissue culture 
HEK293T cells were grown in Dulbecco's modified Eagle's medium (DMEM 
supplemented with GlutaMAXTM) (Life Technologies) to which 10% v/v foetal 
bovine serum (FBS) (Life Technologies) was added. GlutaMAXTM (Life 
Technologies) helps increase the stability of the media, increase cell growth 
performance and reduce ammonia toxicity. All tissue culture work was 
performed in a sterile tissue culture hood and all reagents used were pre-
warmed to 37°C. 
2.2.2.1.1 Cell thawing 
Thawing refers to removing stored cells from liquid nitrogen and initiating their 
growth. Removed cells were defrosted using a 37°C pre-heated water bath 
until the storage media was 90% defrosted to avoid over heating the cells. The 
stored cells were then mixed with 5ml media and centrifuged at 1500 x g for 5 
min. The media was then discarded and the cell pellet re-suspended in 13ml 
fresh media and incubated in a T75 flask at 37°C and 5% CO2 in a humidified 
environment until 80-90% confluent. 
2.2.2.1.2 Cell passaging (splitting) 
When cells reached 80-90% confluence, they became ready for passaging. 
Although the colour of the culture media could be used as an indication on the 
readiness of the cells for passaging (fresh media was red in colour and began 
turning yellow when cells started to become confluent, resulting from a change 
in pH), a microscope was also used to check the confluence of the cells and 
percentage confluence was recorded depending on the percentage of area 
covered with cells. A rapid (1 day) change in colour from red to yellow was 
also used as an indication of infection and if this occurred the cells were 
investigated under the microscope and disposed of if contamination observed. 
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Once cells were ready for passaging, the media was discarded and the cells 
washed with 7ml phosphate-buffered saline (PBS) (Life Technologies) to 
remove any leftover media and dead cells. 2ml 1X trypsin prepared by adding 
10ml 5X trypsin to 40ml Dulbecco's PBS (DPBS, Life technologies) was then 
added to detach the cells from the flask. The cells were incubated for 3 min 
followed by addition of 7ml media (to inhibit the trypsin activity) and centrifuged 
at 1500 x g for 5 min. The media was then discarded and the cell pellet re-
suspended in 5ml fresh media. Depending on the pellet size 300-500µl of cell 
suspension was then added to a new T75 flask with 13ml fresh media. 
2.2.2.1.3 Cell counting  
Cells were counted when a specific number of cells was required to perform a 
specific downstream experiment. The protocol for cell passaging was followed 
until the cell suspension was prepared. At this stage 20µl of cell suspension 
was then added to a counting chamber (AC6000 Modified Fuchs Rosenthal 
haemocytometer, Hawksley, Sussex, UK), after which the cells were then 
counted in four 4X4 small squares under a microscope at 10X magnification 
(Figure 2-3). The total number of cells was then divided by 4 to obtain the 
average number of cells which was then multiplied by 10 to get the number of 
cells per 1µl (as each square contained ~0.1µl media). 
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Figure 2-3: Cell counting method.  Four 4X4 squares were counted 
(orange boundary) and the results divided by four to obtain the average cells 
per square which was then multiplied by 10 to indicate the total cells in 1 µl of 
cell suspension.   
Cover slip 
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2.2.2.1.4 Freezing of cells 
Cells were frozen down at early passages (2nd to 3rd passage) and stored in a 
-80°C freezer (for up to one year) or liquid nitrogen (for long term storage). 
Freezing was performed by mixing 1X106 cells with 1ml of freezing media 
(70% DMEM, 20% FBS and 10% dimethyl sulfoxide (DMSO) v/v). 
2.2.2.2 DNA preparation 
2.2.2.2.1 Site-directed mutagenesis 
Mutagenesis was performed on the VWF plasmid to study the effect of 
different genetic changes on VWF expression using a QuikChange® Lightning 
site-directed mutagenesis kit (Agilent Technologies).  
Mutagenesis was performed in 50µl reactions which included 5µl reaction 
buffer, 125ng each primer, 1µl dNTP mix, 1.5µl Quick solution reagent, 
100ng/µl plasmid (WT VWF expression plasmid), and 1µl QuickChange 
lightening enzyme. Finally, dH2O was added to bring the reaction mix to 50µl. 
Reactions were run on a thermal-cycler using the following settings: 95°C for 
2 min, [95°C for 20 sec, 60°C for 10 sec, 68°C for 7 min and 30 sec] for 18 
cycles, 68°C for 5 min. Next, the reaction was treated with 2µl DpnI restriction 
enzyme and incubated at 37°C for 15 min to digest the original (methylated) 
plasmid. The product was then used to transform a competent E.coli.   
2.2.2.2.2 Transformation 
Transformation refers to insertion of plasmid DNA of interest into competent 
E.coli cells which in turn divide to further produce a large number of copies of 
the inserted plasmid. Two different competent strains were used in this project, 
NM554 (previously prepared, section 2.2.2.1.7) and XL-10 gold 
ultracompetent cells (provided with the mutagenesis kit). The DpnI treated 
mutagenesis product was transformed alongside dH2O (to check for possible 
contamination) and previously prepared wild-type plasmid DNA, which was 
used as a positive control. Slightly different transformation protocols were used 
for each of the two competent strains. 
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In the case of XL-10 gold ultracompetent cells, the cells were gently defrosted 
on ice and 45µl were transferred to a 14-ml BD Falcon polypropylene round-
bottom tube to which 2µl ẞ-mecraptoethanol (ẞ-ME) was added to increase 
the transformation efficiency. 9µl of DpnI treated product was then added to 
the cells and mixed well, and the whole mixture incubated on ice for 15 min. 
Following incubation, heat shock at 42°C for 45 sec was carried out and then 
the mixture was transferred to ice and incubated for a further 5 min. 250µl 
preheated (at 42°C) NZY broth was then added and the whole mixture 
incubated at 37°C for 45min on an orbital shaker. Finally, the whole mixture 
was plated on a prepared agar plate with 0.1% ampicillin (1M sodium 
bicarbonate and 1.2M of ampicillin trihydrate (Sigma)) and incubated overnight 
at 37°C. Ampicillin is a selective reagent, which means it eliminates 
contamination and prevents the growth of competent cells without the plasmid 
of interest because the plasmid contains an ampicillin resistance gene.    
Using NM554 competent cells required some alteration to the XL-10 protocol. 
90µl of gently defrosted cells were transferred to a 14-ml BD Falcon 
polypropylene round-bottom tube (no ẞ-ME was added). 14µl of DpnI treated 
product was then added and heat shock performed at 42°C for 90 sec. 150µl 
preheated (at 42°C) LB broth was added per reaction. The mixture was then 
plated as described above. 
The next day, the plates were checked for availability of colonies, if colonies 
were available the plates were moved to the fridge to stop further colony 
growth, whilist, if no colonies were available, the plates were incubated for an 
additional 6 h. 
2.2.2.2.3 Preparation of competent E.coli NM554 cells  
Competent E.coli are bacterial cells that can incorporate foreign DNA after 
treatment of their cell membrane, allowing DNA to pass through. A scraping of 
previously prepared NM554 glycerol stock was grown in 10ml LB broth 
overnight at 37°C in an orbital shaker. The culture was then transferred to 
500ml LB broth and grown for an additional 2 h at 37°C in the orbital shaker. 
The culture optical density (OD) was measured using a Biophotometer 
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spectrophotometer (Eppendorf UK Ltd., Stevenage) at 600nm. The culture 
was used when an OD between 0.2-0.4 was achieved, indicating that the cells 
were in log phase. The culture was then centrifuged at 6400 x g for 7 min and 
the LB broth discarded, after which the cell pellet was re-suspended in 40ml 
transformation buffer (prepared using 15% glycerol, 10mM PIPES (piperazine-
N,N′-bis 2-ethanesulfonic acid) and 50mM CaCl2 w/v). The mixture was then 
incubated on ice for 20 min followed by centrifuging at 6400 x g for 7 min. The 
cell pellet was then re-suspended in 25ml transformation buffer. Aliquots of 
300µl were prepared and stored at -80°C. To assess the competent cells, 
negative control (dH2O only to check for possible contamination) and positive 
control (VWF WT expression plasmid to test that competent cells were working 
as intended) transformations were performed and colony growth was 
observed. 
2.2.2.2.4  Bacterial plasmid miniprep 
Bacterial miniprep was performed to extract plasmid DNA from the grown 
competent cells. It was used to extract a low yield of transformed plasmid for 
further testing before performing bacterial maxiprep which is intended to 
produce a much higher yield. 
Bacterial colonies were inoculated overnight in 8ml LB broth with 0.1% 
ampicillin at 37°C on an orbital shaker. 2ml was used to prepare a glycerol 
stock (Section 2.2.2.1.9) and the rest used for DNA extraction utilising the 
QIAprep Spin mini-prep kit (QIAGEN Ltd.) following the manufacturer’s 
guidelines as follows. Cultured broth was centrifuged at 5000 x g for 5 min, 
then the broth was discarded and the pellet was suspended in 250µl buffer P1 
(re-suspension buffer). 250µl buffer P2 (lysis buffer) to lyse the cells was 
added and the mixture was incubated for 5 min at room temperature. Stopping 
the lysis reaction was performed by adding 350µl N3 buffer. Following that, 
the mixture was centrifuged at 13000 x g for 10 min to precipitate the cell 
contents. The supernatant was then transferred to the provided filter and 
centrifuged at 13000 x g for 1 min to allow the DNA to bind to the filter. After 
that, washing the cell residue was performed using 750µl PE buffer (washing 
buffer) and centrifuged at 13000 x g for 1 min. 30-50µl (depending on the cell 
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pellet size) EB buffer (elution buffer) was added to the filter and incubated at 
room temperature for 1 min and then centrifuged at 13000 x g for 1 min. The 
DNA concentration was then measured (Section 2.2.2.1.10). 
2.2.2.2.5  Glycerol stock 
The purpose of making a glycerol stock was to create a stock of transformed 
E.coli for long-term storage at -80°C. It was performed by centrifuging 2ml pre-
inoculated LB broth at 5000 x g for 5 min, discarding 1ml and re-suspending 
the pellet in the remaining 1ml LB broth to concentrate the bacterial stock. 
Following that, 300µl 10% glycerol was added. Glycerol is a cryoprotectant 
substance which protects the cells from freezing damage. 
2.2.2.2.6  DNA concentration 
DNA concentration was measured using a NanoDrop® ND-1000 (Thermo 
Fisher Scientific, Inc., Wilmington MA, USA) at an absorbance of 260nm. 1µl 
of dH2O or EB was used as a blank, depending on the solution in which the 
plasmid DNA had been re-suspended. Following that, 1µl of each sample was 
used to measure the concentration (ensuring no air bubbles were present and 
that the DNA was well mixed for accurate measurement). The mean of three 
measurements was used. The quality of the DNA was also checked using the 
given ratio of A260/A280, with results from 1.8-2.3 considered of good quality, 
while higher or lower values would indicate protein contamination. In addition, 
the ratio of A260/A230 was also checked, with a ratio >2 considered of good 
quality; whereas <2 indicated the presence of contaminating salt impurities. 
2.2.2.2.7  Bacterial plasmid maxiprep 
A scraping of prepared -80°C glycerol stock was taken and incubated in 250ml 
freshly prepared LB broth with 0.1% ampicillin overnight at 37°C on the orbital 
shaker. The broth was then transferred to a clean 250ml Beckman tube and 
centrifuged at 6000 x g for 15 min at 4°C. The broth was discarded and the 
pellet re-suspended in 10ml buffer P1 (re-suspension buffer) followed by the 
addition of 10ml buffer P2 (lysis buffer) and incubation for 5 min at room 
temperature. Next, 15ml buffer P3 (neutralising buffer) was added to stop the 
lysis process. The mixture was poured into a capped cartridge and incubated 
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for 5 min at room temperature to allow the solid cell contents to separate from 
the liquid part containing the DNA. At this point 10ml QBT equilibration buffer 
(which enhances the DNA binding activity of the filter) was also added to a 
QIAGEN-tip 500 filter and was allowed to flow through using gravity. The 
cartridge was then uncapped and the solution was forced through the cartridge 
into the pre-equilibrated filter and allowed to flow through using gravity. The 
filter was then washed twice using 30ml of QC washing buffer (which cleans 
cell residue from the filter). 10ml QF elution buffer was then added to the filter 
and allowed to flow through using gravity into a clean 40ml Beckman tube. 
10.5ml isopropanol was then added (to precipitate the DNA) and the mixture 
centrifuged at 15000 x g for 30 min at 4°C. Following that, the solution was 
discarded carefully and the DNA pellet washed using 5ml 70% ethanol. The 
solution was centrifuged at 15000 x g for 15 min at 4°C. The supernatant was 
discarded carefully and the tube was air-dried at room temperature for 10 min. 
Finally, the DNA pellet was re-suspended using 300-500µl of dH2O depending 
on the pellet size. The DNA was stored at -20°C. 
2.2.2.3 Protein and mRNA quantification 
2.2.2.3.1 Transfections  
The aim of transfection is to get the required plasmid into the nucleus of the 
cell to be expressed in order to study the product. There are two types of 
transfections which are transient and stable transfection. Transient 
transfection is used for short term study where the plasmid DNA does not 
integrate with the host cell DNA, while stable transfection is used for long term 
study and the plasmid DNA integrates with the host cell DNA; transient 
transfection was used in this study. Transfection was used in this project to 
express VWF in HEK293T cells and study the effect of different variants on 
protein expression, and RNA expression and half-life.  
Before proceeding with transfection, 250,000 HEK293T cells were seeded into 
each well of a 6-well plate (Section 2.2.2.1.2). The seeded cells were 
incubated for 24 h prior to transfection to allow the cells to attach to the plate 
surface. Following that, transient transfection was carried out using 
transfection reagent Xfect (Takara Clontech, Saint-Germain-en-Laye France) 
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as follows. Per well, a mixture of 100µl Xfect buffer, 2.5µg expression plasmid 
DNA, 1.0µg Renilla plasmid and 1.1µl Xfect was prepared, mixed well and 
incubated at room temperature for 10 min. Then the mixture was added to 
each well and incubated for 24 h. Following that, the media was discarded and 
2ml fresh media was added (due to the toxicity of the transfection reagent) to 
each well and the plate was incubated for an additional 48 h before harvesting.  
For each variant expressing plasmid, three transfection experiments were 
performed independently each of which was carried out using three wells using 
either 100% WT VWF expression plasmid (to mimic homozygous WT state), 
100% mutant (variant of interest expressing plasmid to mimic homozygous 
mutant state) and 50:50 co-transfection of WT and mutant plasmids (to mimic 
the heterozygous state of that variant). 
After final incubation, harvesting took place in the exact same way regardless 
of transfection reagent used as follows: the culture media was collected in 
separate clean tubes and the wells washed using 400µl PBS. Following that, 
300µl of 1X passive lysis buffer (Promega) was added to the wells (to lyse the 
cells and extract VWF from inside the cells) and the plate incubated at room 
temperature for 10 min at 60 rpm. The media and cell lysate were then stored 
at -20°C until needed.  
Transfection for mRNA quantification was conducted using Xfect as follows. 
250,000 HEK293T cells were seeded as per Section 2.2.2.1.2 in 6-well plates 
and incubated for 24 h. Following that, a mixture of 100µl Xfect buffer, 0.9µl 
Xfect and 2.5µg DNA was incubated at room temperature for 10 min followed 
by the addition of the mixture to each well. The wells were incubated for 24 h 
post transfection. Following that, media was discarded, wells were washed 
with 0.5X PBS followed by the addition of 300µl trypsin and incubation of 5 min 
at room temperature was carried out. Next, 1ml of fresh media was added and 
the mixture was transferred to a 1.5ml Eppendorf tube. The tubes were 
centrifuged at 4000 x g for 5 min, the media was discarded and the cell pellet 
was used for RNA extraction. The experiment was repeated three independent 
times. 
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2.2.2.3.2 Protein quantification 
2.2.2.3.2.1 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a technique used to measure protein level by comparing against a 
standard curve of the protein of interest at known concentrations. Several 
different ELISA methods are available, however, in this project, the sandwich 
based ELISA method was used. It uses a primary antibody that binds to the 
surface of the well, followed by the addition of the sample where the target 
protein binds to the primary antibody. Next, a secondary antibody is added 
which binds to the protein that is bound to the primary antibody, substrate is 
then added which can be detected and quantified (Figure 2-4). 
 
 
 
Substrate 
Secondary antibody 
Target protein 
Primary antibody 
Well 
 
Figure 2-4: ELISA sandwich assay system. 
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For measurement of VWF, the antibodies (obtained from Enzyme Research) 
were used to perform ELISA according to the manufacturer’s guidelines. The 
primary (capture) antibody was diluted in coating buffer (50 mM carbonate 
coating buffer, pH 9.6) 1 in 100 and 100µl added to each well and incubated 
overnight at 4°C to allow it to bind to the 96-well (flat bottom) plate. The 
antibody was discarded and 150µl blocking buffer (PBS-BSA, 1% w/v, pH7.4) 
added and incubated for 1 h at room temperature to block unbound areas and 
prevent further non-specific binding. Following that, the wells were washed 
twice using 100µl washing buffer (PBS-Tween, 0.1% v/v) to remove any 
unbound antibodies. 100µl of collected cell lysate or supernatant was then 
added and incubated for 90 min at room temperature to allow VWF to bind to 
the primary antibody. Two washes were then performed (to remove unbound 
sample) using 100µl washing buffer per well. Next, 100µl of 1/100 secondary 
(detection) antibody in sample diluent (100mM HEPES, 1% w/v BSA, 0.1% v/v 
Tween-20, 100mM NaCl, pH7.2) was added to bind to the bound VWF. Finally, 
two washes were carried out (to remove unbound secondary antibody) 
followed by the addition of 100µl of o-phenylenediamine (OPD) per well 
(prepared with one OPD tablet (Sigma Aldrich, UK) dissolved in 25ml substrate 
(27mM Citric acid, 97mM Na2HPO4, pH5.0), and 50µlH2O2). The plate was 
incubated for 5-10 min to allow the colour to develop. The reaction was 
stopped by adding 50µl of 2.5M sulphuric acid and the plates were then read 
using the Varioskan Flash plate reader at 490nm (Thermo Fisher Scientific). 
The required standard curve was also prepared on the same reaction plate 
using a standard calibrator plasma (Quadratech). Eleven different dilutions (in 
sample diluent) of calibrator plasma were used: 1/10, 1/20, 1/40, 1/80, 1/160, 
1/320, 1/640, 1/1280, 1/2560, 1/5120, 1/10240, with the last well left without 
calibrator. The calculations of the standard curve values were obtained using 
a previously designed Excel sheet (obtained from Nasher Alyami, 
Haemostasis Research Group). 
Optical density (OD) data obtained from the plate reader was converted using 
the VWF standard curve of known concentrations into VWF:Ag levels, using 
GraphPad Prism v5.04 (GraphPad Software Inc., La Jolla, CA, USA).  
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2.2.2.3.2.2 Normalisation and analysis 
Renilla luminescence was measured in cell lysates using the Renilla 
Luciferase Assay System (Promega) according to the manufacturer’s 
guidelines. 1µl 100X Renilla assay substrate was diluted in 100µl Renilla 
assay buffer and added to 20 µl cell lysate. The 94 well plates were read 
immediately at 480nm.   
Following that, the analysis was performed by normalising ELISA values using 
the Renilla readings to obtain a more accurate measurement of VWF 
concentration using Excel software. The final values of 100% mutant and 
50:50 co-transfections were then compared to WT transfections (considered 
as 100%) to measure the effect of VWF mutations on VWF:Ag levels. 
2.2.2.3.3 mRNA Quantification and mRNA half-life 
Measurement of mRNA levels was carried out in this project to assess the 
effect of different genetic changes on RNA expression level.  
2.2.2.3.3.1 RNA extraction 
RNA extraction was performed using an EZ-RNA total RNA isolation kit 
(Geneflow Ltd., Lichfield, UK) following the manufacturer’s guidelines. 
Previously prepared cell pellets were re-suspended in 500µl reagent A (re-
suspension buffer) and incubated at room temperature for 5 min. Following 
that, 500µl reagent B (extraction buffer to break down the cells and extract the 
RNA) was added and incubated at room temperature for 10 min. The mixture 
was then centrifuged at 12000 x g for 15 min. The top clear layer of the 
resulting supernatant (which contains the RNA) was transferred to a new tube 
and the pink layer (which contains cell debris) was discarded. 500µl 
isopropanol was then added (to precipitate the RNA) and incubated at room 
temperature for 10 min followed by centrifuging the mixture at 12000 x g for 8 
min. The mixture was then stored at -20°C overnight to increase the yield of 
the RNA. Next, the mixture was centrifuged again at 12000 x g for 8 min and 
the supernatant discarded. The RNA pellet was washed using 1ml 75% 
ethanol and centrifuged at 13000 x g for 15 min. The supernatant was then 
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discarded and the pellet air dried at room temperature for 5 min. Finally, the 
pellet was re-suspended in 30-50µl 0.1% diethylpyrocarbonate (DEPC) –
treated water (RNAse free water) and stored at -20°C. 
2.2.2.3.3.2  Reverse transcription 
Reverse transcription was carried out to produce the complementary DNA 
(cDNA) required for quantification using quantitative real time polymerase 
chain reaction (qRT-PCR). A QuantiTect Reverse Transcription Kit (QIAGEN) 
was used for this purpose following the manufacturer’s guidelines. 1µg RNA 
was dissolved in 10µl sterile dH2O followed by the addition of 2µl genomic 
DNA wipe-out solution. The mixture was then incubated at 42°C for 10 min 
before being transferred to ice. Following that, 1µl reverse transcriptase, 1µl 
provided primer mix and 4µl reverse transcription buffer were added and the 
whole mixture incubated at 42°C for 30 min and then at 95°C for 3 min to de-
activate the enzyme. Finally, the cDNA was stored at -20°C. The experiment 
was performed on ice due to the sensitivity of RNA to heat and using a sterile 
environment to avoid any possible DNA contamination.  
2.2.2.3.3.3  qRT-PCR 
qRT-PCR was performed to quantify the RNA in a given sample following its 
conversion into cDNA. This procedure uses a probe (with fluorescent dye) 
made specifically for the specific target sequence in addition to forward and 
reverse primers covering the region where the probe is expected to bind. The 
primers are prepared to bind to exon-exon boundaries to avoid binding and 
detecting DNA. Each cycle starts with cDNA denaturation, followed by 
annealing of primers and probe, amplification and finally detection. Following 
each cycle, after the amplification takes place any dye released is detected, 
measured and reported at the end of each cycle. A relative quantification 
method was used to measure the RNA level. This method relies on comparing 
the measurement of the gene of interest in relation to the level of an 
endogenous control. 
TaqMan® Gene Expression Master Mix was used following the manufacturer’s 
guidelines. Duplex qRT-PCR was used which measures the target (VWF; 
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assay ID Hs01109446_m1) and endogenous control (Beta-2 microglobulin 
(B2M); assay ID Hs00984230_m1) in the same well. This had the benefit of 
reducing the variation between VWF and B2M readings compared to taking 
readings in two separate wells (Livak and Schmittgen 2001).  
100ng cDNA, 1µl VWF probe, 1µl B2M probe and 16µl master mix were mixed 
and added per sample per well in a 384-well plate. The plate was centrifuged 
at 2000 x g for 1 min to eliminate air bubbles and analysed on an Applied 
Biosystems 7900HT Fast Real-Time PCR System (Life Technologies) using 
the following conditions. 2 min at 50°C, initial denaturing for 10 min at 95°C 
followed by 50 cycles of denaturing for 15 sec at 95°C and extension for 1 min 
at 60°C.  
After completion of the analysis, ∆∆ cycle threshold (CT), which is the 
difference of expression between two genes, was measured (by deducting the 
values of the endogenous control (i.e. B2M) from the values of the target (i.e. 
VWF)) (Livak and Schmittgen 2001). The final value was taken as an indication 
of VWF RNA quantity. 
2.2.2.3.3.4  Measurement of mRNA half-life 
The purpose of measuring mRNA half-life was to test the effect of different 
variants on mRNA stability. mRNA half-life was measured using the same 
qRT-PCR protocol (Section 2.2.2.1.12.3) except that 24 h after transfection, 
the cells were treated with 5µg/ml actinomycin D (Life Technologies), which is 
a drug that inhibits the transcription process (through binding to DNA at the 
transcription initiation complex and preventing RNA formation), thus inhibiting 
the production of more mRNA. Cells were harvested at 0, 2, 3 and 4 h post-
treatment and half-life was calculated as the period of time in which mRNA 
level was 50% of the original level detected at 0 h post treatment (Leclerc, et 
al 2002). 
2.2.2.4 RNA splicing assays 
2.2.2.4.1 Exon splice enhancer (ESE) assay  
An ESE assay was used to investigate the effect of given SNV on exon splice 
enhancers or silencers using a pcDNA-Dup (SF2-ASF3x) plasmid. For splicing 
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to take place, it requires splicing site in addition to splice enhancer sites. 
Therefore, loss of splicing enhancer site(s) or gain of splice silencer site(s) 
could result in reduction of splicing efficiency or even complete loss of splicing. 
The plasmid used has three expressing exons in addition to the backbone 
(Figure 2-5). The middle exon contains ~5 bases on each side that has weak 
splice (donor and acceptor) sites in addition to 30 bases containing the variant 
of interest in the middle, which need to exon splice enhancers for the splicing 
to take place. For each variant examined, there were WT and mutant plasmid 
that only differ in the middle nucleotide (SNV of interest).  
The expressed product of WT and mutant plasmids were compared to check 
whether the reference and non-reference alleles produced different sized 
products, which would lead to the conclusion that the non-reference allele has 
an effect on an ESE. A drawn example of the expected results is shown in 
figure 2-6, which shows results of a complete loss or gain of splicing. However, 
two bands can also be observed instead of just single one which could indicate 
a reduction or increase in splicing efficiency rather than complete gain or loss 
of splicing.  
 
 
Figure 2-5: Diagram of the pcDNA-Dup (SF2-ASF3x) and PET01 
plasmids.  
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Figure 2-6: Sketch diagram illustrating expected results from the 
pcDNA-Dup (SF2-ASF3x) plasmid following transfection. 
  
r 
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2.2.2.4.2 Acceptor / donor motif splicing assay  
Acceptor / donor motif splicing assay uses a predesigned plasmid that aims to 
investigate the effect of a given SNV on splicing using PET01 plasmid. It uses 
a similar plasmid structure to pcDNA-Dup (SF2-ASF3x), however, the 
difference is that the insertion includes the whole exon and 300 bases of the 
flanking intron from each side to have better indication of the effect of SNV in 
reality.  
In this project, it was used to assess the effect of VWF SNV on splicing. WT 
and mutant plasmids were prepared for each SNV. The expected outcome of 
this plasmid is shown in figure 2-7. Given that the whole exon is inserted, the 
outcome may vary depending on the position of the variant. For instance, there 
could be full or partial exon skipping, a full or partial intron included with the 
product or mix of these effects. 
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Figure 2-7: Expected results from the PET01 plasmid following transfection. Expected results could be products containing 
three exons, the middle exon being considered as an intron, an intron being considered as an exon or part of the intron or part of 
the exon only recognised as an exon.  
 
Intron2 
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2.2.2.4.2.1 Plasmid digestion  
In order to allow ligation of the desired DNA sequence the pcDNA-Dup (SF2-
ASF3x) plasmid was digested using EcoRI and BamHI while the pET01 
plasmid was digested using NotI and BamHI (New Englands Biolabs) following 
the manufacturer’s guidelines: 1µg plasmid DNA was digested using 1µl of 
each of the two enzymes and 5µl CutSmart® buffer in a 50µl reaction made 
up with dH2O. The mixture was incubated at 37°C overnight and the enzymes 
were then deactivated at 65°C for 20 min. Following that, the digestion product 
was run on either 1% (PCR products) or 0.5% agarose gel (plasmids) (Section 
2.2.1.7) in order to assess the digestion efficiency and specificity.  
2.2.2.4.2.2 Insertion preparation  
The insertion used for the pET01 plasmid was prepared by amplifying the 
region of interest in VWF using Q5 high fidelity polymerase (New England 
Biolabs). Gel extraction was then performed to eliminate any unwanted 
products (Section 2.2.1.9). Finally, the product was used for the ligation step 
(Section 2.2.2.2.2.3). 
The insert for pcDNA-Dup (SF2-ASF3x) plasmid was a 30 base oligo (where 
the SNV of interest is in the middle). Complementary forward and reverse 
oligos were prepared by Eurofins and then were diluted to 20pmol. 5µl of each 
primer were mixed and annealed by being heated to 95°C in a heat block and 
left to cool down to 30°C. 
2.2.2.4.2.3 Ligation 
Ligation of the plasmid and insert was performed using T4 DNA ligase 
(Promega). Per ligation, 1µl T4 DNA ligase, 1.2µl ligation buffer, 10ng plasmid 
and 100ng PCR product/oligo were mixed and incubated at room temperature 
for 90 min. The enzymes were then deactivated at 70°C for 7 min. The ligated 
product was then transformed in NM554 competent cells (Section 2.2.2.1.6) 
followed by extracting the plasmid DNA using bacterial miniprep (Section 
2.2.2.1.8). The samples were sequenced to check that the correct insertion 
had been obtained (Section 2.2.2.1.10). If the insertion was successfully 
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obtained, mutagenesis was performed (Section 2.2.2.1.5) to obtain the mutant 
plasmid. 
2.2.3 Statistical analysis 
The statistical analyses in this project were performed using GraphPad Prism 
v5.04 (GraphPad Software Inc., La Jolla, CA, USA). The t-test was used to 
compare any two groups (ordinary t-test to compare the mean, while the 
Mann-Whitney test was used to compare median). The One-way ANOVA was 
used to compare any three or more groups (ordinary One-way ANOVA used 
to compare the mean, while Kruskal Wallis test was used to compare the 
median) (Zhang and Zhang 2009). Tests performed on the population 
compared the median because VWF level is not normally distributed in the 
general population while tests performed on in vitro experiments compared the 
mean (Lethagen, et al 2008). A p-value <0.05 was considered significant. 
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3 Chapter three: Investigation of the association of 
polymorphic VWF SNV with VWF level 
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3.1 Background 
Genetic variation within VWF has been associated with VWF plasma level in 
VWD patients as well as in normal individuals. Several genome wide 
association studies have identified variants within VWF and other genes to be 
significantly associated with VWF plasma level (Smith, et al 2010, Zabaneh, 
et al 2011). However, to date, there are very limited studies that have 
investigated the mechanism by which SNV influence VWF plasma level. 
Sequence variants that have been reported by association studies in relation 
with VWF plasma level include c.2365A>G (p.Thr789Ala; rs1063856) and 
c.2385T>C (p.Tyr795=; rs1063857) both of which are located in exon 18 and 
are in perfect LD with each other (Lacquemant, et al 2000, Smith, et al 2010, 
van Schie, et al 2011a, Tang, et al 2015). A recent study assessed the 
association of rare and common VWF variants in African Americans, The study 
identified several variant with significant and independent effect on VWF level 
including p.Thr789Ala (Johnsen, et al 2013) 
The aim of this chapter was to investigate VWF SNV and their association with 
VWF plasma level. Subsequently, the mechanism by which these SNV 
influence VWF level was investigated. It was hypothesised that SNV within 
VWF act as phenotypic modifiers; they may impact VWF level, but to a lesser 
extent than for a pathogenic mutation. 
3.2 In silico analysis of VWF SNV 
Genotyping of SNV across VWF and flanking regions had been conducted 
prior to the start of this project by Dr Christer Halldén (Lund University, 
Sweden). This genotyping study analysed 111 variants in ~1100 HC from the 
MCMDM-1VWD study using Sequenom genotyping (Appendix 1) (Johnsen, et 
al 2013). This data along with previously available phenotypic data including 
VWF:Ag level and ABO blood group (Goodeve, et al 2007) were analysed to 
identify any variants having a significant association with VWF plasma level. 
Eleven SNV (10%) were found to be significantly associated with VWF plasma 
level (Table 3-1). Four of these variants were located within VWF exons, four 
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were located within VWF introns, one was located between VWF and ANO2 
and two were located within ANO2 (3’ of the VWF locus). 
Of the 11 SNV highlighted, c.2385T>C had previously been identified in the 
CHARGE association study to have a significant association with VWF level 
(p=1.7x10-32) (Lacquemant, et al 2000, Smith, et al 2010). Another SNV 
highlighted during analysis of the genotyping data c.2365A>G was found to be 
in very strong LD with c.2385T>C (r=99.1%) and had also been reported in an 
earlier study showing a similar association with a ~12% increase in VWF 
plasma level (Zabaneh, et al 2011). These two variants were also shown to be 
in strong LD using the available HapMap data and were located 20bp apart in 
VWF exon 18 (Figure 3-1). Therefore, further investigation was carried out to 
investigate their association with VWF level. 
An additional two SNV highlighted following analysis of the genotyping data 
rs11063953 (c.7888-2310T>C) and rs10849362 (c.7888-3501A>G) located 
1.5kb apart in VWF intron 47 were both found to be significantly associated 
with ~15% and ~10% reduction in VWF plasma level respectively (with the 
non-reference allele) and were also investigated further for association with 
VWF level. 
Although the remaining SNV showed a significant overall association with 
VWF level, they did not show consistent association with level when 
comparing the levels of reference allele, heterozygous and the non-reference 
allele (i.e. there was no gradual increase or decrease in VWF level between 
the three groups). Thus, these SNV were not further investigated (Table 3-1). 
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Table 3-1: VWF and ANO2 SNV significantly associated with VWF plasma level in HC.  
SNV Nucleotide  
Change 
a.a change Location Association with VWF level (median VWF:Ag; IU/dL) p value1 LD (r2) 
R/R R/NR NR/NR 
rs12580835 c.22+4578A>G  ANO2 intron 1 91 99 95 0.010 99.7% 
rs7310736 c.22+2097G>A  ANO2 intron 1 91 99 95 0.007 
rs1063857 c.2385T>C p.Tyr795= VWF Exon 18 94 95 103 0.002 99.1% 
rs1063856 c.2365A>G p.Thr789Ala VWF Exon 18 94 96 103 0.001 
rs11063951 c.-1342C>G  3’ of VWF 98 94 83.5 0.035 99.5% 
rs11063953 c.7888-2310T>C  VWF Intron 47 98 94 83 0.022 
rs216321 c.2555G>A p.Arg852= VWF Exon 20 97 89 95 0.005 92.8% 
rs216339 c.2443-3627A>G  VWF Intron 18 97 88.5 95 0.007 
rs4764482 c.1533+2387A>G  VWF Intron 13 97 93 98 0.048  
rs10849362 c.7888-3501A>G  VWF Intron 47 98 95 90 0.022  
rs7312411 c.1548T>C p.Tyr516= VWF Exon 14 95 94 101.5 0.041  
*R= reference allele, NR= non-reference allele, LD= linkage disequilibrium, SNV= single nucleotide variant 
1 One-way ANOVA (Kruskal-Wallis test).  
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Figure 3-1: HapMap data of VWF gene.  The LD between variants alleles is shown, in red square is the variant identified by the 
CHARGE study. White squares indicate weak LD, red squares indicate strong LD while Grey boxes indicate a lack of data for any 
given SNV association. 
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3.2.1 In silico analysis of c.7888-3501A>G and c.7888-2310T>C  
Although c.7888-2310T>C and c.7888-3501A>G were significantly associated with 
VWF plasma level, they were not in strong LD with one another (r2= 34%) which 
suggested that they may have an independent effect on VWF plasma level. These two 
variants were analysed using various prediction tools to try and predict their 
mechanism of action. SNV within 3kb of each of the two variants were investigated as 
well to check whether the observed association was because of these two specific 
SNV or other surrounding SNV that were potentially in strong LD with one or both 
variants.  
According to the prediction tools, c.7888-3501A>G seemed to be introducing a new 
donor splice site (by 4 out of 5 tested tools) within intron 47, therefore the observed 
association was potentially due to this variant. However, c.7888-2310T>C was not 
predicted to have any major effect on splicing, ESE motifs, miRNA binding sites or 
transcription factor binding sites (Table 3-2). Therefore, the observed association 
could be due to another variant in strong LD with this variant. However, no other variant 
was found to be in strong LD with c.7888-2310T>C using the available genotyping 
data set, which was missing a large proportion of known VWF variants due to it being 
selective and covering only a small proportion of SNV throughout VWF. Therefore, 
HapMap data was used to test the LD in that region further, however, this variant still 
did not show strong LD with any other variant in that region. This in turn suggested 
that c.7888-2310T>C is either in strong LD with a variant(s) not covered in the HapMap 
data or it has an effect that could not be predicted using the in silico tools. Due to time 
limitations, c.7888-3501A>G and c.7888-2310T>C were excluded from further 
investigation. 
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Table 3-2: In silico analysis of variants surrounding and including c.7888-3501A>G and c.7888-2310T>C. 
 ESE effect Splicing effect Transcription factors    
Variant HSF ESE ESE  
finder** 
HSF splice fruitfly Netgen2 ASSEDA* ASSP* Promo**  MET miRNA** Rs number MAF 
c.7888-17T>C Minor  1 No effect  Loss acceptor  No effect     1 Minor  0 rs12297370 0.02 
c.7888-93G>A Major  0 Minor  No effect No effect     0 No effect 3 rs3759320 0.4181 
c.7888-118C>T Minor  0 No effect  No effect No effect     -3 Minor  1 rs3759321  0.4391 
c.7888-129T>C Major  2 No effect  Minor  No effect     0 Minor 0 rs12297442  0.2234 
c.7888-382G>A Minor  1 Minor  No effect No effect minor  0 Minor  0 rs12317523 0.26 
c.7888-405G>T Major  1 Major  New acceptor  No effect   0 Major  0 rs7969672  0.2398 
c.7888-669T>G Major  1 Major  No effect New acceptor  0 Minor  -1 rs10774387   0.2424 
c.7888-1016_7888-
1015insT 
Minor 0 Major  Minor  No effect NA  0 Major  0 rs143246250 0.0339 
c.7888-1145C>T Major  2 Minor  Minor  No effect minor  0 Major  1 rs723188   0.2762 
c.7888-1199G>A Major  2 Major  No effect No effect No effect  1 Minor  0 rs723189   0.3808 
c.7888-1214A>G Major  0 Major  No effect No effect No effect  0 Minor  -1 rs723190 0.0785 
c.7888-134T>C Major  0 Major  No effect No effect     0 Major  1  rs57040304 0.0984 
c.7888-1421_7888-
1420insTG 
Major  1 Major  No effect No effect   0 No effect 0 rs145581063  0.0337 
c.7888-1514_7888-
1513insT 
Major  0 Major  No effect No effect   0 Minor  0 rs140939660  0.0781 
c.7888-1603C>T Major 1 No effect  No effect No effect   0 Minor  0 rs114446920 0.0785 
c.7888-1626A>G Major  0 No effect No effect No effect   0 Minor  0 rs10849360   0.4111 
c.7888-1654C>T Minor  0 Minor  No effect No effect   0 Minor  -1 rs78329863  0.1667 
c.7888-1686C>T Major  2 No effect No effect No effect   0 Major  0  rs12305676  0.2821 
c.7888-1789G>T Major  1 Major  No effect No effect   0 Minor  -3 rs12319598 0.2821 
c.7888-184G>C Major  0 Major  No effect No effect     0 No effect 0 rs115804723 0.0218 
c.7888-1932C>T Minor  1 No effect  No effect No effect   0 No effect 0 rs12819922   0.2173 
c.7888-223A>T Major  1 Major  New acceptor  No effect     -2 Minor  0 rs7958883  0.381 
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 ESE effect Splicing effect Transcription factors    
Variant HSF ESE ESE  
finder** 
HSF splice fruitfly Netgen2 ASSEDA* ASSP* Promo**  MET miRNA** Rs number MAF 
             
c.7888-2310T>C Major  1 No effect  No effect New donor Minor   0 Major  0 rs11063953 0.22 
c.7888-2564C>T Major 1 No effect  No effect No effect Minor   0 Minor 0 rs10774388 0.2033 
c.7888-2856C>T Major 2 No effect No effect No effect Minor   0 Minor  0 rs117889430 0.013 
c.7888-2991A>G minor -1 No effect No effect No effect     -1 Major  0 rs10849361 0.2039 
c.7888-3047delC Major  0 Major  Stronger new 
acceptor 
No effect     1 Minor  -1 rs199571870 NA 
c.7888-3124T>G Major  0 No effect No effect No effect     -1 Minor  -1 rs115726920 0.0196 
c.7888-3274A>C Minor 1 No effect No effect No effect     0 Minor  0 rs76879130  0.0146 
c.7888-3372T>C Minor  1 No effect  No effect No effect     0 Minor  -1 rs78818158 0.0793 
c.7888-3501A>G Minor 1 Major  
New donor 
Strong New 
donor  
No effect New 
donor 
New 
donor 
0 Minor  0 rs10849362  0.4213 
c.7888-3597T>C Minor  1 No effect  No effect No effect     0 No 0 rs10849363 0.4996 
c.7888-3779T>C Major  2 No effect  No effect No effect     -2 Major  7 rs78245005 0.0793 
*Websites that give limited access, empty boxes refer to unanalysed variants. ** + refers to the introduction of a new site while – 
refers to the loss of a previous site. 
 
78 
 
3.2.2 In silico analysis of c.2385T>C and c.2365A>G 
Given the strong LD and close proximity of c.2385T>C and c.2365A>G, the 
observed association with VWF level could theoretically be due to just one of 
the two variants or a combined effect of the two variants together.  
Before proceeding with in vitro experiments, the effect of the two variants was 
tested using various prediction tools. They were tested for any effect on protein 
or mRNA structure, function or splicing. Apart from SNV c.2385T>C showing 
a minor effect on ESE motifs and SNV c.2365A>G predicted to be damaging 
to VWF (using Align GVGD; Table 3-3), neither of these two variants were 
predicted to have any major effect.  
Codon usage, which compares the abundance of different codons that encode 
the same a.a within the human genome or a given gene, was also investigated 
for the silent variant c.2385T>C. This showed that the non-reference codon 
was more abundant compared to the reference codon within the human 
genome as well as within VWF (Table 3-4) suggesting that the more non-
reference allele could result in a faster translation rate, due to its abundance, 
and thus a higher VWF level. 
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Table 3-3: Predicted effect of c.2385T>C and c.2365A>G on the VWF 
protein and VWF RNA. 
SNV 
VWF protein VWF RNA 
Align 
GVGD 
SIFT PolyPhen 
HSF 
Splicing 
NetGen2 Fruitfly 
ESE 
Finder 
c.2365A>G 
Most 
likely 
damaging 
Benign Benign Benign Benign Benign 
No 
effect 
 
c.2385T>C NA* NA NA Benign Benign Benign 
Minor 
effect 
* NA: not analysed; prediction tools were not able to analyse synonymous 
changes. 
 
Table 3-4: Tyrosine codon usage statistics.  
Genome Codon Codon /1000 
Human 
genome 
TAT 12.2 
TAC 15.3 
VWF 
TAT 9.8 
TAC 17.3 
* The values represent the number of codons present per 1000 codons. 
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3.3 Association of c.2385T>C and c.2365A>G with VWF level in the HC 
population 
The two SNV were previously associated with VWF level, further analysis of 
association was carried out specifically in a European healthy control (HC) 
population to further confirm the observed association. The association of the 
two variants with VWF plasma level was analysed in 1035 HC from the 
MCMDM-1VWD study. Individuals with the non-reference alleles for both SNV 
were found to have significantly higher levels of plasma VWF by ~9% when 
compared to individuals with the reference allele (Figure 3-2).  
 
 
Figure 3-2: Association of c.2385T>C and c.2365A>G with VWF plasma 
level in 1035 HC.  Significant differences were observed for c.2385T>C 
(p=0.003) and c.2365A>G (p=0.002) using the One-way ANOVA (Kruskal-
Wallis test). The t-test (Mann-Whitney test) was used to compare genotypes 
(**≤0.005, ***≤0.0005). Bars indicate standard error. 
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3.4 Association of c.2385T>C and c.2365A>G with FVIII:C level in the 
HC population 
These two SNV also showed significant association with FVIII:C level similar 
to that observed with VWF plasma level when examined in the 1030 HC. 
These two SNV are significantly associated with ~9% higher level of FVIII:C in 
the normal population (Figure 3-3).  
 
Figure 3-3: Association of c.2385T>C and c.2365A>G with FVIII:C 
plasma level in 1030 HC.  Significant differences were observed for 
c.2385T>C (p=0.007) and c.2365A>G (p=0.005) using the One-way ANOVA 
(Kruskal-Wallis test). The t-test (Mann-Whitney test) was used to compare 
genotypes (**≤0.005, ***≤0.0005). Bars indicate standard error. 
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3.5 In vitro study of the effect of c.2385T>C and c.2365A>G 
In order to investigate the mechanism by which c.2385T>C and c.2365A>G 
were influencing VWF level, in vitro studies were conducted on expressed 
VWF mRNA and protein. The independent effect of these SNV on VWF 
expression was investigated as well as their combined effect to determine 
whether one or both SNV were associated with VWF level.  
3.5.1  Protein quantification 
1.1.1.1 Transfection optimisation 
The initial optimisation of transfection was performed within this research 
group previously (Ashley Cartwright, previous PhD student). However, some 
of the generated results showed wide variation. This led to the investigation of 
possible ways of improving the transfection protocol.  
After experimenting with the protocol, no differences in renilla reading (used 
to normalise for transfection efficiency) were observed between empty wells 
and wells containing samples (Figure 3-4) suggesting that the sample plate 
and/or the renilla assay kit used were not appropriate. After reviewing the 
literature, neither were found to be appropriate. Previously used full white 
plates were replaced with white plates with a clear bottom to allow the plate 
reader to measure the samples. In addition, the assay kit used (Dual-
Luciferase kit) was not the right option as it required measurement of firefly 
luciferase before renilla could be measured. It was replaced with the Renilla 
Luciferase Assay System which measures renilla luciferase only.  
 
 
Figure 3-4: Renilla readings.  Random samples in row A and B and empty 
wells in row C. There were no differences between the values of empty well 
or wells with samples. 
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1.1.1.2  Protein quantification of c.2385T>C and c.2365A>G 
VWF protein level was measured after transfection of 4 different VWF 
expression plasmids (incorporated into pcDNA3.1/Hygro (-)) into a HEK293T 
cell line; wild-type (WT) plasmid, a plasmid containing the c.2385T>C change, 
a plasmid containing c.2365A>G and a plasmid containing both variants. Co-
transfection of renilla was performed which was used for normalisation 
(section 2.2.2.3.1 for transfection and section 2.2.2.3.2 for protein 
quantification). 
Quantification of VWF level was carried out to measure VWF protein in 
HEK293T cells transfected with WT VWF plasmid or VWF plasmid carrying 
the desired change (i.e. c.2385T>C and c.2365A>G). The results indicated 
that the non-reference allele of each SNV was associated with a significantly 
increased level of expression of VWF both within the cell and secreted from 
the cell. The plasmid containing both variants showed an additive increase in 
VWF protein expression (Figure 3-5).  
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Figure 3-5: VWF expression in cell lysate and supernatant for 
c.2385T>C, c.2365A>G and both variants in cis compared to WT and 
heterozygous plasmids.  Significant differences were observed for A) 
c.2385T>C: cell supernatant (p=0.006) and cell lysate (p=0.03), B) 
c.2365A>G: cell supernatant (p=0.0009) and cell lysate (p<0.0001), C) both 
variants: cell supernatant (p=0.03) and cell lysate (p<0.0001) using the 
ordinary One-way ANOVA. The t-test (Mann-Whitney test) was used to 
compare genotypes (*≤0.05, **≤0.005, ***≤0.0005 and ****≤0.00005). The 
experiment was repeated three independent times. Bars indicate standard 
error.   
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3.5.2  RNA quantification 
Given that the non-reference allele of each of c.2385T>C and c.2365A>G led 
to increased protein levels, the effect of both SNV on mRNA expression was 
investigated. RNA quantification was carried out on plasmids containing each 
SNV independently and together to study their independent and combined 
effect on VWF RNA expression level.  
1.1.1.3  qPCR optimisation 
Optimisation of qPCR went through various steps to ensure that reliable and 
reproducible data was generated as follows: 
Singlex master mix was initially used following the standard protocol (Section 
2.2.2.1.123). VWF and B2M (endogenous control) RNA were measured for 
each sample in separate wells. However, the data generated showed a large 
variation which was confirmed by large variation in standard error (Figure 3-
6).  
 
Figure 3-6: VWF RNA expression using plasmid expressing c.2385T>C, 
c.2365A>G and both variants compared to WT and heterozygous 
expression. WT: 100%; heterozygous (c.2385T>C): 159.4%; c.2385T>C 
261%; heterozygous (c.2365A>G): 167.4%; c.2365A>G: 239.7%; 
heterozygous (c.2385T>C and c.2365A>G): 175.2%; both variants: 207.9%. 
The experiment was repeated three independent times. The bars represent 
standard error.  
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The experiment was repeated using the same protocol but measuring VWF 
and B2M in the same well to reduce this variation. However, as VWF was over 
expressed (compared to the endogenous control) due to the expression 
plasmid, the nucleotides were exhausted before B2M was detected. This was 
shown by the B2M curve not reaching its peak after either 40 or 50 cycles 
(Figure 3-7). Therefore the suggestion (as recommended by the manufacturer) 
was to use the multiplex mastermix which has concentrated nucleotides.   
Measuring the RNA of VWF and B2M in the same well was repeated using a 
multiplex mastermix. However, the data generated could not be analysed. The 
multiplex mastermix was found to use a different reference dye (mustang 
purple), which is used to normalise the detection against variables including 
air bubbles or evaporation, compared to the dye ROX that is used in singlex 
mastermix. Due to the available qPCR machine not being calibrated for the 
mustang purple reference dye, the alternate option was to try using singlex 
mastermix without adding any dH2O to the mix and instead add more 
mastermix. This would provide more nucleotides for the reaction. In addition, 
primer-limiting probes for VWF were also used, which provides a limited 
quantity of VWF primers in order to limit its amplification giving more chance 
to amplify and detect B2M. 
The experiment was repeated using these conditions and the results suggest 
that both VWF and B2M were amplified and detected before the end of the 
40th cycle (Figure 3-7). The significant improvement in amplification 
reproducibility demonstrated that the qPCR was now optimised. 
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Figure 3-7: Detection of VWF RNA expression and B2M during 50 PCR 
cycles.  A) Within the first 40 cycles, VWF (orange) peaked (exhausting the 
nucleotides), while even after 50 cycles, B2M (green) did not peak. B) 
Optimised conditions allowed for early peak and detection (before the 40th 
cycle) of both VWF (green) and B2M (orange).  
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1.1.1.4  RNA quantification of c.2385T>C and c.2365A>G 
As with protein expression, quantification of c.2385T>C and c.2365A>G RNA 
was carried out to test their independent and combined effect on RNA 
expression. The results supported the previous findings for protein expression. 
Furthermore, both variants were again shown to have an additive effect on 
RNA expression (Figure 3-8). 
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Figure 3-8: RNA expression of c.2385T>C, c.2365A>G and both SNV 
compared to WT and the heterozygous variant.  Significant differences 
were observed for A) c.2385T>C (p=0.02), B) c.2365A>G (p=0.005), C) both 
variants (p<0.0001) using the ordinary One-way ANOVA. The t-test (Mann-
Whitney test) was used to compare genotypes (*≤0.05, **≤0.005 and 
****≤0.00005). The experiment was repeated three independent times. Bars 
indicate standard error. 
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3.5.3  mRNA splicing analysis 
Variant alleles of c.2385T>C and c.2365A>G showed significantly higher VWF 
protein and mRNA expression. One of the possible mechanisms that might 
cause this was that the reference allele for both variants could be causing a 
slight defect to the splicing mechanism thus reducing the VWF level compared 
to the non-reference allele. Even though neither variant had been predicted to 
have any effect on splicing using various in silico tools, the experiment was 
carried out as these tools are only used for an indication and they are not error 
proof. To test for a possible effect on splicing, an ESE assay and an acceptor 
/ donor motif splicing assay were used to investigate the effect of the two 
variants on ESE motifs and mRNA splicing respectively. 
 
3.5.3.1  Exon splice enhancer (ESE) assay  
In this project, a pcDNA-Dup (SF2-ASF3x) plasmid was used to assess the 
effect of c.2385T>C and c.2365A>G on ESE (Section 2.2.2.2.1).  
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3.5.3.1.1  Optimisation 
The oligos for the minigene were designed to include the 30 bases of interest 
(the variant of interest and 15 bases each side), digestion sites and M13 tails 
to give enough space for the digestion enzyme to bind and perform the 
digestion. The standard protocol (Section 2.2.2.2.2.1) was followed with 
digestion of the oligos and the plasmid in addition to ligation using T4 DNA 
ligase. The final product was transformed into E.coli NM554 competent cells. 
However, no colonies were found even after changing the digestion time of the 
plasmid from 1.5h to 4h. New enzymes were ordered and the experiment was 
repeated. 
Using the new enzymes and the same conditions, colonies were obtained, 
DNA was extracted and sent for sequencing. The sequence revealed that the 
majority of the colonies carried the WT plasmid without any modifications. 
However, some plasmids showed digestion ~1.1kb downstream of the 
expected site. Therefore, new primers were designed to sequence this area to 
check for the presence of another digestion site for the enzymes that were 
used. Sequencing that area in the original plasmid revealed a site with a 4/5 
nucleotide match to the digestion site. Further investigation showed that the 
reaction buffer used was not 100% compatible with both restriction enzymes 
which could explain the non-specificity in the observed digestion in the 
sequence obtained as well as an extra band when it was run on a gel (Figure 
3-9). Therefore, a reaction buffer 100% compatible with both enzymes was 
ordered and the experiment was repeated. 
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Figure 3-9: Digestion of pcDNA-Dup (SF2-ASF3x) plasmid.  Digestion 
performed using new enzymes and old reaction buffer showing an extra 
band (2) in D and F below the main band (1). A) ladder; B) single digest; C) 
0.5µl of double digest for 30 min; D) 2µl of double digest for 30 min; E) 0.5µl 
of double digest for 2h; F) 2µl of double digest for 2 h.  
 
  
A          B          C         D        E          F 
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Colonies were obtained and the DNA was sent for sequencing. However, the 
sequence returned was either WT or empty plasmid (i.e. plasmid without the 
middle exon) suggesting that the digestion succeeded but the ligation failed 
possibly due to insufficient oligo being present. Therefore, double the amount 
of oligo was added to the ligation step. However, the results remained the 
same suggesting that the oligo might not be digested for long enough. 
Therefore, digesting the plasmid and oligos overnight was performed. 
The oligo and plasmid were digested overnight and run on a polyacrylamide 
gel and on an agarose gel respectively. The aim was to test the digestion 
efficiency between 4h and overnight. The results suggested that overnight 
digestion resulted in much better efficiency with more double digestion 
observed in the oligo (Figure 3-10). These newly digested oligos were then 
used with the same protocol to perform the ligation. However, the results 
remained the same. The obtained colonies either had WT plasmid or empty 
plasmid. Further modification to the protocol included gel extraction of the 
digested plasmid before proceeding to the ligation step in order to limit the 
presence of WT (undigested) plasmid from the digested WT and limit their re-
ligation during the ligation process. 
 
Figure 3-10: Comparison between digestion of oligos for 4 h and 
overnight. A) ladder; B) undigested oligo; C) 4hr digested oligo; D) overnight 
digested oligo. 1) single digestion (~40bp); 2) double digestion (~30bp); 3) 
digested product (~20bp)., electrophoresed on a 4% polyacrylamide gel.  
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After repeating the experiment using the newly digested plasmid and oligo, 
and gel extracting the digested plasmid, the sequence of the obtained colonies 
showed an empty plasmid but no WT plasmid suggesting that the gel 
extraction step is important. However, it did not completely solve the problem.  
During the previous optimisation steps, items improved included using new 
enzymes with a 100% compatible reaction buffer, a greater quantity of oligo to 
increase the chance of ligation, better digestion overnight and gel extracting 
the plasmid to eliminate the possibility of obtaining WT plasmid. However, no 
successful cloning was obtained. This would lead to two possibilities (Figure 
3-11) which are; 1) the oligo is not ligating at the desired site, 2) the oligo is 
ligated but then the plasmid is ligating again with itself. Therefore, new oligos 
were ordered that did not require digestion (i.e. they had the 30 bp of interest 
and the required digestion overhangs) and the whole experiment was 
repeated.  
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Figure 3-11: Possible reason for the non-successful cloning.  Theory 
one shows that the oligo did not bind to the plasmid so that the plasmid self-
ligated. In theory two, the oligo was successfully ligated, then the plasmid re-
ligated with itself leading to the same observed result.  
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However, the obtained results remained the same. Thus, assuming the 2nd 
theory was right, ligation at 3 h was too long. Therefore, the experiment was 
repeated and the ligation time was reduced to 15 or 30min. 
The experiment was repeated using the original protocol with the following 
changes, overnight digestion of the plasmid, pre-digested oligo, double the 
quantity of the oligo, gel extracting the digested plasmid, and reducing the 
ligation time to 15min and 30min. Colonies were obtained, DNA was extracted 
and sent for sequencing. Finally, successful insertion of the middle exon was 
obtained (Figure 3-12). 
 
 
Figure 3-12: Sequence of the middle exon for original plasmid pcDNA-
Dup (showing the +ve control (referred to as sequence), -ve control and 
both alleles for c.2385T>C).  Outlined in red is the nucleotide difference 
between reference and non-reference allele. Outlined in blue is the middle 
exon insertion. 
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3.5.3.1.2 Effect of c.2385T>C and c.2365A>G on ESE 
Following the previous optimisation, the experiment was performed on 
c.2385T>C and c.2365A>G using the obtained plasmids (including WT and 
mutant for each variant separately and in the same plasmid as well as positive 
and negative controls). The results suggest that these variants do not affect 
ESE when comparing the band of the reference and non-reference alleles 
which were of identical size (Figure 3-13).  
 
Figure 3-13: ESE assay results for c.2385T>C and c.2365A>G.  Similar 
band sizes were observed in WT and mutant plasmids suggesting no effect 
on ESE. -ve control, plasmid with an insertion that is known not to express 
the middle exon (thus showing a small product size with only 2 exons); +ve 
control plasmid with an insertion that is known to be expressed (thus 
showing a larger product size 3 exons). 
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3.5.3.2 Acceptor / donor motif splicing assay 
In this project, pET01 plasmid was used to assess the effect of c.2385T>C and 
c.2365A>G on mRNA splicing. Therefore, four plasmids were made in addition 
to the +ve and –ve controls (Section 2.2.2.2.2). These plasmids included a WT 
exon 18 insertion, exon 18 insertion with c.2385T>C, exon 18 insertion with 
c.2365A>G and exon 18 insertion with both c.2385T>C and c.2365A>G. 
Following preparation, these plasmids were transfected into HEK293T cells, 
mRNA was extracted and cDNA was prepared and amplified using specific 
primers. The results were then analysed in the same way as for the ESE assay 
where the product size was compared between WT and mutant plasmids. The 
results showed no differences between WT and any of the three mutant 
plasmids suggesting no effect of these variants on mRNA splicing (Figure 3-
14).  
 
Figure 3-14: The effect of c.2385T>C and c.2365A>G on splicing. 1: 
ladder; 2: -ve control missing the middle exon; 3: exon 18 WT; 4: exon 18 
with c.2385T>C; 5: exon 18 with c.2365A>G; 6: exon 18 with both 
c.2385T>C and c.2365A>G. Exon 18 size is ~160bp, -ve control size 
~100bp, final product size ~260bp.  
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3.6 mRNA half-life 
The effect of c.2385T>C and c.2365A>G on mRNA half-life was then 
investigated. Previously prepared VWF plasmid (for protein and mRNA 
quantification; section 3.5.1) was used for this experiment. The aim was to 
compare mRNA half-life between WT plasmid and plasmid containing either 
or both of the variants. mRNA half-life refers to the amount of time needed for 
50% of the mRNA to be degraded. Actinomycin D treatment of the cells was 
used for this purpose as it inhibits the production of mRNA (Section 
2.2.2.1.12.4). 
WT plasmid was transfected into HEK293T cells then treated with 2.5µg/ml, 
5µg/ml and 10µg/ml of actinomycin D 24h post transfection. Cells treated with 
5µg/ml were harvested at 0h, 2h, 4h and 6h while 2.5µg/ml and 10µg/ml 
treated cells were harvested at 6h post-treatment. The results showed that 
2.5µg/ml did not efficiently inhibit mRNA production, while 5µg/ml and 10µg/ml 
gave similar results. Therefore, treatment with 5µg/ml was used for this 
experiment. The mRNA half-life was predicted to be between 2h and 3h post 
treatment. Therefore, the following modifications were made to the conditions; 
5µg/ml actinomycin D was used, and cells were harvested at 0h, 2h, 3h and 
4h post treatment. 
The four plasmids (WT, c.2385T>C, c.2365A>G and both c.2385T>C and 
c.2365A>G) were transfected into HEK293T cells and treated with 5µg/ml 
actinomycin D and mRNA was harvested. The results indicated that both 
variants significantly increased RNA half-life compared to the WT (Figure 3-
15, 3-16 and 3-17). In addition, the presence of both variants together in the 
same plasmid showed a combined increase in mRNA half-life suggesting that 
each of these two variants increase mRNA half-life resulting in the observed 
increase in the mRNA and levels of protein expression. 
In order to test how these SNV influence mRNA half-life, their effect on mRNA 
secondary structure was tested using the in silico RNAsnp (Section 2.2.1). 
However, they were not predicted to have any significant effect (c.2365A>G 
p=0.57 and c.2385T>C p=0.22). Given that miRNA has been suggested to 
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influence mRNA stability (Valencia-Sanchez, et al 2006, Fabian, et al 2010), 
the effect of both SNV on miRNA, using miRBASE (Section 2.2.1), was also 
investigated but again showed that neither had any effect. 
 
Figure 3-15: RNA half-life for VWF.  WT at 0h (100%), 2h (76.6%), 4h 
(18.5%), 6h (11.9%) using 5µg/ml actinomycin D, 6h 10µg/ml (9.4%).and 6h 
using 2.5µg/ml (21%).  
 
Figure 3-16: Half-life of WT VWF mRNA following actinomycin D 
treatment in HEK293T cells.  Graph used to calculate the half-life of WT 
VWF mRNA. 
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A  
B  
Figure 3-17: mRNA half-life for c.2385T>C, c.2365A>G and both 
c.2385T>C and c.2365A>G in comparison with WT.  A) mRNA half-life 
was calculated for WT VWF (red), VWF plasmid with c.2385T>C (black), 
VWF plasmid with c.2365A>G (blue) and VWF plasmid with both c.2385T>C 
and c.2365A>G in cis (green). B) mRNA half-life for WT VWF: 100% (2:36 
h); c.2385T>C: 107.67% (2:49 h); c.2365A>G: 108.1% (2:51 h); combined: 
109.97% (2:54 h). Significance was observed using the ordinary One-way 
ANOVA test (p=0.0187). The t-test (Mann-Whitney test) was used to 
compare between two groups (*≤0.05 and **≤0.005). The experiment was 
repeated three independent times. The bars represent standard error.   
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3.7 Discussion 
The scope of this part of the project was to investigate the effect of VWF SNV 
and examine their possible effect on VWF plasma level. SNV were previously 
thought to have minor functional importance. However, there is growing 
evidence that SNV can have an effect on protein function or expression. Even 
though they might not cause an actual disease, they might contribute to one.  
Analysis of SNV throughout VWF and its flanking regions revealed several 
variants with a significant association with VWF plasma level. In silico analysis 
was conducted which showed no major effect on protein structure or function 
which is not unexpected given that these variants are not disease causing. 
Following that, in vitro investigation was carried out to assess the effect of 
c.2385T>C and c.2365A>G on protein and mRNA expression as well as their 
effect on splicing and mRNA half-life. The results suggest that both SNV cause 
a significant increase in VWF protein and mRNA expression without affecting 
mRNA splicing, however, these SNV cause an increase in mRNA half-life. 
Although these SNV are not disease causing on their own, the presence of 
several SNV having a similar effect might exhibit or contribute to a disease like 
phenotype (for example, the presence of several SNVs each of which reduces 
VWF level could in turn result in an individual with a VWD-like phenotype). In 
addition, the presence of SNV co-inherited with a VWF mutation could result 
in a more or less severe phenotype (for example, a VWD patient with a SNV 
increasing VWF level may have a less severe VWD phenotype compared to a 
patient with the same mutation without this SNV). 
In this study, 111 SNV throughout the VWF gene and surrounding region were 
analysed in ~1100 HC from the MCMDM-1VWD study looking for an 
association with VWF plasma level. Eleven of these SNV were found to be 
significantly associated with VWF plasma levels including 4 intronic, 4 exonic 
(3 silent and 1 synonymous), one 3’ of VWF and two ANO2 intronic variants. 
The majority of VWF variants were intronic or silent exonic, although these 
variants were historically thought to have no or a minor effect. However, 
growing evidence suggesting that these variants are of no less importance 
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than non-synonymous exonic variants as shown by a recent study that 
investigated VWF variants and their association with VWF level and only 
identified intronic or silent exonic variants having a significant association with 
VWF plasma level (Campos, et al 2011). Interestingly none of them 
overlapped with SNV reported in this study apart from c.2385T>C.  
Six SNV showed an inconsistent increase or decrease in VWF level when 
comparing the reference allele, non-reference allele and heterozygous forms 
which could be due to partial LD with other SNV and therefore these were not 
investigated further. 
On the other hand, some SNV were significantly associated with VWF level 
and were in strong LD with another SNV such as c.-1342C>G and c.7888-
2310T>C, r2=99.5%, which were associated with a 15% reduction in VWF 
plasma level and c.2385T>C and c.2365A>G, r2=99.1%, which were 
associated with ~9% increase in VWF level in comparison with the reference 
allele, supporting previous findings for c.2365A>G (Johnsen, et al 2013). The 
reason for not having 100% LD could be due to genotyping errors that might 
have occurred. The LD between these SNV suggests either that one of the 
two SNV is associated with VWF level and the other one is showing 
association with VWF purely due to the strong LD or that both variants are 
having an additive effect on VWF level. The last SNV significantly associated 
with VWF plasma level by this study, c.7888-3501A>G was linked to an 8% 
reduction. 
c.-1342C>G and c.7888-2310T>C have not previously been associated with 
VWF plasma level. c.-1342C>G is present ~1.5kb downstream of VWF where 
no regulatory elements have been predicted to be present. On the other hand, 
c.7888-2310T>C is present in intron 47 and was not predicted to have any 
major effect using any web tool suggesting that the observed association is 
due to another SNV that is in strong LD with these two variants but not included 
in this study.  
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c.7888-3501A>G was also present in intron 47 of VWF within ~1.5kb of 
c.7888-2310T>C. However, they do not share strong LD between them 
(r2=34%).  
Investigation of c.7888-3501A>G, c.7888-2310T>C and all surrounding SNV 
within 2kb each side was carried out using various web tools looking at their 
possible effect on mRNA splicing, ESE motifs, miRNA binding sites and 
transcription factor binding sites. c.7888-3501A>G was predicted to introduce 
a new donor splice site by four out of five web tools. This strongly suggests 
that this SNV is associated with VWF plasma levels through interfering with 
the splicing system. However, due to time limitations, the intronic variants were 
not investigated further.  
c.2385T>C and c.2365A>G have previously been strongly associated with 
VWF plasma level (Smith, et al 2010, Zhou, et al 2014). In this study, both 
SNV were associated with increased VWF levels which is in line with a 
previous report (Zabaneh, et al 2011), but unlike anther more recent study that 
did not identify a significant association probably due to the small sample size 
(Shahbazi, et al 2012). However, their mechanism of action has not been 
previously investigated. Therefore, further work was conducted to investigate 
this. 
The CHARGE association study found that c.2385T>C had the highest 
significant association with VWF level (Smith, et al 2010), although c.2385T>C 
and c.2365A>G are in perfect LD and thus expected to have a similar 
association with VWF plasma level. However, one of the main weaknesses of 
this study type is that not all variants were analysed in all individuals. In this 
case c.2385T>C was analysed in more individuals than c.2365A>G, therefore, 
a higher significance was found with c.2385T>C. 
Prediction tools did not show a significant effect for these variants on VWF 
protein or mRNA splicing. However, performing quantification of protein level 
in HEK293T cells showed an increase (~40%) in cell lysate for c.2385T>C, 
~50% for c.2365A>G and ~90% for both SNV. This suggests that these two 
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SNV independently cause an increase in VWF level resulting in the observed 
additive effect.  
On the other hand, VWF level in the cell supernatant was found to be similar 
for all three variants (c.2385T>C, c.2365A>G and both variants together) with 
~25% increase in VWF secreted compared to WT. VWF is known to go 
through extensive post-translational modification and complex storage and 
secretion processes (Lenting, et al 2015), so even though the intracellular 
VWF level is higher in the cells that have both variants, the cells could not 
process and release VWF faster than cells with only one of the variants. This 
means the expression of VWF increased while the cells’ processing capability 
had not changed resulting in intracellular retention (in this case due to inability 
to process higher quantities of VWF). Therefore, both SNV are predicted to 
increase VWF expression rate in comparison with WT.  
To investigate the effect of these two SNV on mRNA expression, quantification 
of mRNA was carried out. HEK293T cells were transfected with the same 
plasmid and procedure used for protein quantification in order to produce 
consistent results. mRNA expression was found to be increased by 50% for 
c.2385T>C, 50% for c.2365A>G and 70% for both variants in cis. These 
results support previous findings that these two SNV increase VWF expression 
rate in comparison to WT and they do so independently resulting in an additive 
increase in level when present together. These findings suggest that the 
increase in protein level is due to an increase in mRNA expression.  
Although the two SNV were not predicted to have a major effect on splicing 
using various in silico tools, it is known that these tools are not error proof. In 
addition, given that c.2385T>C results in a silent change, it was still a 
possibility that one or both SNV had an effect on splicing. Therefore, acceptor 
/ donor motif splicing assays were used to investigate this possibility. The 
results showed no effect of these two SNV on splicing. Following that, the 
effect of these SNV on ESE motifs was also investigated but similarly neither 
of the two SNV showed any effect. 
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The effect of the two SNV on VWF mRNA half-life was subsequently 
investigated. The results suggested that c.2385T>C and c.2365A>G increase 
mRNA half-life by ~7.7% (2:49 h:min) and ~8.1% (2:51 h:min) respectively in 
comparison with the reference allele. An additive increase was observed when 
both SNV were present together ~10% (2:54 h:min). These findings suggest 
that the increase in mRNA and protein levels was due to an increase in mRNA 
half-life. The reason for increased mRNA half-life is not clear given that these 
SNV do not have an effect on splicing, mRNA secondary structure or an effect 
on miRNA. However, a recent study suggested that a nucleic acid change from 
A or T to C or G (which is the case for both SNV) increases mRNA stability (by 
a yet to be known mechanism) and thus mRNA half-life (Duan, et al 2013). 
The current study provides evidence that c.2385T>C and c.2365A>G are 
associated with an increase of VWF level in the normal population. Both SNV 
are shown to have an independent and an additive effect on VWF level. The 
two SNV result in an increase in mRNA half-life which in turn results in an 
increase in the intracellular mRNA quality, and therefore, a higher VWF protein 
level. This increase is not expected to be disease causing. However, it can be 
considered as a risk factor for cardiovascular disease where elevated VWF 
level is a risk factor such as in venous thrombosis, myocardial infarction or 
coronary heart disease (Jansson, et al 1991, Thompson, et al 1995, 
Lacquemant, et al 2000, Morange, et al 2011, Morange, et al 2015). This data 
also supports previous findings that c.2385T>C is a risk factor for 
cardiovascular diseases (van Schie, et al 2011a). An earlier study has also 
suggested an association of this variant with coronary heart disease 
(Lacquemant, et al 2000). In conclusion, these findings support the hypothesis 
that SNV within VWF influence VWF plasma level in the normal population.
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4 Chapter four: Association of VWF SNV c.2771G>A 
and c.4146G>C with VWF level 
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4.1 Background 
Previous work within this research group identified two SNV as being 
associated with VWF plasma level, c.4146G>C (p.Lys1382=) and c.2771G>A 
(p.Arg924Gln; rs33978901).  
Previous studies have identified c.2771G>A (occurring in VWF exon 21) and 
classified it as a VWD causative mutation (Goodeve, et al 2007, James, et al 
2007) while other studies suggested it to be benign (Cumming, et al 2006, 
Lester, et al 2008). c.2771G>A was found to be present in HC and index cases 
(IC) at frequencies of 3.1% and 4.1% in the European population (Table 4-1) 
and 1.0% and 8.5% in the Canadian population respectively (Goodeve, et al 
2007, James, et al 2007). More recent studies observed a significant reduction 
in VWF plasma level in the heterozygous state of this variant, yet, in vitro 
expression did not show a significant reduction in VWF level nor an effect on 
splicing using in silico web tools (Berber, et al 2009, Hickson, et al 2010). 
However, abnormal mRNA splicing was observed in an individual carrying 
c.2771G>A that resulted from introduction of a possible cryptic splice site (i.e. 
where an alternate splice site is recognised due to the presence of sequence 
variation) (Berber, et al 2009).  
c.4146G>C is silent change occurring in VWF exon 28 (which encodes the A1 
domain) and was originally identified in a VWD patient (P10F5II:2, with VWF 
level = 48 IU/dL) from the MCMDM-1VWD study (Hampshire, et al 2010). The 
variant has also since been reported in two Spanish individuals with VWD1 in 
cis with two other variants (Corrales, et al 2012), unlike the previous study 
where the patient had only c.4146G>C (Hampshire, et al 2010). Protein 
expression of this variant was investigated which showed that it caused a 
significant reduction (~25%) in secreted VWF level (Alyami, PhD thesis, 2014). 
Further analysis also showed that the variant had no effect on multimerisation, 
but in silico analysis suggested that it might have a possible effect on an ESE 
(Alyami, PhD thesis, 2014). 
Although both variants (c.4146G>C and c.2771G>A) were suggested to be 
associated with VWD1, the mechanisms by which these SNV have an effect 
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on VWF level were not clear. Therefore, the aim of this part of the study was 
to identify the mechanism by which these variants influence VWF level. 
 
Table 4-1: Phenotype of EU members with c.2771G>A. 
Family Individual Status* FVIII:C 
IU/dL 
VWF:Rco 
IU/dL 
VWF:Ag 
IU/dL 
Allele 1 Allele 2 
P8 F1 II:1 IC 61 49 49 p.R924Q  
P9 
F14 
II:2 IC 7 3 3 p.[R924Q+C1927R] c.1533+1G>T 
P9 
F14 
I:2 AFM 63 58 57 p.[R924Q+C1927R]  
P9 
F14 
III:1 AFM 25 18 19 p.[R924Q+C1927R]  
P9 
F14 
I:1 UFM 82 79 88  c.1533+1G>T 
P9 
F14 
II:3 UFM 50 80 57 p.[R924Q+C1927R]  
P7 F3 II:1 IC 15 38 25 p.R924Q p.R854Q 
P7 F3 I:2 AFM 104 88 81 p.R924Q  
P7 F3 I:1 UFM 77 87 75  p.R854Q 
P6 F5 II:1 IC 18 7 11 p.R924Q p.R1205H 
P6 F5 III:1 AFM 28 17 15  p.R1205H 
P6 F5 II:3 UFM 107 95 131 p.R924Q  
P6 
F11 
II:1 IC 52 34 40 p.R924Q c.3675-14G>A 
P6 
F11 
II:4 AFM 71 50 49 p.R924Q p.R924Q 
P6 
F11 
III:1 AFM 68 52 62 p.R924Q  
P6 
F11 
II:3 UFM 77 69 64 p.R924Q  
P6 
F11 
III:2 UFM 96 82 84  c.3675-14G>A 
P3 
F13 
I:1 IC 78 13 42 p.[R924Q+R1315RL]  
P3 
F13 
II:1 AFM 35 3 18 p.[R924Q+R1315RL] p.Y1584C 
*IC, index case; AFM and UFM, affected and unaffected family member. 
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4.2 In silico analysis 
The effect of c.4146G>C on ESE motifs was previously predicted and 
suggested a possible effect (Alyami, PhD thesis, 2014). The effect of 
c.2771G>A on ESE motifs was predicted in this study showing a possible 
effect (Table 4-2).  
 
Table 4-2: In silico prediction of the effect of c.2771G>A and c.4146G>C 
on ESE using two different tools.  
 Human Splice Finder ESE finder 
c.2771G>A +2 / -1 +2 / -0 
c.4146G>C +1 / -1 +0 / -1 
*+ refers to the gain of an ESE motif and - refers to the loss of an ESE motif 
(i.e. human splice finder predicted c.2771G>A to cause gain of two new ESE 
motifs and to lose of one ESE motif). 
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4.3 Exon splice enhancer assay 
Investigation of the potential effect of c.4146G>C and c.2771G>A on ESE 
motifs was conducted in vitro using an exon splice enhancer assay (Section 
2.2.2.2.1).  
The ESE assay was used to investigate the WT codon (c.4146G), mutant 
codon (c.4146C) and the other 2 possible variants that would result in a leucine 
codons (c.4146A and c.4146T) in order to assess whether these two 
hypothetical changes would have an effect similar to the WT or mutant codon. 
pcDNA-Dup (SF2-ASF3x) plasmid was used for this purpose (Section 
2.2.2.2.2). WT and mutant were prepared for each variant and transfected into 
HEK293T cells. 24hr post-transfection, RNA was extracted, reverse 
transcription performed and amplification of the product took place. The PCR 
product was then run using gel electrophoresis to check the product size. The 
results showed a lower band size for all mutant sequences compared to WT, 
suggesting that these changes either caused a loss of exon splice enhancer 
motifs and/or a gain of exon splice silencer motifs resulting in the lack of 
identification of the middle exon leading to a smaller band size (Figure 4-1A).  
On the other hand, c.2771G>A had a single band with the non-reference allele 
(c.2771A) compared to two bands in the WT state (c.2771G), suggesting that 
the change caused a gain of exon splice enhancer motif(s) and/or a loss of 
exon splice silencer motifs (Figure 4-1B).  
  
112 
 
 
Figure 4-1: The effect of c.4146G>C and c.2771G>A on ESE.  A) lane 1: 
ladder; lane 2: -ve control (470bp); lane 3: +ve control (500bp); lane 4: WT 
c.4146G; lane 5: mutant c.4146C; lane 6: mutant c.4146A and lane 7: mutant 
c.4146T. B) lane 1- ladder; lane 2- -ve control; lane 3- +ve control; lane 4- 
WT c.2771G; lane 5- mutant c.2771A.  
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4.4 RNA quantification 
Given that c.4146G>C and c.2771G>A are associated with an alteration in 
ESE motifs, mRNA level was then investigated in order to assess whether this 
led to a reduction in mRNA level. This was performed by comparing VWF 
mRNA expression of both variants with WT. HEK293T cells were transfected 
with either VWF WT plasmid, VWF c.4146C plasmid or VWF c.2771A plasmid, 
RNA was extracted 24hr post-transfection followed by reverse transcription 
and finally mRNA was quantified using qPCR. The results suggested a 
significant reduction in mRNA level of both variants compared to WT (Figure 
4-2).  
 
 
Figure 4-2: VWF mRNA level of c.4146G>C (A) and c.2771G>A (B) 
compared to WT.  Significant differences were observed between WT and 
c.4146G>C (p=0.001) and between WT and c.2771G>A (p=0.007). Two-
tailed Student’s t-test. The experiment was done three independent times. 
Bars indicate standard error.  
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4.5 RNA degradation rate 
The effect of c.4146G>C and c.2771G>A on mRNA half-life was investigated 
in order to identify whether the alteration in ESE motifs reduced mRNA stability 
and thus mRNA half-life. Both variants showed a significant reduction (~40%) 
in mRNA half-life compared to WT (Figure 4-3).  
A 
 
B 
 
Figure 4-3: mRNA half-life of c.4146G>C and c.2771G>A compared to 
WT.  A) mRNA level at 0hr, 2hr, 3hr and 4hr post actinomycin D treatment 
for WT (2:38 h:min), c.4146G>C (1:44 h:min) and c.2771G>A (1:38 h:min). 
B) Fold change in mRNA half-life for c.4146G>C and c.2771G>A compared 
to WT. Significant differences were observed between WT and c.4146G>C 
(p=0.0003) and between WT and c.2771G>A (p=0.0002). Two-tailed 
Student’s t-test. The experiment was done three independent times. Bars 
indicate standard error.   
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4.6 Discussion 
The aim of this chapter was to investigate the mechanism by which the 
previously identified variants (c.2771G>A and c.4146G>C) influence VWF 
plasma level. The two variants were identified in VWD patients and were found 
to be associated with VWD1. In vitro protein expression showed that 
c.4146G>C was associated with a reduction in secreted VWF level while 
c.2771G>A showed no effect. However, the previous work did not reach a 
conclusion on the mechanism of influence of either SNV on VWF level. The 
current work investigated their possible effect on ESE motifs as well as on 
mRNA level and mRNA half-life. The current findings suggest that both SNV 
are associated with an alteration in ESE motifs leading to a defect in splicing, 
possibly producing an abnormal mRNA that is degraded faster than WT 
resulting in a reduction in mRNA half-life and mRNA level. 
In silico analyses on c.4146G>C and c.2771G>A showed a possible effect on 
ESE. Therefore, an ESE assay was used to investigate the effect of these SNV 
on ESE in vitro. The results of the ESE splicing assay for the c.4146G>C 
variant showed that the WT codon (c.4146G) expressed 3 exon product while 
the mutant codon (c.4146C) and the other 2 possible leucine codons (c.4146A 
and c.4146T) expressed only 2 exon product suggesting that either the WT 
codon contained an exon splice enhancer motif(s) required to splice the middle 
exon or that the other three codons introduce a new exon splice silencer 
motif(s) resulting in splicing out the middle exon. The effect of the c.4146G>C 
variant on ESE function appears to explain the VWD1 phenotype as a defect 
could lead to a splice defect which could result in a premature stop codon.  
c.2771G>A is present within the D3 domain of VWF which is important for FVIII 
binding, multimerisation and storage. However, previous studies showed that 
this variant had no effect on FVIII binding (Hilbert, et al 2003), multimerisation 
(Hickson, et al 2010) or storage (Berber, et al 2009). Therefore, the suggestion 
is that this variant is having an effect at the mRNA level rather than protein 
level. 
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Investigating the effect of c.2771G>A on ESE motifs showed that the WT 
codon expressed both a 2 and a 3 exon product, while the mutant codon 
expressed only a 3 exon product. This suggest that the mutant codon results 
in an introduction of a new ESE motif(s) or loss of an exon splice silencer 
motif(s). This finding is in line with a previous finding where a cryptic splice site 
was suggested to be the reason for the association of this variant with 
abnormal VWF mRNA (Berber, et al 2009). Cryptic splice sites have been 
observed in many diseases including VWD1 (Gallinaro, et al 2006).  
However, an older study did not find any defect on splicing in an individual 
heterozygous for c.2771G>A (Cumming, et al 2006) which was explained by 
Berber, et al (2009) as “not all 924Q alleles are created equal”. Nevertheless, 
a possible explanation could be the presence of another variant within that 
region that might have a counter effect to c.2771G>A on ESE motifs leading 
to normal splicing of VWF. In addition, haplotype background for 924 alleles 
can also be responsible for the observed differences. 
A similar case was reported where a loss of ESE motif(s) due to a silent exonic 
variant has recently been associated with factor V deficiency as a result of a 
splicing defect (Nuzzo, et al 2015). The effect of sequence variants on ESE 
motifs are not commonly reported to be disease causing as they have been 
under investigated given that they were only recently suggested to be of 
functional importance suggesting the possibility of overlooking such variants 
in association with other disorders. 
Having observed an effect on ESE motifs, the effect of both c.2771G>A and 
c.4146G>C on mRNA level was subsequently compared to WT. The results 
showed that the mRNA level of c.2771G>A was 35% lower compared to WT 
while the mRNA level of c.4146G>C was 40% lower. The reductions in mRNA 
levels for both SNV were significant.  
mRNA half-life was then compared between the two SNV and WT. The results 
suggest that both SNV cause a significant reduction in mRNA half-life 
compared to WT. This could be explained due to an ESE motif defect caused 
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by both SNV because this could disrupt mRNA stability leading to more rapid 
RNA degradation. 
In summary, both SNV were previously associated with a reduction of VWF 
level in VWD patients, however, their mechanisms of action had not been 
previously identified. This study identified that both SNV are associated with 
defects in ESE motifs which in turn led to a reduction of mRNA stability and 
thus mRNA half-life. This also suggests that the reduction in mRNA level is 
due to reduction in mRNA stability instead of a reduction in the level of mRNA 
expression. Finally, these findings support previous predictions that these two 
SNV are disease causing.
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5 Chapter five: Association of fucosyltransferases 
FUT3, FUT5 and FUT6 with VWF plasma level 
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5.1 Background 
There are currently 13 human fucosyltransferases encoding genes reported, 
FUT1 to FUT13 (National Center for Biotechnology Information (NCBI), 
www.ncbi.nlm.nih.gov, accessed February 2012). Fucosyltransferases add 
fucose to different glycans and are expressed in different locations (Costache, 
et al 1997). Fucose is added to a basic precursor glycan, converting it to Lewis 
A antigen (Lea) either by FUT3 (expressed in exocrine secretions such as 
saliva) or FUT6 (expressed in plasma), suggesting that FUT6 can possibly 
substitute for FUT3. Addition of fucose to Lea by FUT2 (expressed in both 
exocrine secretions and plasma) further converts it to Lewis B antigen (Leb) 
(Figure 5-1) (Mollicone, et al 1995, Costache, et al 1997).  
FUT3 is located on chromosome 19 and has one coding exon of around 1kb 
(University of California Santa Cruz (UCSC) human genome browser, 
genome.ucsc.edu, accessed February 2012). The association between FUT3 
and plasma VWF level was first reported by Orstavik and colleagues (1989) 
who suggested that individuals with Lea have higher VWF levels compared to 
those individuals without any Lea and Leb, or with Leb only. A later study 
showed similar results (Green, et al 1995). Recently, these previous 
observations were further confirmed by research conducted in Sheffield using 
a larger number of samples, which showed that individuals with inactive FUT3 
have ~10% lower VWF plasma levels (Figure 5-2) (Hickson, et al 2009). This 
study focused on a c.202T>C variant in FUT3 (rs812936) because it was the 
most common variant in the Caucasian population that results in inactivation 
of FUT3 as a result of the significant differences of the a.a changed 
(p.Trp68Arg) (Elmgren, et al 1997, Hickson, et al 2009, Soejima, et al 2009). 
It was also reported in another study to be one of the common FUT3 variants 
leading to its inactivity and Le- (Salomaa, et al 2000). However, FUT3 is 
reported to be expressed in exocrine secretions but not in plasma, thus its 
influence on VWF level in plasma is questionable (Costache, et al 1997). 
The association of FUT genes with VWF level has been previously studied 
including FUT3, FUT1 and FUT2, with only FUT3 showing significant 
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association (Hickson, PhD thesis, 2010). However, due to the lack of 
expression of FUT3 in endothelial cells, other FUT genes were investigated. 
 
 
 
Figure 5-1: Lewis antigen synthesis. The figure shows the process 
resulting in the conversion of the precursor glycan to Lea by α-3-
fucosyltransferase (encoded by FUT3 and FUT6) and Leb by α-2-
fucosyltransferase (encoded by FUT2).  
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Figure 5-2: Association of SNV c.202T>C in FUT3 with VWF plasma level 
in HC.  Comparing the three groups showed significant association using the 
One-way ANOVA (Kruskal-Wallis test) (p=0.01). Comparing T/T with T/C 
(p=0.0072) and T/T with C/C (p=0.041) was significant using the t-test (Mann-
Whitney test), (Hardy-Weinberg p=0.033) (data from (Hickson, et al 2009)). 
 
FUT6 is a member of the fucosyltransferase family and has been linked to the 
conversion of the precursor glycan to Lea antigen in plasma (Mollicone, et al 
1995). Given that FUT6 is expressed in plasma, shares 84% homology with 
FUT3 and is located ~5kb from FUT3 (Figure 5-3) (NCBI, 
www.ncbi.nlm.nih.gov, accessed February 2012), FUT6 may be responsible 
for the observed FUT3 association. However, whether FUT6 actually 
influences VWF plasma level and the mechanism by which 
fucosyltransferases influence VWF level is not currently known. 
Several studies have investigated mutations influencing FUT6 function or 
FUT6 expression. Variants p.Gly739Ala and p.Cys954Ala were found to 
inactivate the expression of FUT6 (Mollicone, et al 1994, Brinkman-Van der 
Linden, et al 1996, Elmgren, et al 2000), while variants p.Cys730Gly and 
p.Cys907Gly were found to reduce the activity of FUT6 (Pang, et al 1999, 
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Elmgren, et al 2000), and variant p.Cys370Thr was found to increase the 
activity of FUT6 (Mollicone, et al 1994, Pang, et al 1999, Elmgren, et al 2000). 
However, none of these studies investigated the association of these variants 
with VWF plasma level.  
Based on the close proximity (~60kb) and 85% homology (Figure 5-3) 
observed between genes FUT3, FUT5, and FUT6, further analysis was 
conducted to investigate whether any of the three genes were associated with 
VWF plasma level. A phylogram generated to predict the evolution of FUT 
genes indicates that FUT5 and FUT6 are more closely related to FUT3 than 
any of the other FUT genes (Figure 5-4).  
Therefore, the aim was to investigate the association of FUT3, FUT5 and 
FUT6 with VWF plasma level. We hypothesised that the apparent association 
of the FUT3 SNV to VWF levels is influenced by variation in FUT5 and/or FUT6 
with which the FUT3 SNV is in strong LD.  
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Figure 5-3: The FUT3, FUT5 and FUT6 locus on chromosome 19. The 
figure shows: A) the location of (from left to right) FUT5, FUT3 and FUT6 on 
chromosome 19. B) an alignment between FUT3, FUT5 and FUT6 proteins 
and shows the similarity between their a.a sequences. Completely conserved 
a.a are highlighted in black, while a.a highlighted grey have similar chemical 
characteristics.   
A 
B 
124 
 
 
Figure 5-4: Predicted phylogram of the evolution of FUT genes.  
Generated from CLUSTALW2 phylogram prediction. 
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5.2 In silico analysis of FUT3, FUT5 and FUT6 
The linkage disequilibrium (LD) between c.202T>C and other variants in FUT5 
and FUT6 was investigated based on the theory that the observed effect of 
c.202T>C on VWF level was actually due to another variant in strong LD with 
it.  
Using HapMap data (accessed August 2013) there was a high degree of LD 
observed between variants within FUT3 and FUT6, while FUT5 was not in 
strong LD with either FUT3 or FUT6 (Figure 5-5). The coding region including 
100 bases flanking each of three genes was amplified and sequenced in ~100 
healthy control individuals (HC) and LD identified between variants in the three 
genes was investigated using SNPStats (Figure 5-6). The investigation 
resulted in identification of two SNVs in FUT6 which were in strong LD with 
c.202T>C, rs778805 (c.370C>T; p.Pro124Ser) and rs61739552 (c.977G>A; 
p.Arg326Gln).  
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Figure 5-5: Observed LD between FUT3, FUT5 and FUT6 based on the 
available HapMap data.  White squares refer to weak LD, red squares refer 
to strong LD while blue squares refer to missing data. The number 
represents the percentage of the LD. Highlighted in a red circle is the 
previously identified FUT3 variant c.202T>C. 
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Figure 5-6: LD between reported SNVs in FUT3, FUT5 and FUT6 when 
analysed in 96 HC.  Yellow indicates very weak LD (<50%); orange indicates 
medium LD (50-75%); red indicates strong LD (>75%). “Novel” are variants 
found in our population that were not previously reported. The FUT3 variant 
(c.202T>C) is highlighted with a red oval.  
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5.3 Prediction of FUT6 variant effect on the FUT6 protein  
Following the identification of variants in FUT6 with a possible effect on VWF 
plasma level due to their strong LD with the previously identified c.202T>C 
variant in FUT3, these two variants were tested for any effect on protein 
structure or function using different online prediction tools. One of the three 
tools predicted these two variants to have an impact on the FUT6 protein and 
therefore, a potential effect on VWF plasma level even though these tools are 
not always reliable, instead they give an indication (Table 5-1).  
 
Table 5-1: Prediction of the effect of c.370C>T and c.977G>A on the 
FUT6 protein. 
FUT6 
variants 
PolyPhen ** SIFT** Align GVGD*** 
c.370C>T Benign 
(0.006) 
Tolerated (0.15) Most likely damaging 
(C65) 
c.977G>A Benign (0.03) Tolerated (0.33) Moderate (C35) 
*The number between brackets are the scores given by each web tool. 
** Score ranges between 0-1 where 1 more likely to have an effect 
*** Score can be 0-15-25-35-45-55-65 where higher value is more likely 
damaging  
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5.4 Association of FUT6 SNVs with VWF level 
Following TaqMan® genotyping of the two SNV in FUT6 (c.370C>T and 
c.977G>A) against the rest of the HC sample population (n=1098), statistical 
analysis was performed to investigate the association of these two SNVs with 
VWF plasma level compared to what was previously observed for c.202T>C 
in FUT3. Analysis indicated that neither of the two SNVs were associated with 
VWF plasma level (Figure 5-7) because these variants were not found to be 
in strong LD after looking at larger sample size. 
This observation could have been caused by a possible genotyping error, 
therefore, Hardy-Weinberg equilibrium (HWE) was investigated. HWE refers 
to each allele’s frequencies within a population which can be calculated in 
order to predict possible genotyping errors; it was calculated using SNPStats. 
HWE was significant for c.202T>C variant in FUT3 suggesting possible 
genotyping error (i.e. a missing allele, possibly due to the presence of another 
SNV within a primer binding site), while both FUT6 SNV were in HWE. 
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Figure 5-7: Association of c.370C>T and c.977G>A with VWF plasma 
level.  A) SNV c.370C>T in FUT6 with VWF plasma level in HC (Hardy-
Weinberg p=0.63) and B) SNV c.977G>A in FUT6 with VWF plasma level in 
HC (Hardy-Weinberg p=0.72). No significant association was observed by 
comparing the three groups using One-way ANOVA (Kruskal-Wallis test) or 
by comparing between each groups using the t-test (Mann-Whitney test). 
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5.5 Re-analysis of LD between SNVs in FUT3, FUT5 and FUT6 
The LD between FUT3, FUT5 and FUT6 was reanalysed in an additional 47 
HC (to the original 96) with the aim to identify any other SNV(s) in strong LD 
with c.202T>C. However, the results suggested that no other SNVs were in 
strong LD with c.202T>C including the previously identified SNVs in FUT6. 
This in turn suggests that c.202T>C in FUT3 was completely responsible for 
the observed association with VWF plasma level.  
5.6 Association between FUT3 and VWF clearance 
Given that FUT3 is predicted to affect VWF plasma level through influencing 
glycosylation and thus clearance of VWF, the association between c.202T>C 
and VWFpp/VWF:Ag ratio was investigated. VWFpp ratio data was available 
for ~370 HC. Although not significant, the results showed a trend where more 
clearance (high VWFpp/VWF:Ag ratio) occurred when FUT3 was active (had 
the reference c.202T allele) (Figure 5-8).  
 
Figure 5-8: Association between c.202T>C and VWFpp/VWF:Ag ratio 
(p=0.48).  No significant association was observed by comparing the three 
groups using One-way ANOVA (Kruskal-Wallis) or by comparing between 
each group using the t-test (Mann-Whitney test).  
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5.7 Investigation of FUT3 expression in endothelial cells 
Given that only FUT3 showed significant association with VWF plasma level 
and the lack of evidence of it being expressed in endothelial cells, investigation 
of the expression of FUT3 in human umbilical vein endothelial cells (HUVECs) 
was conducted, given that this is the only endothelial cells that we have access 
to that normally produce VWF. mRNA (to assess the expression level) as well 
as DNA (used as positive control) were extracted from HUVECs and qPCR 
was performed. The same probe was used to detect FUT3 mRNA and cDNA 
to avoid any possible differences. 
Taking into account that FUT3 expression might be low, specific primers were 
designed and the cDNA and DNA were amplified using these primers. VWF 
mRNA was not detected even after (x) cycle of amplification while VWF DNA 
was detected (~33rd cycle) and was detected earlier (~24th cycle) when pre-
amplified with specific primers (Figure 5-9). The results suggested that FUT3 
was not expressed in HUVECs. FUT3 mRNA and DNA were also 
electrophoresed to confirm the lack of expression obtained from qPCR. FUT3 
DNA could be seen, while FUT3 mRNA was not detectable. 
Following that, FUT3 mRNA quality and presence were measured using a 
Nanodrop which confirmed that the RNA obtained was of high quality and 
quantity. FUT3 mRNA was also run on RNAse-free gel electrophoresis (Figure 
5-10). The results suggested the presence of mRNA and the presence of 18S 
and 28S bands without any smears again suggesting that the mRNA was of 
good quality (Figure 5-11). The bands were small which was due to a small 
volume being used as a limited quantity of mRNA was available.  
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Figure 5-9: FUT3 mRNA expression in HUVECs.  FUT3 mRNA was not 
detected even after 40 cycles while DNA was detected at ~35 cycles and 
DNA amplified by specific primers prior to doing qPCR was detected at ~25 
cycles. cDNA was prepared from 4 different individuals. 
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Figure 5-10: Investigation of FUT3 mRNA expression in HUVECs using 
PCR and gel electrophoresis.  No mRNA was detected in two samples, 
while DNA was detected in the same individuals. 
 
 
Figure 5-11: The quality of mRNA extracted from HUVECs using gel 
electrophoresis.  28S and 18S bands were detected in the two mRNA 
samples. 
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5.8 Discussion  
FUT3 c.202T>C was reported to be associated with VWF plasma level by 
previous work conducted within this research group (Hickson, et al 2009). 
However, due to the lack of evidence for the expression of FUT3 in plasma, 
other genes have also been investigated previously, including FUT1 and 
FUT2. However, only this variant in FUT3 seemed to be associated with VWF 
plasma level. Therefore, this research was conducted to investigate the 
association of other FUT genes including FUT5 and FUT6 on VWF plasma 
level. However, neither of these two genes were associated with VWF plasma 
level, again supporting the observation that only FUT3 seemed to be 
significantly associated with VWF plasma level. 
We made the prediction that FUT3 influences VWF plasma level in similar way 
as ABO due to the similarity of their function, i.e. via glycosylation and 
therefore clearance. Given that ABH antigens only account for 13% of the 
glycans glycosylated on VWF (Matsui, et al 1992, McKinnon, et al 2008), yet 
they are associated with ~25% variation in VWF level (Gill, et al 1987, 
McGrath, et al 2010). Therefore, other glycans are expected to have an 
influence on VWF plasma levels. 
FUT3 (as well as FUT6) is reported to be required for the conversion of the 
precursor to Lea which is then converted to Leb by FUT2. Therefore, the lack 
of FUT3 expression due to c.202T>C, leads to lack of both Lea and Leb, which 
might lead to reduction of VWF level similar to that reported for O-blood group 
(where there is no A or B antigens). However, FUT3 has only been reported 
to be expressed in exocrine secretions while FUT6 performs a similar function 
to FUT3 in plasma (Mollicone, et al 1994). Therefore, whether FUT3 or FUT6 
were responsible for the observed association in HC needed further 
investigation. 
In silico analysis suggested FUT5 and FUT6 to be good candidates for further 
analysis due to their close proximity to FUT3 and they were also the most 
related FUT genes to FUT3. Reinvestigation of FUT3 was also carried out to 
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ensure that only the c.202T>C variant in FUT3 was significantly associated 
with VWF plasma level. 
In subset of random 47 HC samples. LD analysis identified two SNV in FUT6 
that showed strong LD with FUT3 c.202T>C. However, the results from a 
larger sample (n=1098) suggested that neither of these SNV was significantly 
associated with VWF level. This was due to the LD not being strong with 
c.202T>C after adding more samples. 
Sequencing of additional HC for FUT3, FUT5 and FUT6 did not provide any 
evidence of further SNV being in strong LD with c.202T>C in FUT3. This 
finding suggests that c.202T>C variant is responsible for the observed 
association with VWF level instead of other SNV and other FUT genes. 
To confirm what is reported about the lack of FUT3 expression in plasma, 
mRNA was extracted from HUVECs, and qPCR was run along with gel 
electrophoresis. The results did not show the presence of mRNA in these cells 
confirming previous findings (Costache, et al 1997). This in turn suggest that 
either there is no expression of FUT3 in HUVECs or the expression is very low 
to a level that is not detectable via the used method. Even though there was 
no FUT3 detected, there is not enough evidence denying any interaction 
between FUT3 and VWF, as FUT3 might still be expressed in other endothelial 
cell types (for example human sinusoidal endothelial cells). 
Investigation of the FUT3 c.202T>C variant with VWF clearance showed a 
trend similar to that expected (high VWF clearance for active (WT) FUT3), but 
the differences were small and did not produce significant results due to the 
small sample size. This suggests that inclusion of more samples may achieve 
significance. 
This study has provided evidence that FUT3 is associated with VWF plasma 
level. Even though the previous CHARGE association study did not identify 
c.202T>C as a candidate locus with a strong association with VWF or FVIII 
levels (Smith, et al 2010), this is potentially due to the fact that c.202T>C was 
not analysed in the study. Thus, the results of the CHARGE study cannot 
preclude any association between c.202T>C and VWF plasma level. 
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The mechanism by which FUT3 influences VWF plasma level is still unclear. 
However, a study has shown that Lewis antigens are not glycosylated on VWF 
(Canis, et al 2012), suggesting that either FUT3 is influencing VWF indirectly 
or c.202T>C is in strong LD with another SNV not covered in this study (either 
variants outside FUT5 and FUT6 or in one of these genes but in a region not 
investigated such as introns or promoter regions). 
An indirect effect of FUT3 on VWF could work in one of three ways. First, FUT3 
could be performing another unknown function or second, it could be involved 
in the glycosylation of other proteins that are involved in the processing, 
secretion or clearance of VWF (such as ADAMTS13 (Sorvillo, et al 2014)). 
Therefore, a defect in FUT3 because of the c.202T>C variant could still lead 
to the observed association. 
Third, ABH and Lewis antigens have been reported to use the same starting 
precursor (Mollicone, et al 1994, Costache, et al 1997), thus, the presence or 
absence of FUT3 could affect the amount of precursor available to be used by 
ABH and other antigens and thus have an effect on the glycosylation pattern 
of VWF, and subsequently VWF level through clearance. 
In conclusion, the c.202T>C variant in FUT3 is significantly associated with 
VWF plasma level. Analysis was previously conducted on FUT1 and FUT2 
and the current study looked at FUT5 and FUT6, none of which seems to have 
any association with VWF plasma level. The exact mechanism by which FUT3 
is influencing VWF is still unclear although it appears to be through clearance. 
Further investigation is therefore required to clarify the mechanism involved. 
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6 Chapter six: Investigation of the association 
between CLEC4M with VWF level 
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6.1 Background 
CLEC4M (also known as CD209L) is located on chromosome 19 (19p13.2-3) 
and is ~26kb long. It is expressed in the liver by endothelial cells and is also 
expressed in lymph nodes (Bashirova, et al 2001, Chan, et al 2006). The 
encoded protein L-SIGN, is a transmembrane receptor that is involved in the 
innate immune system by binding to glycosylated and fucosylated products 
(Guo, et al 2004, Zandberg, et al 2012). It is involved in pathogen adhesion 
and recognition; recognising bacteria (such as Mycobacterium tuberculosis), 
parasites (such as Leishmania pifanoi) and viruses (such as HIV-1 and Ebola) 
(Barreiro, et al 2005). L-SIGN also acts as a cell adhesion receptor (Feinberg, 
et al 2005, Yu, et al 2009, Li, et al 2012). However, another study has reported 
that L-SIGN does not internalise pathogens, but instead recruits macrophages 
to clear them (Guo, et al 2004). The same study reported that L-SIGN binds 
to ABH antigen as well as Lewis antigens which are known/predicted to be 
glycosylated on VWF (Guo, et al 2004). 
L-SIGN is reported to form a tetramer before being expressed on the cell 
surface (Mitchell, et al 2001). Each L-SIGN monomer consists of three main 
domains; C-terminal, N-terminal and neck region (Bashirova, et al 2001, Li, et 
al 2012). The neck region contains a 23 a.a variable number of tandem repeats 
(VNTR) region ranging from 4–9 repeats in size (Figure 6-1) (Chan, et al 
2006). A previous study suggested that, longer VNTR repeats enhance the 
stabilisation and activity of L-SIGN compared to shorter repeats (Feinberg, et 
al 2005), which increases the flexibility of the L-SIGN tetramer binding sites 
and therefore the ability of L-SIGN to bind to more than one glycan (Feinberg, 
et al 2005). Another study suggested that homozygous L-SIGN tetramers clear 
pathogens more efficiently compared to heterozygous L-SIGN tetramers, so 
homozygous tetramers may be more stable regardless of the VNTR size 
(Soilleux, et al 2000, Chan, et al 2006, Khoo, et al 2008). 
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Figure 6-1: Proposed effect of short and long VNTR repeats in the neck 
region of L-SIGN receptor. 
A previous association study identified a variant (rs868875; c.631+73A>G) in 
CLEC4M to be significantly associated with VWF plasma level (Smith, et al 
2010) which was supported by a recent study in VWD1 patients (Sanders, et 
al 2015). Further work has also suggested an association of the VNTR in the 
neck region of L-SIGN with VWF plasma level (Rydz, et al 2011). A similar 
observation has previously been reported for the Gplbα receptor where an 
increase in the neck region size leads to increased exposure of the receptor 
binding site, which in turn results in increased receptor activity (Lopez, et al 
1992, Di Paola, et al 2005). Because CLEC4M is expressed in the liver, it has 
been suggested that L-SIGN may be involved in the clearance of VWF from 
the circulation (Rydz, et al 2011).   
Therefore, the aim of this research was to investigate further the association 
between CLEC4M and VWF levels. We hypothesised that the VNTR in 
CLEC4M is in strong LD with the SNV identified by the CHARGE study 
(c.631+73A>G ) suggesting an association with VWF level through alteration 
in the neck size.  
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6.2 In silico analysis of CLEC4M 
CLEC4M was initially investigated to identify any SNV that might be in strong 
LD with SNV c.631+73A>G, which had been associated with VWF levels by 
the CHARGE study (Figure 6-2). This was conducted in order to eliminate the 
possibility that other SNV in strong LD with SNV c.631+73A>G were 
responsible for the observed association with VWF level. Analysis highlighted 
that CLEC4M was a relatively small gene (compared to other genes 
highlighted by the CHARGE study) with only a few variants that were in strong 
LD with SNV c.631+73A>G. 
In silico analysis of CLEC4M suggested regions with the gene that might be of 
importance which will be investigated further (Figure 6-3). This includes 
several SNV found to be in strong LD with the SNV identified in the CHARGE 
study. In addition, exon 7 of CLEC4M was reported to encode amino acids 
involved in ligand binding, so was also investigated further (Guo, et al 2004).  
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Figure 6-2: LD analysis of the CLEC4M locus on chromosome 19.  The LD between variants within CLEC4M (6.4kb) and ~5kb 
each side of the gene was investigated. SNV c.631+73A>G identified by the CHARGE association study is highlighted in the red 
box. White squares indicate weak LD while red squares indicate strong LD, the number in each square shows the percentage of 
the LD. Grey boxes indicate a lack of data for any given SNV association.  
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Figure 6-3: The structure of CLEC4M highlighting the areas of interest. 
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6.3 Relationship between CLEC4M, CLEC4L and CLEC4G 
CLEC4G, CLEC4L and CLEC4M are all present within 43kb (chromosome 19) 
and share homology (CLEC4M and CLEC4L share 83% homology while 
CLEC4M and CLEC4G share 34% homology) (Figure 6-4). All three are also 
reported to have similar functions but with varying affinities to bind to different 
sugar groups (Guo, et al 2004). The LD between the three genes was 
investigated by looking for any possible variants in CLEC4L or CLEC4G that 
might be in strong LD with the variant identified by the CHARGE study in 
CLEC4M. However, the CHARGE variant did not appear to be in strong LD 
with any variant in CLEC4L or CLEC4G (figure 6-4).  
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Figure 6-4: The relationship between CLEC4M, CLEC4L and CLEC4G.  
The location of CLEC4G, CLEC4L (commonly known as CD209) and 
CLEC4M and the LD between CLEC4G, CLEC4L and CLEC4M are shown.  
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6.4 Investigation of CLEC4M variants 
2 exonic SNVs were shown to be in strong LD with the CHARGE SNV 
c.631+73A>G, which are c.718G>A (rs2277998, p.Asp240Asn; 
NP_001138376) and c.585G>A (rs868878, p.Lys195=, NP_001138376) 
(Figure 6-5), and were further analysed in silico to investigate the possible 
effect of these SNVs on the function, structure, or expression of L-SIGN and 
thus a possible effect on VWF level. However, neither of the SNVs were 
predicted to have a significant effect on CLEC4M (Table 6-1). 
Further in silico investigation was conducted on c.718G>A in exon 5 as it was 
the only exonic SNV to cause an amino acid change and likely to have an 
impact on L-SIGN structure or activity. Using in silico prediction tools, 
c.718G>A was shown to have a potential impact on the protein structure, 
however, c.585G>A was not shown to have any effect and was excluded from 
any further analysis (Table 6-1). Analysis of the 3D structure of the extra 
cellular domain of L-SIGN (using PyMol v1.3) showed that SNV c.718G>A was 
present on the surface (Figure 6-6).  
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Figure 6-5: LD analysis of the CLEC4M SNV identified in the CHARGE 
study (based on HapMap data). SNVs present in CLEC4M exons are 
indicated. The remaining SNVs were intronic or located in the 3’ UTR 
(rs15282). The numbers within squares refer to the degree of LD (completely 
red squares represent 100% LD; completely grey squares represent missing 
data, light red squares refer to weaker LD while white squares refer to lack of 
LD). The blue oval represents the SNV identified in the CHARGE study. SNVs 
highlighted in red ovals were in strong LD with the CHARGE SNV. The arrows 
show the SNVs that are in perfect LD with the CHARGE SNV.    
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Table 6-1: Prediction of the effect of c.718G>A and c.585G>A on the L-
SIGN protein.  
CLEC4M 
variants 
SIFT PolyPhen-2 Align 
GVGD 
Mutation Taster 
c.585G>A Tolerated  Benign  Less 
likely  
Protein structure 
less likely to be 
affected 
c.718G>A Tolerated Benign  Most 
likely  
Might affect 
protein structure 
 
 
  
149 
 
 
Figure 6-6: 3D structure of the L-SIGN extracellular domain.  A) The image 
represents L-SIGN as a dimer. Highlighted in red is the position of 
p.Asp240Asn (c.718G>A). B) 3D structure of L-SIGN focusing on the position 
of SNV p.Asp240Asn. Comparison of the WT and mutant alleles at p.240 
(green arrow, reference allele; grey arrow, non-reference allele).  
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Two primer sets were designed to genotype c.718G>A by amplifying and 
sequencing CLEC4M exon 5 in 921 HC from MCMDM-1VWD study. Two sets 
were designed due to the presence of repetitive sequence within this region in 
addition to the presence of several different splice variants. The exon was 
amplified successfully using both primer sets in four randomly selected HC 
individuals. Primer set 2 was chosen to amplify the rest of the samples 
because it produced a more consistent amplification (Figure 6-7). 
 
 
Figure 6-7: PCR product of exon 5 amplified using two different sets of 
primers in 4 different HC.  
 
  
151 
 
After genotyping c.718G>A in the 921 HC, the data showed no significant 
association with VWF plasma level (Figure 6-8). However, the analysis did 
show that individuals homozygous for the non-reference allele had a VWF 
level 5% lower compared to those homozygous for the reference allele 
(p>0.05). Additionally, due to the proximity of SNV c.718G>A and the 
CHARGE SNV c.631+73A>G, both were genotyped and the data confirmed 
that both SNV were in strong LD (r2=98.5%). Both SNV were also shown to be 
in Hardy-Weinberg equilibrium in the HC samples. 
 
 
Figure 6-8: Association of SNV c.718G>A with VWF plasma level in all HC 
(n=921).  No significant differences were observed between the three 
genotypes (p>0.05) using the One-way ANOVA (Kruskal-Wallis test). The t-
test (Mann-Whitney test) was used to compare between two groups. Bars 
indicate standard error. Hardy-Weinberg p=0.82. 
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6.4.1 Investigation of SNVs in exon7 of CLEC4M  
A previous study had suggested that CLEC4M exon 7 encodes a.a involved in 
ligand binding, suggesting that this exon is of high importance to the function 
of encoded L-SIGN (Guo, et al 2004). Therefore, sequencing of this exon was 
conducted to identify further variants that might alter binding affinity of L-SIGN, 
and therefore the clearance of VWF. CLEC4M exon 7 was amplified and 
sequenced in 20 randomly selected HC to look for any variant that might 
influence binding of L-SIGN. However, no SNV were identified.  
6.5 CLEC4M VNTR analysis 
As mentioned, a previous report suggested that the VNTR in the neck region 
of L-SIGN was associated with VWF plasma level (Rydz, et al 2011). However, 
this study failed to differentiate the effect of different VNTR sizes on VWF 
plasma level due to a lack of sufficient individual samples available for study. 
The decision was therefore taken to investigate the influence of this VNTR 
further utilising the large EU HC cohort (n=1160) available in Sheffield. 
The VNTR was genotyped and to confirm that the genotyping was accurate, 
two randomly selected samples were amplified and run on an electrophoresis 
gel (Figure 6-9). The results from the gel matched the results obtained from 
the genotyping, therefore, the genotyping was presumed to be accurate. 
 
Figure 6-9: The figure shows two HC heterozygous for two different 
CLEC4M VNTR repeat sizes.   
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6.5.1 VNTR stability  
Before investigating the association of the VNTR with VWF plasma levels, the 
VNTR stability was tested to ensure that the VNTR was inherited between 
generations without any random addition or removal of one or more VNTR 
repeats. This was studied by genotyping the VNTR in two families, each 
containing at least three generations which could be genotyped. The results 
indicate that the VNTR was stably inherited in these families (Figure 6-10). 
 
 
 
 
 
Figure 6-10: VNTR size in the two families (A, P6F16; B, P12F3).  ND= 
DNA not available).  
B 
A 
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6.5.2 VNTR association with VWF plasma level 
The VNTR was successfully genotyped in 921 HC. In addition, genotypic and 
phenotypic data for 120 Canadian HC was kindly provided by Prof. Lillicrap 
(Queens University, Kingston, Canada). Before proceeding with analysing the 
effect of the VNTR from the combined Canadian and EU HC population, the 
median VWF:Ag levels observed in the two populations were compared to 
ensure that the results were not affected by any population differences. The 
results indicated that both populations had comparable VWF:Ag levels (Figure 
6-11) (median Canadian VWF:Ag 96 IU/dL; median EU VWF:Ag 98 IU/dL), 
allowing data from both populations to be combined. 
Sizes of VNTR range between 4-9 repeats. Due to relatively small population 
size available for study, having 21 different genotypes (i.e. six homozygous for 
a single VNTR size and 15 heterozygous for two different size repeats) would 
make it difficult to observe any significant association, especially given that 
some VNTR sizes (such as 4 and 9) were present in a very small number of 
individuals. Therefore, the decision was to make two groups based on small = 
(4-6) and large = (7-9) repeats where the population was divided into three 
main group (small/small, small/large, and large/large) and numbers of 
individuals were equally distributed between the three groups. 
This classification was chosen as 6-7 repeats were the most common repeat 
size so it was selected as a cut-off point as it would provide balanced 
distribution of the population samples between different groups (small/small= 
239 individuals; small / large= 524 individuals; large/large= 305 individuals). 
There was a significant association between VNTR size and VWF level 
(p=0.038). Individuals homozygous for the small repeats had a ~10% lower 
VWF level compared to individuals homozygous for the large repeats (Figure 
6-12). Although not significant, the association was similar after taking into 
account ABO blood group with ~8% lower VWF plasma level for the 
small/small group when compared to the large/large group for both O (71 IU/dL 
and 79 IU/dL respectively) and non-O (101 IU/dL and 109 IU/dL respectively) 
blood group individuals (Figure 6-13). In all instances the genotypes were 
shown to be in Hardy-Weinberg equilibrium.   
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Figure 6-11: Median VWF plasma in European and Canadian HC.  Bars 
indicate standard error. 
 
Figure 6-12: Association of CLEC4M VNTR size with VWF plasma level. 
Small, 4-6 VNTR repeats; large, 7-9 repeats. Significant differences were 
observed between the three alleles (p=0.038) using the One-way ANOVA 
(Kruskal-Wallis test). The t-test (Mann-Whitney test) was used to compare 
between two groups; a significant difference was observed between 
small/small and large/large groups (p=0.012) Bars indicate standard error.  
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Figure 6-13: The association of different VNTR sizes with VWF plasma 
level.  A) O blood group individuals and B) non-O blood group individuals. 
No significant differences were observed using the One-way ANOVA 
(Kruskal-Wallis test) to compare the three groups nor the t-test (Mann-
Whitney test) was used to compare between two groups. Bars indicate 
standard error. 
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6.5.3 Association of homozygous and heterozygous VNTR genotypes 
with VWF level 
It had been reported by a previous study that L-SIGN tetramer with different 
VNTR sizes (heterozygous VNTR size) are less active than tetramer with a 
similar VNTR size (homozygous VNTR size) (Bashirova, et al 2001). 
Therefore, VWF levels were also compared between HC who were 
homozygous and HC who were heterozygous for VNTR genotypes. Analysis 
of the data obtained in this study showed that homozygous HC had a 5% 
higher VWF level compared to heterozygous HC, although the results were 
not significant (Figure 6-14).  
 
 
Figure 6-14: Association of homozygous and heterozygous CLEC4M 
VNTR genotypes with VWF plasma level.  No significant differences were 
observed between the two groups (p>0.05) using the t-test (Mann-Whitney 
test). Bars indicate standard error. 
  
158 
 
6.5.4 Association between CLEC4M VNTR and VWF SNV c.2385T>C 
and c.2365A>G with VWF plasma level 
The CLEC4M VNTR and VWF SNV c.2385T>C and c.2365A>G had all been 
shown to be significantly associated with VWF plasma level. Therefore, further 
analysis was conducted to assess whether they had an overall additive effect 
on VWF level (Figure 6-15). The results suggested that these variants did have 
an additive effect on VWF level when both the non-reference VWF SNV alleles 
and the large VNTR repeats were present in the same individual. Although no 
mechanism interaction between VWF and CLEC4M variants is expected. 
 
Figure 6-15: The graph shows the effect of different combinations of 
the CLEC4M VNTR and VWF SNV (c.2385T>C and c.2365A>G) 
genotypes on VWF level. VWF Reference in the figure refers to reference 
allele from both c.2385T>C and c.2365A>G (three individuals were excluded 
from this analysis due to having different alleles between both SNV), non-
reference also refers to non-reference allele for both SNV. For CLEC4M 
VNTR, small refers to 4-6 repeats while large refers to 7-9 repeats. 
Significant differences were observed between reference, small/small (95 
IU/dL) and non-reference, large/large (121 IU/dL) (p=0.003) using the One-
Way-ANOVA (Kruskal-Wallis multiple comparison test). Bars indicate 
standard error.  
** 
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6.5.5 Association between CLEC4M VNTR and VWF clearance 
CLEC4M has been suggested to influence VWF clearance from the circulation 
(Rydz, et al 2013). The rate of VWF clearance can be measured using the 
VWFpp/VWF:Ag ratio; a higher ratio indicates faster clearance of VWF from 
the circulation. Therefore, the association of VNTR size with VWFpp/VWF:Ag 
ratio was also investigated. The results did not show any significant differences 
between VWFpp/VWF:Ag ratio in the different VNTR groups  and thus no 
significant effect on clearance (Figure 6-16). 
 
 
Figure 6-16: Association of CLEC4M VNTR on VWFpp/VWF:Ag ratio in 
~280HC.  No significant differences were observed between the three alleles 
(p>0.05) using the One-Way ANOVA test (Kruskal-Wallis test). The t-test 
(Mann-Whitney test) also showed no significance comparing between two 
groups. Bars indicate standard error. 
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6.6 LD between different CLEC4M genotypes 
After identifying several variants within CLEC4M (other than the CHARGE 
SNV) with a possible association with VWF plasma level, the LD between 
these variants and the CHARGE SNV was analysed (Figure 6-17). As 
mentioned, the data highlighted strong LD between SNV c.718G>A and the 
CHARGE SNV (c.631+73A>G; 98.5%). However, the CHARGE SNV was also 
in strong LD with the VNTR when 4-5 repeats were classified as small and 6-
9 repeats were classified as large (86.5%; Figure 6-17).  
 
 
Figure 6-17: Observed LD between different CLEC4M genotypes.  
  
4-6 small 
7-9 large 
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Changing the groups of the VNTR from small=4-6 and large=7-9 to small=4-5 
and large=6-9 showed a greater LD with the SNV identified by the CHARGE 
association study. The association between the VNTR (using the new 
classifications) and VWF plasma level was investigated. This showed a 
significant VWF increase of ~11% (Figure 6-18).  
 
 
Figure 6-18: Association of CLEC4M VNTR size with VWF plasma level. 
Small, 4-5 VNTR repeats; large, 6-9 repeats (Hardy-Weinberg p=0.23). 
Significant differences were observed between the three alleles (p=0.031) 
using the One-Way ANOVA (Kruskal-Wallis test). Significance differences 
were also observed between Small/Small and Large/Large repeats using the 
t-test (Mann-Whitney test) (p=0.011). Bars indicate standard error. 
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6.7 CLEC4M expression 
To assess the possible effect of CLEC4M on VWF level, investigation of the 
expression of CLEC4M in HUVECs was conducted. HUVECs DNA and mRNA 
from two individuals were amplified using two sets of primers due to the 
presence of repetitive sequences and the presence of several splice variants. 
All the primers were designed to be in the middle of the exon to amplify RNA 
as well as DNA. 
CLEC4M DNA was amplified using both primers sets, while CLEC4M mRNA 
was not detected. The results suggest the lack of expression of CLEC4M in 
these cells (Figure 6-19). Therefore, CLEC4M expression appears to be 
limited to liver endothelial cells where VWF clearance has been reported 
(Denis, et al 2008). 
 
Figure 6-19: Investigation of CLEC4M expression in HUVECs from 2 
individuals using 2 primers sets.  1) DNA with primer set 1; 2) mRNA from 
primer set 1; 3) DNA with primer set 2 (non-specific bands are seen due to 
no specificity for the primers used); 4) mRNA with primer set 2.  
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6.8 FUT3 and CLEC4M 
From the previous findings, FUT3 and CLEC4M are significantly associated 
with VWF plasma level. The two genes are present within 2Mb (Figure 6-20) 
on chromosome 19. Therefore, the LD between the two genes was 
investigated using HapMap data, however, no LD data was available (Figure 
6-21). Our data for the CLEC4M VNTR and FUT3 variant was used to 
investigate the LD between them, however, there was no LD identified 
between the two (r2= 0.032). 
 
 
 
 
 
 
 
 
 
Figure 6-20: Location of FUT3 and CLEC4M on chromosome 19. 
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Figure 6-21: LD between CLEC4M SNV and FUT3 c.202T>C variant 
(shown in red oval).  Completely red squares represent 100% LD; 
completely grey squares represent missing data, light red squares refer to 
weaker LD while white squares refer to lack of LD) 
 
  
165 
 
6.9 Discussion  
The aim of this chapter was to investigate the effect of CLEC4M on VWF 
levels. A previous association study identified a variant (c.631+73A>G) in 
CLEC4M with significant association with VWF plasma level (Smith, et al 
2010). It was suggested that L-SIGN (encoded by CLEC4M) contributes to the 
clearance of VWF from the circulation (Rydz, et al 2013). Therefore, this study 
investigated the association of CLEC4M with VWF level further. This 
investigation showed a significant association between the CLEC4M VNTR 
with VWF plasma level. 
Using the Gene Cards web tool, the possible proteins potentially involved in 
the CLEC4M pathway, i.e. being co-expressed or having a physical interaction 
with CLEC4M were investigated to try and identify any known proteins that 
were also previously reported to interact with VWF which could possibly 
provide an indication of a possible mechanism of interaction between L-SIGN 
and VWF. However, the results did not suggest any known mechanism of 
interaction (Figure 6-22). Further investigation using the Genemania web tool 
gave similar results (data not shown). 
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Figure 6-22: Proteins potentially involved in the CLEC4M pathway.  
Proteins that physically interact with L-SIGN (purple connections), involved in 
a similar pathway (blue connections) described in the same reference 
publication (yellow connections) sharing homology (light blue connections) 
and neighbouring proteins (green connections). 
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Three main regions of CLEC4M were highlighted to be of importance to L-
SIGN function and therefore potentially influencing VWF level. Firstly, exon 7 
which encodes a.a directly involved in L-SIGN ligand binding (Guo, et al 2004). 
Secondly, LD investigation identified two SNV (c.585G>A in exon 4 and 
c.718G>A in exon 5) with strong LD to the CHARGE SNV. Thirdly, the VNTR 
in exon 4 that had been previously suggested to influence the binding affinity 
of L-SIGN (Feinberg, et al 2005, Rydz, et al 2011).  
Exon 7 was sequenced in 20 random HC, but no SNV was found in any of 
them (completely WT), suggesting that this exon in the European population 
has no variation (which was confirmed using HapMap data). However, 
populations from other ethnic backgrounds might still have SNV of functional 
importance. Nevertheless, this region was excluded from any further 
investigations. 
c.585G>A was not predicted to have any effect on L-SIGN using four different 
protein prediction tools and was excluded from further investigation. c.718G>A 
was predicted to have an effect using two out of four tools and was 
investigated further. While the results showed that individuals with the non-
reference allele had ~5% reduction in VWF level compared to individuals with 
the reference allele this association was not significant.  
The CHARGE study identified c.631+73A>G to have the weakest significant 
association with VWF plasma level (compared to other identified SNV in 
different genes) in a much larger population and our data showed that 
c.718G>A is not in perfect LD with c.631+73A>G. In addition, variants with a 
known association to VWF level (such as ABO blood group) could not be taken 
into account in this investigation due to the small population size. It is therefore 
not unexpected to see a lack of significant association in our population which 
does not mean that the association is absent.  
Genotyping the VNTR in the EU HC combined with previous genotyping data 
from Canadian HC showed significant association between the CLEC4M 
VNTR and VWF plasma level. The suggestion is that the association is weak 
given that data was required from two study populations, which is similar to 
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what was observed with the CHARGE study. In addition, this supports the 
possibility that a significant association of c.718G>A with VWF level could be 
seen if investigated using a larger population sample (no genotypic data was 
available for this SNV from the Canadian population). 
A previous study had suggested that tetramer L-SIGN with each subunit 
having the same size (i.e. CLEC4M homozygous for one VNTR repeat) were 
more stable and more efficient at binding targets compared to any 
heterozygous tetramers (Bashirova, et al 2001). This theory was investigated 
in our study, with the expectation that higher VWF levels would be observed 
in individuals heterozygous for CLEC4M VNTR size due to lowered VWF 
clearance efficiency. However, the opposite trend (although not significant) 
was observed. This does not completely abolish the theory as suggested by 
the previous study because in our study different VNTR sizes were combined 
together which would have an impact on the observed association as 
comparing each group alone would give more accurate indication of the 
association. An ideal study would be to compare homozygous and 
heterozygous repeats of each size together (for example comparing 4/4, 4/5 
and 5/5 together, and the same for all sizes) which was not done in this study 
due to the small population sample that made this impractical. 
Due to the similarity of the observed association between the CLEC4M VNTR 
and VWF variants c.2385T>C / c.2365A>G with VWF levels, the decision was 
taken to investigate whether the associations were linked in some way or 
whether they had completely separate effects. The results suggest that these 
variants are independently influencing VWF plasma level and combining them 
demonstrates an additive effect on VWF level. This in turn suggests that VWF 
variants c.2385T>C / c.2365A>G and CLEC4M influence VWF level 
independently and the presence of both variants combined lead to a greater 
influence on VWF level. 
Other C-type lectin family members including CLEC4L and CLEC4G were 
found to be present within close proximity to CLEC4M and share some 
homology with CLEC4M. In addition, a previous study showed that CLEC4L, 
expressing DC-SIGN interacts with several antigens that form part of the 
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glycosylated glycans present on VWF such as ABH antigens (Guo, et al 2004). 
HapMap data suggested no LD between CLEC4M with either CLEC4L or 
CLEC4G. However, this does not deny any possible association between L-
SIGN and VWF, but could instead, suggest that if there is any association, it 
will be independent of the L-SIGN association. Due to time limitations, no 
further work was conducted to study any possible association between DC-
SIGN (encoded by CLEC4L) and VWF levels. In addition, the lack of 
interaction between CLEC4M and some antigens does not implicate lack of 
direct interaction with VWF as the interaction could be with glycans not 
included in this study or with VWF protein itself (Guo, et al 2004). 
Following that, the association between FUT3 c.202T>C variant and CLEC4M 
VNTR was analysed looking for possible LD between the two variants. 
However, no LD was observed suggesting that these two variants influence 
VWF plasma level through independent pathways.  
 In summary, this work provided evidence of association between CLEC4M 
VNTR with VWF plasma level. It also suggested a SNV (c.718G>A) with a 
potential effect on VWF plasma level that requires investigation of additional 
samples to achieve significance. A previous study showed no interaction 
between L-SIGN and some antigens glycosylated on VWF but this does not 
deny the association (Guo, et al 2004). Recent work has provided more 
evidence supporting the interaction and association between CLEC4M and 
VWF level (Rydz, et al 2011, Rydz, et al 2013). Finally, these findings support 
the hypothesis that the VNTR in CLEC4M is in strong LD with the SNV 
identified by the CHARGE study suggesting an association with VWF level 
through alteration in the neck size.  
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7 Chapter seven: General discussion 
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7.1 Discussion  
VWF is large plasma glycoprotein that plays an important role in blood 
coagulation by enhancing platelet adhesion and aggregation to sites of injury 
and carrying FVIII and protecting it from degradation. VWF level varies 
between 50-200 IU/dL in the normal population (Gill, et al 1987). Several 
factors are known to influence VWF plasma level including both genetic 
factors, such as ABO blood group, and environmental factors such as age and 
stress. In addition to the variation of VWF plasma level in the normal 
population, VWF plasma level also varies between VWD patients with the 
same causative mutations. In addition, some individuals exhibiting a VWD 
phenotype were found to not have any causative VWF mutations, suggesting 
that an additive effect of several variants influencing VWF level may lead to a 
VWD-like phenotype. The alternate allele of these variants can also be 
considered risk factors for cardiovascular disease, i.e. increasing VWF levels. 
Given that VWF is known to undergo extensive post-translational 
modifications and interacts with a large number of different protein ligands 
during its circulation (Lenting, et al 2015), it is expected that a large number of 
genetic factors might influence VWF level (Figure 7-1). Although the effect of 
several genetic factors influencing VWF levels has been established, others 
are suggested to influence VWF level but need further investigation. This study 
initially aimed to identify additional genetic loci and variants associated with 
VWF plasma level that are responsible for VWF level variations reported in the 
normal population and then to investigate their mechanism of action. 
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Figure 7-1: Life cycle of VWF.  Genes encoding proteins involved at 
different stages of the VWF life cycle are highlighted. 
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Several genome wide association studies identified genetic loci both within 
and other than VWF to be significantly associated with VWF plasma levels 
(Souto, et al 2003, Smith, et al 2010, Zabaneh, et al 2011). These studies 
provided evidence that genetic loci other than VWF are associated with VWF 
plasma level. In addition, they provided evidence that variants present in the 
normal population, previously referred to as neutral polymorphisms, also have 
an effect on VWF levels. However, none of these reports or any other study 
investigated the mechanism by which a “polymorphism” could be influencing 
VWF plasma level.  
This work also aimed to complement previous studies which were conducted 
to identify mutations in VWF associated with VWD1 in the European and 
Canadian populations (Goodeve, et al 2007, James, et al 2007). These studies 
failed to identify the causative mutations in a subset of patients diagnosed with 
VWD1 suggesting either that other genetic loci outside of VWF could be 
associated with VWF level or that possibly a combined effect of two or more 
SNVs, not disease causing on their own, led to a VWD1-like phenotype. In 
addition, a better understanding of other genetic factors that influence VWF 
level will lead to better understanding of the variation of VWF level in patients 
with the same causative mutations. 
There have been numerous published works highlighting an association of 
several VWF variants with VWF level either as part of genome wide 
association studies or VWF specific studies (Souto, et al 2003, Smith, et al 
2010, Campos, et al 2011, Zabaneh, et al 2011, Zhou, et al 2014). This study 
confirmed the association of previously described VWF variants with VWF 
level including c.2385T>C and c.2365A>G. In addition, it also identified 
variants that have not been suggested to have an association with VWF levels 
such as c.7888-3501A>G, c.7888-2310T>C and c.-1342C>G, which due to 
time limitations were not studied in detail as part of this work. Most of the VWF 
variants identified in this study were intronic or silent exonic variants 
supporting previous findings regarding the importance of these type of variants 
which were reported as the majority of variants influencing VWF level 
(Campos, et al 2011). However, as of yet, there is no published work 
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investigating the mechanism by which these variants influence VWF levels. 
Therefore, the next step was to investigate their mechanism of action. 
Both c.2385T>C and c.2365A>G were found to be associated with ~9% 
increase in VWF level compared to the reference allele in this study as well as 
in an earlier study (Zabaneh, et al 2011). In vitro investigation showed that 
they are also associated with a significant increase in protein expression, 
mRNA expression and mRNA half-life. However, they were not found to have 
any effect on splicing nor were they predicted to have any effect on mRNA 
secondary structure or on miRNA binding motifs, which are the three main 
factors influencing mRNA half-life (Duan, et al 2013). However, the same study 
suggested that a change of nucleotide from A or T to C or G would increase 
mRNA half-life by an unknown mechanism which could be the reason for the 
observed increase on mRNA half-life observed in this study (Duan, et al 2013). 
VWF c.2771G>A and c.4146G>C variants were identified by this research 
group and by others to be significantly associated with VWF plasma levels 
(Goodeve, et al 2007, James, et al 2007, Corrales, et al 2012). Therefore, this 
study aimed to investigate their mechanism of action. Previous studies had 
ruled out an effect of c.2771G>A on VWF multimerisation, storage or FVIII 
binding but none looked at its effect on mRNA level (Hilbert, et al 2003, Berber, 
et al 2009, Hickson, et al 2010). Prediction of the effect of c.2771G>A and 
c.4146G>C on ESE motifs showed a possible effect and in vitro investigation 
confirmed an alteration of ESE motifs caused by these variants. The effect of 
both SNV in mRNA and mRNA half-life showed a reduction suggesting that 
the reduction in mRNA half-life is due to a defect in splicing through disruption 
of ESE sites supporting previous findings for c.2771G>A (Berber, et al 2009). 
The effect of intronic VWF variant c.1534-3C>A was previously reported to 
causes a defect in splicing and therefore VWD1 which would support our 
finding that defect in splicing could lead to VWD1 (Gallinaro, et al 2006). 
Previous studies suggested an association between Lewis blood group 
antigens and VWF level (Orstavik, et al 1989, Green, et al 1995, Hickson, et 
al 2009) and provided evidence against what was suggested by another study 
that did not see these associations. However, this study used a much smaller 
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sample size which could be the reason for their observed lack of association 
(O'Donnell, et al 2002). The conversion of the precursor glycan chain to Lewis 
antigen is performed by α-3-fucosyltrasferase (encoded by either FUT3 or 
FUT6). The c.202T>C variant in FUT3 was reported to be specifically 
associated with VWF plasma level (Hickson, et al 2009). However, FUT3 
expression had only been reported in exocrine secretions while FUT6 (which 
shares 84% homology and is located within 40kb of FUT3) is expressed in 
plasma (Mollicone, et al 1994, Costache, et al 1997).  
Investigation of LD between FUT3 c.202T>C and SNVs in FUT6 and 
additionally FUT5 (also highly homologous and present in close proximity to 
FUT3), revealed that no other SNVs were in strong LD. Therefore, the 
c.202T>C variant in FUT3 seems to be entirely responsible for the observed 
association with VWF level. Although FUT3 has not been reported to be 
expressed in plasma, this could be explained by the high degree of homology 
between FUT3 and FUT6; FUT6 expression could obscure plasma expression 
or detection of FUT3. Even if FUT3 is not expressed in plasma, it might still be 
associated with VWF level through an indirect effect. Further work is therefore 
required to investigate the mechanism by which FUT3 expression influences 
VWF plasma level.  
This study also investigated the proposed association of CLEC4M with VWF 
plasma level. A variant (c.631+73A>G) in CLEC4M was reported to be 
significantly associated with VWF plasma level (Smith, et al 2010). Analysing 
SNVs in strong LD with this SNV identified two other SNVs in CLEC4M 
(c.585G>A, and c.718G>A). Only c.718G>A was predicted to affect L-SIGN 
structure, further analysis of SNV c.718G>A revealed that it was present in 
exon 5 (encoding the outer surface of the extracellular domain) which 
suggested that the SNV might influence ligand binding. Analysis of this SNV 
showed a trend towards a ~5% variation in VWF level with the non-reference 
allele associated with higher levels, thus an increase in L-SIGN affinity towards 
possible binding and clearance of VWF. However, the results did not achieve 
significance suggesting that data from additional samples was needed in order 
to achieve significance. 
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Several studies have also reported an association between a VNTR within the 
neck region of L-SIGN and receptor affinity (Soilleux, et al 2000, Guo, et al 
2004, Chan, et al 2006), and a recent study reported an association between 
this VNTR and VWF level (Rydz, et al 2011). Analysis of the VNTR performed 
in this study suggested that large alleles of the CLEC4M VNTR (7-9 repeats) 
were associated with an ~10% increase in VWF plasma level compared to 
small VNTR  alleles (4-6 repeats). The observed trend was visible both before 
and after taking into account ABO blood group, but additional samples need 
to be added to the study to achieve significance when taking into account ABO 
blood group. 
L-SIGN forms tetramers on the cell surface. A previous study reported that L-
SIGN tetramers with the same VNTR size had a higher binding affinity than 
tetramers of different VNTR sizes (Soilleux, et al 2000). However, investigation 
of VWF level between individuals homozygous and heterozygous for the 
VNTR showed that homozygous individuals had ~5% higher VWF levels which 
is not in line with a previous report (Bashirova, et al 2001), which could be due 
to dividing all similar genotypes into two groups (i.e. individuals homozygous 
for any VNTR size were one group and heterozygous individuals was the other 
group). Therefore the differences were not clearly shown. The small sample 
size did not allow individuals to be divided into sub-groups. 
The LD between the CLEC4M CHARGE SNV (c.631+73A>G), exon 5 SNV 
(c.718G>A) and the VNTR was also investigated in our population. The results 
showed that all were in strong LD (Figure 6-17). This might suggest that these 
variants are having an additive effect (because the variants have a similar 
effect on VWF level and are in strong LD), or potentially only one variant has 
an effect but due to the strong LD, the other variants showed a similar 
association. Further functional work is still required to test whether these 
variants have a separate or combined effect. 
Both FUT3 and CLEC4M are suggested to be associated with VWF clearance 
(Hickson, et al 2009, Rydz, et al 2013). Little is currently known about the VWF 
clearance mechanism. Lewis antigens were predicted to be associated with 
glycosylation and clearance in the same way as ABH antigens. However, 
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recent study showed evidence that Lewis antigens are not glycosylated on 
VWF (Canis, et al 2012), nevertheless, FUT3 might still be associated with 
VWF level either through glycosylation of other proteins that interact with VWF 
(such as ADAMTS13 which is reported to be glycosylated) or it directly 
interacts with VWF in an unknown way. It has been reported that the liver 
(which is reported to express L-SIGN) plays an important role in VWF 
clearance (van Schooten, et al 2008). Macrophages are also involved in VWF 
clearance (van Schooten, et al 2008) and are reported to be recruited by L-
SIGN to clear glycosylated products (Guo, et al 2004). L-SIGN clears 
glycosylated and fucosylated products such as viruses, bacteria and ABH and 
Lewis antigens (Guo, et al 2004, Zandberg, et al 2012) and is predicted to 
clear VWF in a similar way. 
7.2 Study limitations  
The current study, like any other study, has some limitations. As the study 
looked at three main genes, the limitations of looking at each gene will be 
discussed separately. First, the analysis of VWF only covered a small number 
of SNV (111) within a gene that is known to be highly polymorphic and this 
means that a large number of variants were overlooked, which does not mean 
they are of less importance. However, due to limited time and costs, the 
analysis was only conducted on the available data. In addition, several SNV 
identified in this study that were found to be significantly associated with VWF 
level including c.7888-3501A>G, c.7888-2310T>C and c.-1342C>G were 
excluded from further investigation due to time limitations. Furthermore, all of 
the mRNA splicing work was done in vitro, which may not entirely reflect 
human mRNA, but due to the lack of access to individual RNA samples 
carrying these variants, such investigation was not performed.  
The main weakness when looking at FUT3 and CLEC4M work was that some 
areas (i.e. introns, UTRs and the promoter region) within FUT3, FUT5, FUT6 
and CLEC4M were not analysed and variants may therefore have been 
missed that could also possibly be associated with VWF plasma level. In 
addition, only variants found to be in strong LD with FUT3 c.202T>C and 
CLEC4M c.631+73A>G were considered for further investigation, therefore, 
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other variants with an independent effect on VWF level may have been 
missed. 
7.3 Future work 
The current association analysis was performed on HC. Similar analysis could 
be performed on VWD1 patients, especially those that have similar causative 
mutations but show variation in VWF level within the same family, in addition 
to patients who were not identified to have VWF mutation(s) or the identified 
mutations did not fully explain their phenotype. This would be done by 
investigating whether these patients carry any of the previously reported 
variants in VWF, FUT3 and/or CLEC4M and determining whether these 
variants explain the variation in VWF level and VWD severity. This could 
indicate whether these variants potentially contribute to the severity of VWD. 
c.2385T>C and c.2365A>G are both present within the VWF D3 domain that 
is known to be associated with FVIII binding and VWF multimerisation 
(Goodeve, et al 2007). Both SNV were found to be significantly associated 
with FVIII level in the previous CHARGE study (Smith, et al 2010). Therefore, 
analysis of the effect of these two SNV on FVIII binding would be undertaken. 
In addition, multimer analysis would be performed to test the effect of both 
SNV on VWF multimerisation.  
The effect of VWF c.7888-3501A>G and c.7888-2310T>C in intron 47 on VWF 
plasma level still needs to be studied further. From the current in silico 
analysis, c.7888-3501A>G appears to be directly associated with VWF 
splicing by introducing a new donor site (predicted by 4 out of 5 web tools). 
Therefore, ESE and acceptor / donor motif splicing assays would be used to 
test the effect of this variant on ESE motifs and splicing (Bonnet, et al 2008). 
c.7888-2310T>C did not seem to be directly influencing VWF level as it was 
not predicted to have any major effect on ESE motifs, splicing or transcription 
factor binding. However, surrounding SNV showed a possible effect. The first 
step in investigating this association further would be to amplify and sequence 
1kb of DNA each side of the c.7888-2310T>C variant and look for other SNV 
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in strong LD with it, then those SNV would be tested in silico to predict any 
potential effect which would then be investigated further.  
VWF c.2771G>A and c.4146G>C were found to have an effect on ESE motifs, 
however, it would be interesting to also test their effect on acceptor / donor 
motif splicing as it would provide better indication of their effect on splicing as 
an effect on ESE alone can less likely be of major impact, however, 
subsequent effect on splicing can be disease causing (Gallinaro, et al 2006). 
This experiment was not performed due to time limitations. In addition, testing 
the effect of c.2771G>A on splicing using mRNA extracted from blood, which 
became available at the time of writing this thesis, would be performed which 
will provide a more accurate indication of the effect of this variant in vivo. 
Investigation of the association and interaction between L-SIGN and VWF was 
not carried out during this project due to it being conducted by a group led by 
Prof. Lillicrap (Queen’s University, Kingston, ON, Canada) who work in 
collaboration with our research group. The results of the association was 
published earlier, thus, no further investigation was conducted by our research 
group (Rydz, et al 2013). What would have been done was to study the 
mechanism by which L-SIGN is influencing VWF plasma level. This could be 
done using plasmids with CLEC4M cDNA inserted for different VNTR sizes. 
Additionally, the effect of c.718G>A (both separately and in combination with 
different VNTR sizes) would be examined. Following that, different plasmids 
would have been transfected into HEK293T cells and VWF internalisation 
would have been compared. This would be done using recombinant VWF 
(Humate-P) and measured using flow cytometry (looking for changes in the 
extracellular and intracellular intensity which would be indicate internalisation). 
An empty plasmid (the same plasmid but without CLEC4M) would be used as 
a negative control to take into account any other receptors that might 
internalise VWF. Not adding recombinant VWF would also be used as a 
negative control, to check that what increases the intracellular intensity is the 
recombinant VWF used. 
The association of FUT3 with VWF level would also be investigated first by 
examining intronic and promoter SNV in FUT3, FUT5 and FUT6 to make sure 
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that the c.202T>C variant was responsible for the observed association with 
VWF level. Second, co-transfecting plasmids carrying WT of both VWF and 
FUT3 cDNA and comparing the secreted VWF level with that obtained using 
plasmid containing WT VWF with FUT3 plasmid carrying c.202T>C variant. In 
addition, the secreted VWF could be used to test for effect on clearance using 
other cells expressing CLEC4M. This would give an indication of the effect of 
FUT3 c.202T>C on VWF expression and clearance.  
Furthermore, variants in FUT5 and FUT6 were only analysed by looking for 
SNVs in strong LD with c.202T>C, however some variants might have an 
independent effect on VWF level. Therefore, in silico analysis would be 
conducted on other variants found in FUT5 and FUT6, then SNV found to have 
potential effect would be genotyped in more individuals and any significant 
effect on VWF level examined further. 
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7.4 Concluding remarks 
SNV have historically been believed to be benign, however, there is growing 
evidence that several SNV are important for gene function or expression. In 
this study, several SNV were found to be associated with VWF plasma level 
within VWF and other genetic loci including CLEC4M and FUT3. These 
findings provide a better understanding of the variation in VWF level in the 
normal population as well as variation in the bleeding severity observed in 
VWD patients with the same causative mutation. In addition, although these 
SNV are not disease causing, they may be potential risk factors for bleeding 
or for cardiovascular disease and an additive effect can increase the risk 
further as suggested by this study. This study reported the first case of SNV 
associated with VWF plasma level through interfering with mRNA half-life. This 
study has also provided evidence, for the first time, of mutations affecting ESE 
contributing to VWD1. In conclusion, these findings support the hypothesis 
that SNV influence VWF level and that genetic loci other than VWF influence 
VWF plasma level. 
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9 Appendices 
Appendix 1: VWF SNV analysed in this study 
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Appendix 2: pET01 plasmid used for acceptor / donor motif splicing 
assay (MoBiTec molecular biotechnology). 
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Appendix 3: pcDNA3.1/Hygro (-) plasmid map with VWF insertion 
(Figure generated using SnapGene viewer v.2.1). 
VWF gene insertion 
